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1 Introduction 
1.1 Proteomics 
The proteome is defined as the entity of proteins expressed by a genome in a specific 
context and at a certain time [1]. In contrast to the genome which is distinct for an 
organism or cell, the proteome is dynamic and influenced by the environment [2, 3]. It 
varies between tissues, time points and disease states. Examining the proteome with 
high throughput approaches is referred to as proteomics [4]. Proteomics comprises 
methods for protein purification from complex matrices, their identification and 
quantification as well as elucidation of structural information and comparison to 
protein and DNA sequence databases [5]. Two-dimensional gel electrophoresis and 
chromatographic approaches such as ion-exchange chromatography and reversed 
phase chromatography are the major methods for protein purification [5, 6]. For 
protein identification, western blotting, Edman sequencing, and mass spectrometry 
(MS) can be employed [6, 7]. The listed protein content of a sample or a list of 
differentially expressed proteins are the typical result of a proteomics analysis [4]. 
Depending on the experimental setup and sample preparation, the proteomics 
workflow can also be used to investigate protein localization, turn-over, protein-
protein-interaction and post-translational modification [3, 4]. No matter the question, 
approaches with MS - based read out prevail nowadays [2, 3, 8-13].  
 
1.2 Mass spectrometry-based proteomics 
For all MS-based methods, it is crucial to reduce the complexity of the biological 
samples because proteins are identified solely by the mass-to-charge ratios of their 
peptides and fragments thereof. Therefore, sensitivity and accuracy of MS-based 
analyses are linked tightly on efficient sample separation. Separation methods, which 
lead to fractionated samples are often coupled to matrix-assisted laser 
desorption/ionization (MALDI), while methods resulting in a continuous separation 
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such as liquid chromatography (LC), are typically combined with a continuous 
ionization source like electrospray ionization (ESI) [6]. Using the latter setup, 
insufficient separation can lead to ion suppression by coeluting analytes. Larger 
analytes as well as hydrophobic analytes suppress the ionization efficiency of smaller 
and more polar substances. Also, components of the sample matrix such as non-
volatile or ion-pairing substances affect the ionization. They affect the droplet 
formation and evaporation efficiency and thereby the number of charged molecules 
reaching the gas phase. In order to minimize this effect, long gradients are used as well 
as thorough sample cleanup [14, 15]. There are several methods to reduce the 
complexity of biological samples utilizing different properties of the proteins. As a side 
effect detergents and non-protein components of the biological matrix are removed.  
Depending on the used chromatographic material, analytes can be separated 
according to their size (size exclusion), charge (ion exchange), hydrophobicity 
(reversed phase) or affinity to immobilized molecules [6]. Sample complexity can be 
further reduced by combining orthogonally methods for protein separation. Two- 
dimensional electrophoresis for example combines separation according to the 
isoelectric point and to the size. Another possibility to improve the sensitivity, is to 
deplete the sample of high abundant proteins by immunoprecipitation [16, 17]. This 
however, bears the risk of depleting also substances and proteins which bind either to 
these high abundant proteins or non-specific to the carrier material [16, 18]. However, 
every purification and fractionation step is time consuming and accompanied by loss 
of analytes. Thus, leading to a demand of larger sample amounts. Therefore, an 
efficient assay has to compromise between high purity and fast preparation of small 
sample amounts.  
Depending on the sample preparation, two different types of MS analyses are 
distinguished: Top-down, which means analysis of whole proteins, or bottom-up in 
which case the proteins are digested enzymatically and MS-analysis takes place on the 
peptide level. Generally, it is more demanding to separate intact proteins than 
peptides for LC-MS approaches. [6] 
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The described approaches are well suitable for knowledge independent studies, for 
example to identify potential biomarkers or treatment-induced differences in the 
proteome. However, the identified proteins have to be validated in following studies 
[19]. Therefor knowledge driven MS-methods have been developed. These are selected 
reaction monitoring (SRM) and targeted selected ion monitoring (tSIM) as well as the 
multiplexed variants multiple reaction monitoring (MRM) and multiplexed tSIM 
(msx-tSIM) depending on the type of mass spectrometer. In both cases, parent ions are 
filtered for a certain mass-to-charge ratio, surveyed and fragmented for identification 
[15, 20]. Thereby increasing the number of scans and sensitivity of the measurement 
by one to two orders of magnitude in comparison to full-MS methods [20]. It also 
results in a linear correlation between peptide amount and signal with a dynamic 
range up to five orders of magnitude thereby allowing relative and absolute 
quantification [20].  
 
1.3 Quantitative proteomics 
The main objective of proteomics studies is not only to provide a list of proteins 
expressed under specific conditions but to quantify them, too [6]. The simplest method 
for relative quantification with a LC-MS setup is to compare extracted ion 
chromatograms of full-MS methods. SIM measurements improve the sensitivity by 
restricting the acquisition range to the mass-to-charge ratio of the target peptides. The 
quantification via SRM assays, on the other hand, is based on quantifying one or more 
fragments of the monitored peptide [20]. In each case, the method is based on 
quantifying a protein by analyzing one or more peptides thereof. Hence, the peptides 
have to be proteotypic, which means that its sequence is unique for one protein of the 
given species and can therefore be used as stoichiometric surrogate [20, 21]. Relative 
quantification can be improved and absolute quantification can be achieved by spiking 
isotopically labeled standards into the samples [15]. Coeluting standards correct for 
matrix effects such as ion suppression [20]. There are three types of standards used for 
absolute quantification: peptides (AQUA) and recombinant proteins (PSAQ) labeled 
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with stable isotopes. The third possibility is to use artificial concatemers, which can 
contain several labeled standard peptides (QconCAT) [15, 20, 22]. The type of standard 
defines at which step of the sample preparation the standard is added. While AQUA 
peptides are added after the enzymatic proteolysis, QconCATs and proteins are added 
before. This is done to diminish effects on the quantification by differing proteolysis 
efficiencies. However, it has been shown that peptides are often released more easily 
from QconCATs than from intact proteins [15, 23]. Labeled proteins can be spiked-in 
before the sample preparation in case of liquid samples or after lysis in case of tissues 
and cells. Thereby, using standard proteins allows to correct for analyte losses during 
fractionation and digestion. The earlier the spike-in of the reference substance, the 
more accurate the quantification will be [15]. However, production of high quality 
QconCAT and PSAQ standards is much more difficult than synthesizing AQUA 
peptides [15, 20]. The lower limits for quantification via LC-SRM assays is typically 
between 100 and 1000 ng protein per mL plasma. Sample through-put and sensitivity 
could be improved by enriching the proteins of interest during sample preparation or 
depleting high abundant proteins.  
 
1.4 MS-based read - out of immunoassays 
The enrichment of specific analytes during sample preparation is often done by 
immunoprecipitation. Typically, the antibodies are either immobilized on column 
material or the surface of beads is functionalized with the antibodies [24]. 
Functionalized columns can be used online, but complete analyte elution has to be 
ensured to avoid analyte carry-over. Functionalized beads, on the other hand, are not 
prone to carry-over between the samples, because the immunoprecipitation is 
performed offline and beads are not reused. Bead-based assays are especially 
convenient for low abundant proteins, because the reaction volume can be scaled up 
without scaling up the elution volume. Thereby the used sample volume becomes 
independent of the capacity of the analytical column [22]. 
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The enrichment can be performed either at the protein or the peptide level. Mass 
spectrometric immunoassays (MSIA) use antibodies which target intact proteins. They 
can be coupled to top-down and bottom-up MS methods [24, 25]. As with the 
quantification strategies, it is easier to produce short peptides for the immunization 
than intact proteins and for bottom-up approaches it is sufficient to enrich the 
proteotypic peptide chosen for MS quantification. This approach has been realized as 
stable isotope standards and capture by anti - peptide antibodies assays (SISCAPA) 
[26]. Analytes can be enriched up to 1000 - fold by SISCAPA thereby achieving 
quantification in the ng / mL range [15, 27]. Nevertheless, high quality sandwich 
immunoassays are still more sensitive (fg / mL) [24, 28, 29]. The advantage of MS-
based immnuoassays is that they are not hampered by unspecific bindings to the 
antibodies or the carrier material. Every analyte can be verified by the retention time, 
co-eluting standards and MS/MS before it is quantified. For this reason, it is also easier 
to multiplex MS-based immunoassays than sandwich immunoassays. With each 
additional analyte the background of the sandwich immunoassay is increased by 
cross-reactivity, while the analytes can still be quantified selectively by the MS-based 
read – out [21, 24].  
The major drawback of both methods is that at least one antibody has to be produced 
per protein of interest [24]. Therefore, group-specific antibodies have been developed. 
One approach is to generate antibodies addressing modified amino acids such as 
phosphorylated tyrosine independent of the surrounding amino acids. These 
antibodies can be used to investigate for example signaling cascades which rely on 
protein phosphorylation and dephosphorylation [30, 31]. Antibodies addressing 
modified amino acids can be used to enrich proteins as well as peptides [24, 30]. Global 
proteome survey (GPS) and triple X proteomics (TXP), on the other hand, are designed 
to enrich groups of peptides sharing the same C-terminal epitope. The subsequent LC-
MS measurement provides identification as well as quantification of the enriched 
peptides. [19, 24, 32-36].  
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1.5 Triple X proteomics (TXP) 
Triple X proteomics is a bottom-up approach based on the immunoaffinity enrichment 
with antibodies addressing short C-terminal epitopes of four amino acids [27]. The 
fifth and sixth position are not included during the antibody generation, but it has 
been shown that they can influence the binding. Certain amino acids seem to be 
favored in this positions, even though hardly any amino acid is excluded [22]. Since 
sample preparation always includes proteolysis with trypsin, a C-terminal arginine or 
lysine is an essential part of the epitope [19]. TXP epitopes are too short for peptide 
specific binding, instead they address dozens to hundreds of peptides of a digested 
proteome [37]. This property can be facilitated to reduce the number of antibodies 
needed in comparison to peptide- or protein-specific antibodies. Based on the 
UniProtKB reference proteome, a proteome-wide study in human would require more 
than 70’000 conventional antibodies. This could be reduced tenfold by using TXP 
antibodies [27]. In the context of group specific antibodies, the concepts of specificity 
and absence of cross-reactivity cannot be used to characterize the quality of TXP 
antibodies [35]. Most TXP antibodies do not only enrich the desired epitope but also 
variants thereof [19]. While this is problematic for immunoassays with colorimetric 
read-out, it just enlarges the number of proteins which can be examined with MS-
based read-outs. 
To date, the TXP approach is used for knowledge driven proteomics studies. The 
epitopes are chosen in a manner to cover the proteins of interest with the smallest set 
of antibodies possible [37]. This is especially applicable for sets of homologous proteins 
such as Cytochrome P450 enzymes and G-protein coupled receptors [22, 34, 36]. By 
choosing proteotypic peptides whose C-terminus is located in a conserved region, the 
peptides derived from the target proteins can be enriched with a small number of 
antibodies and still be identified and quantified by the LC-MS read-out [19, 22, 36]. It 
has been shown that the sensitivity of LC-SRM assays can be increased drastically by 
preceding TXP enrichment [36]. Additionally, tSIM and tSIM with data dependent 
MS/MS (dd MS/MS) have been tested as read-out. While dd MS/MS increases the 
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specificity, it also decreases the sensitivity. It has been shown that after TXP 
enrichment and in combination with a coeluting reference peptide, tSIM is already 
sufficient to identify and quantify the surrogate peptides [22]. 
With minor adjustments, the TXP workflow (Figure 1) is used in our laboratory for 
fluid sample types such as urine, plasma and serum as well as tissue and cell culture 
preparations [22, 38]. In the case of tissue and cell pellets, the samples have to be lysed 
first, taking care that the conditions solubilize all proteins of interest for example 
transmembrane proteins. The subsequent steps are the same for all sample types: they 
are proteolyzed with trypsin. Subsequently, stable isotope labeled peptides (IS 
peptides) are added as reference for the quantification. During bead-based 
immunoprecipitation, TXP antibodies enrich all endogenous peptides (EN) with the 
respective epitope as well as the spiked-in reference peptides. Finally, eluted peptides 
are detected and quantified by LC-MS read-out. Since all physicochemical properties 
but the mass of the according EN and IS peptide are identical, EN and IS peptide pairs 
are precipitated stochiometrically and coelute from the analytical column. Therefore, 
quantification via the IS peptide takes into account losses during 
immunoprecipitation, chromatographic separation and ionization [22]. 
 
Figure 1: Workflow of Triple X proteomics (TXP). The TXP methodology is applicable 
for several sample types such as tissue, cell culture preparation, b lood 
preparations and urine.  Tissue and cell pellets must be lysed first. The following 
steps are for all sample types the same: Proteins are enzymatically proteolyzed 
and isotopically labeled standard peptides are added. TXP antibodies coupled to 
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magnetic beads enrich all peptides comprising the according C-terminal epitope. 
S ubsequently, peptides are eluted and quantified via LC -MS . 
The advantage of using the TXP workflow is that the complexity of the biological 
sample is reduced drastically with one purification step and peptides of interest are 
enriched simultaneously. Thereby the peptide signals are increased and suppression 
effects are minimized while allowing short LC gradients at the same time. Overall, the 
assays become more sensitive and high throughput feasible [22, 36]. Additionally, the 
immunoprecipitation removes detergents with high efficiency [34], which makes the 
method more tolerant towards the conditions of sample lysis and proteolysis. 
Therefore, the TXP methodology is suitable for transmembrane proteins, which are 
very hydrophobic [24, 34, 36]. They are solubilized with detergents to make them 
available for proteolysis. The resulting peptides are better soluble than the intact 
proteins and suitable for reverse phase chromatography with less or ideally no 
detergent, which is removed during the precipitation. Furthermore, the bead-based 
approach is very applicable for low abundant proteins because the amount of antibody 
and sample can be scaled up independently of the capacity of the analytical column as 
long as the elution volume is kept constant [22].  
 
1.6 Cytochrome P450 enzymes  
Cytochrome P450 enzymes (CYP) are heme containing mixed - function oxidases 
which are evolutionary conserved [39-41]. Even though they can be found amongst 
others in bacteria, fungi, plants, insects, fish and mammals [40], the sequence identity 
of the superfamily is below 20 % [39]. However, topology and folding of the enzymes 
are conserved. It is composed of a four helices bundle and a signature sequence 
containing a conserved cysteine, which is the proximal ligand of the heme-iron [39]. 
Additionally, they contain a N-terminal membrane anchor and a discontinuous 
membrane binding site, which orients the substrate binding pocket and the heme in 
the catalytic domain towards the membrane surface [39, 42]. In general, CYPs bind an 
oxygen molecule via the iron of the prosthetic group. One oxygen atom is reduced to 
water, the other is introduced into a lipophilic substrate making it more polar. This can 
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result in hydroxylation, dealkylation or oxidation of the substrate [43]. The required 
electrons for the reduction are provided by NADPH and a reductase protein such as 
cytochrome P450 reductase [44, 45]. 
CYPs are classified according to their sequence identity. The CYP superfamily is 
divided into families, which are denoted by a number, and subfamilies, which are 
indicated by letters. The individual proteins of a subfamily are numbered 
consecutively. Proteins of the same family share over 40 % of their primary structure 
and subfamilies over 55 % in the case of mammalians [43, 46]. For some isoforms, there 
are homologs in other species, they were named accordingly, otherwise the isoforms 
were numbered in the order of their discovery irrespective of the species [46]. In case 
of gene clusters there are not always exact orthologs for every gene [46, 47]. In the 
human genome 57 CYPs have been identified, 87 in rats and 102 in mice [41, 47]. 
Examples for orthologous CYPs from are listed in Table 1 [47, 48]: 
 
Table 1: Selected orthologous CYP genes in human, rat and mouse [47, 48]. 
human rat mouse 
CYP1A1 Cyp1a1 Cyp1a1 
CYP1A2 Cyp1a2 Cyp1a2 
CYP2B6 
Cyp2b1 Cyp2b10 
Cyp2b2 Cyp2b13 
Cyp2b3 Cyp2b9 
Cyp2b12 
Cyp2b19 Cyp2b15 
Cyp2b31 
Cyp2b21 Cyp2b23 
CYP2C8 
Cyp2c55 Cyp2c55 
CYP2C9 
CYP2C18 
CYP2C19 
CYP2E1 Cyp2e1 Cyp2e1 
CYP3A4 
Cyp3a9 Cyp3a13 CYP3A5 
CYP3A7 
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In mammals, CYPs are located at the cytosolic side of the endoplasmic reticulum and 
the inner membrane of the mitochondria and serve two major functions [42]. While all 
CYP families are part of the biosynthesis and metabolism of endogenous substances 
such as hormones, bile acids and vitamins, the CYP families 1, 2 and 3 are major parts 
of the oxidative metabolism of xenobiotics [42, 43].  
The subfamily Cyp1a consists of two proteins in human, mouse and rat which are 
highly conserved. Cyp1a1 and Cyp1a2 recognize planar substances like polycyclic 
aromatic hydrocarbons and arylamines as substrates. Similarly, Cyp1b1 and Cyp2e1 
are strongly conserved between species and are the only members of their respective 
subfamily. The Cyp2a subfamily includes three human, three rattine and four murine 
isoforms. Even though, CYPs are classified across species, minor differences may lead 
to drastic changes in substrate specificity and catalytic activity. The rodent Cyp2a 
isoforms, for example, catalyze the hydroxylation of steroids, while human Cyp2a6 
oxidizes substances like aflatoxin B1 and nicotine and shows a great substrate overlap 
with Cyp2e1. Cyp2c is the most diverse subfamily harboring four human, seven rattine 
and nine murine enzymes. As for Cyp2a, the substrate specificities differ greatly 
between human and rodent Cyp2c isoforms. Additionally, the expression of some 
isoforms is gender dependent in adult rats: Cyp2c12 and Cyp2c13 are female – and 
male – specific isoforms respectively. [43] 
The subfamily Cyp3a recognizes a very broad range of substrates and is therefore very 
important in xenobiotic metabolism. Humans express four and rats and mice each 
express six Cyp3a isoforms [43]. It was estimated that together, CYPs are involved in 
the metabolism of 70 -80 % of all clinically used drugs [41]. 
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1.7 Transporters 
Transporters control the traffic of substances such as sugars, amino acids, inorganic 
ions and xenobiotics across membranes [49]. There are estimations that 2-5 % of the 
human genes are transporters or transport related proteins [49, 50]. They can be 
divided into five groups: Channels, carriers, group translocators and primary as well 
as secondary active transporters. Channels and carriers facilitate protein-media ted 
diffusion in the direction of a concentration gradient. Primary active transporters use 
a direct energy source such as ATP hydrolysis or light to transport substrates and 
generate a concentration gradient. Secondary active transporters can also give rise to 
a concentration gradient, but they use a secondary source of energy such as proton or 
sodium gradients which are maintained using primary energy sources. Group 
translocators modify their substrates in the course of the transport [51]. In the 
following ATP-binding cassette (ABC) transporters and solute carriers (SLC) which 
are primary and secondary active transporters respectively, will be discussed.  
The nomenclature of the CYP superfamily has been transferred to other gene families 
including the ABC and SLC transporter families [49, 50, 52]. A letter identifies the 
subfamily and a consecutive number the individual transporter in case of the ABC 
transporters [52]. For SLC transporters, the families are indicated by Arabic numerals 
followed by an A as spacer and a number identifying the individual transporter. In 
contrast to CYPs, SLC proteins with more than 20 % amino acid identity are already 
assigned into the same family [49]. The subfamily SLC21 has been renamed to SLCO 
to be able to classify its members exactly like CYPs [53]. For the proteins, the 
nomenclature is not well standardized. For most proteins, several synonyms are in 
use. Therefore, all CYPs and transporters discussed in this thesis are identified by the 
UniProt ID in the supplemental information (Table 56).  
In general, ABC transporters have four conserved domains and can be found in all 
living organisms [50, 54]: Two transmembrane domains, which consist of six helices 
and two intracellular nucleotide binding domains containing the ATP – binding 
cassette. The multidrug resistance associated proteins MRP1, MRP2 and MRP3 differ 
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in that respect that they have an additional N-terminal transmembrane domain 
consisting of five helices [50, 54]. The breast-cancer-resistance-protein (BCRP), on the 
other hand, is a half-transporter. It consists of one transmembrane domain and one 
nucleotide binding domain. Therefore, it has to form a dimer to become functional [50, 
54, 55]. ABC transporters are efflux pumps, which use the consecutive hydrolysis of 
two ATP molecules to transport their substrates independent of concentration 
gradients [50, 51, 55]. So far 49 different ABC transporters which belong to seven 
subfamilies have been described in humans: Multidrug resistance protein 1 (MDR1) 
and bile salt export pump (BSEP) are the most prominent of the ABCB family. They 
are located in the apical membrane of the cells and transport various hydrophobic and 
cationic substances such as phenobarbital (PB) and bile acids respectively [50, 56]. It 
has been reported that the amount of MDR1 can differ 50-fold in humans [56, 57]. In 
contrast to humans, rodents have two closely related isoforms of MDR1 [50, 56]. They 
have overlapping expression patterns, but while the loss of Mdr1b can be compensated 
by Mdr1a in knockout mice, Mdr1a is essential for the maintenance of the blood – 
brain – barrier [58-61]. The ABCC family consists of twelve members in humans, nine 
of which are transporters [50]. The gene products are designated multidrug resistance 
associated proteins (MRP). MRP1 is located in the basolateral membrane and 
transports organic anions such as glutathione conjugates as well as positive and 
neutral amphiphilic substances. In addition, it can also co-transport ions with 
unconjugated glutathione [50, 55, 56]. MRP2, on the other hand, has a similar substrate 
specificity as MRP1 but is located in the apical membrane. Like BSEP, it is involved in 
the secretion of bile acids. In contrast to BSEP, MRP2 only transports sulfated bile acids 
[50]. The basolaterally expressed MRP3 transports similar substances to MRP1, MRP2 
and BSEP, but binds them with a lower affinity. In contrast, MRP4 is localized 
differentially. In the liver, it is expressed basolaterally and apically in the kidney. 
Thereby, facilitating the clearance of a substance from the liver via the blood into the 
urine. [50].  
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In contrast to the ABC transporters, the SLC transporter superfamily consists of at least 
43 families and the structure has yet to be resolved [49, 62]. For the SLC22A family, 
twelve alpha-helical transmembrane segments are predicted with intracellularly 
located N- and C-termini as well as intracellular consensus sequences for 
phosphorylation [63, 64]. The family consists of organic anion transporters (OAT) and 
organic cation transporters (OCT) as well as zwitterion/cation transporters (OCTN). 
They can function as uniporters, symporters or antiporters [51, 64]. In case of the 
symporters and antiporters, they utilize an existing gradient to drive uphill transport 
of one substrate [65]. OAT1, OAT3 and OAT4 are examples of antiporters. They 
mediate the uptake of extracellular substances such as prostaglandins in exchange for 
2-oxoglutarate [64, 66]. OAT1 and OAT3 are expressed basolaterally while OAT4 is 
expressed apically. Together, they are involved for example in the renal excretion and 
reabsorption process of prostaglandins [64]. The members of the SLCO family, on the 
other hand, transport amphiphilic organic substances such as bile acids and steroid 
conjugates in exchange for intracellular substances such as bicarbonate [66]. While in 
the intestinal tract, SLCO transporters are expressed in the luminal membrane, they 
mediate uptake from the blood in hepatocytes, proximal tubule cells and the 
endothelial cells of the brain capillaries [62]. In contrast to other transporter families, 
they are not conserved well between species and for some human SLCO transporters, 
there are no orthologs described in rodents, yet [66].  
In summary, it can be said, that there is a great overlap in the substrate specificity of 
individual transporters within transporter families as well as between ABC and SLC 
transporters. This allows the net movement of substances through cells as well as from 
one organ to another [50, 62]. But it may also allow very tight regulation and 
specialization by expressing transporters with similar but different substrate 
specificities and affinities only in specific tissues or subcellular localizations [63]. 
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1.8 Regulation of CYP and transporter expression 
The tightly regulated expression of CYPs and transporters has already been addressed 
in the context of subcellular localization and organ differences. But they are also 
differentially expressed within organs. For murine kidney for example it has been 
shown that MRP1 is expressed in cells of Henle’s loop and the cortical collecting duct 
but not proximal tubular cells [50, 67]. Even though it is not as obvious as in the kidney, 
the liver tissue is also not uniform. The liver is composed of structural and functional 
units called lobules. The afferent blood vessels, the portal vein and the hepatic artery, 
are localized at the corners of the lobule and the efferent central vein in the middle. 
Along the blood flow, the hepatocytes can be divided into periportal, midzonal and 
pericentral cells [68-70]. The hepatocytes differ also with respect to their expression 
pattern and metabolic activity. Bile synthesis and glutamine synthesis is restricted to 
pericentral hepatocytes, while cholesterol synthesis is restricted to periportal cells. 
Gluconeogenesis and fatty acid degradation, on the other hand, take place in all 
hepatocytes but is gradually reduced in the direction of pericentral cells. Glycolysis is 
regulated contrarily and picks up towards the pericentral hepatocytes [68]. The 
expression of enzymes belonging to the xenobiotic metabolism, on the other hand, is 
dynamic. Under normal conditions they are expressed in a few layers of pericentral 
hepatocytes, but the expression can expand toward the periportal cells in the presence 
of inducing agents such as phenobarbital. [69] 
The xenobiotic metabolism is highly adaptable to environmental influences such as 
food components. Two receptor types are mainly involved in the regulation of the 
xenobiotic metabolism which are also transcription factors: The aryl hydrocarbon 
receptor (AhR) and orphan nuclear receptors [71]. The AhR binds next to halogenated 
aryl hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) also other 
hydrocarbon ring systems such as polychlorinated biphenyls (PCB) and prochloraz 
(Prz) as long as they can assume a planar conformation [71-73]. The AhR is a cytosolic 
receptor which translocates into the nucleus upon ligand binding. There it dimerizes 
with Ah receptor nuclear translocator (Arnt), which is restricted to the nucleus. The 
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translocation of AhR to the nucleus does not dependent on Arnt, but the dimerization 
is required for DNA binding [71]. The expression of Cyp1a and Cyp1b1 as well as 
BCRP, BSEP, NTCP and MDR1 is influenced by AhR (Table 2) [43, 50, 74]. 
 
Table 2: Regulation of CYP and transporter expression by nuclear receptors.  CAR, PXR 
and AhR can induce as well as repress the expression of CYPs and transporters. 
Target genes are indicated in italics, the according protein in brackets.  
gene (protein) CAR PXR AhR 
 Abcg2 (BCRP) induction [74] induction [74] induction [74] 
Abcb11 (BSEP) repression [74] repression [74] repression [74] 
Cyp1a (Cyp1a)   induction [50] 
Cyp1b1 (Cyp1b1)   induction [43] 
Cyp2a5/6 (Cyp2a5/6) induction [43] induction [43]  
Cyp2b (Cyp2b) induction [43, 50] induction [43]  
Cyp3a (Cyp3a) induction [43] induction [43]  
Abcb1 (MDR1) induction [74] induction [56, 74] induction [74] 
Abcc2 (MRP2) induction [74] 
induction [74] 
repression [50] 
 
Abcc3 (MRP3) induction [50] induction [74]  
Slc10a1 (NTCP) repression [74] repression [74] repression [74] 
Slc22a7 (OAT2) repression [65, 74] repression [74] repression [74] 
Slc22a1 (OCT1) repression [74] repression [74] repression [74] 
SLCO1B3 (SLCO1B3) repression [74]  repression [74] 
SLCO2B1 (SLCO2B1) repression [74] induction [74] repression [74] 
 
Orphan nuclear receptors bind steroid based ligands and consist of a highly conserved 
DNA-binding domain and a ligand binding domain. Pregnane X receptor (PXR), 
constitutive androstane receptor (CAR) and retinoid X receptors (RXR) are examples 
for orphan nuclear receptors. While RXR can also bind as homodimer to its response 
element, CAR and PXR form heterodimers with RXR. CAR, PXR and RXRα are 
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predominantly expressed in the liver [71], which is the main site for xenobiotic 
metabolism [43]. Like AhR, CAR and PXR translocate into the nucleus subsequently 
to ligand binding [75]. While PB and rifampicin are model agonists of CAR and PXR 
respectively [75], there are also substances which can activate both receptors such as 
Clotrimazole and the azole fungicides cyproconazole (Cypro) and epoxiconazole 
(Epoxi) [73, 76]. PXR and CAR address overlapping targets such as Abcg2, Abcb1, Cyp2b 
and Cyp3a (Table 2) [43, 74].  
The expression pattern cannot only be influenced by environmental impacts but it can 
also be changed under pathological conditions. OCT1 has been reported to be down 
regulated in the liver during obstructive cholestasis [63]. The expression pattern of 
tumors can also be very different from the surrounding tissue. Cyp1b1, for example, 
is expressed much higher in breast cancer than the surrounding tissue [43]. In the 
context of multidrug resistance, ABC – transporters are frequently found to be 
overexpressed [55, 56, 77]. 
 
1.9 Biological and medical relevance of CYPs and transporters 
CYPs and transporters are involved in processes, such as xenobiotic metabolism, 
barrier maintenance, bioavailability, drug-drug interaction and multidrug resistance 
[55, 71, 78-82]. The xenobiotic metabolism can be divided into four steps. First, the 
substances have to enter the cell to enable intracellular metabolism. This is 
dramatically accelerated by uptake transporters such as SLC22 transporters [64]. 
During phase I a functional group is introduced into the substrates by oxygenases. 
Among others, Flavin – containing monooxygenases, monoamine oxidases and CYPs 
are counted to the phase I enzymes. Phase II enzymes include transferases such as 
sulfotransferases, glutathione S-transferases, UDP-glucuronosyltransferases and N-
acetyl transferases, but also epoxide hydrolases and reductases. The conjugated 
products of the phase II metabolism are in general better soluble. Thereby phase II 
metabolism improves the excretion via urine and bile. Phase III describes the secretion 
of the metabolized xenobiotics into the blood or the bile. This is mediated by export 
Introduction 
17 
transporters such as MDR1 and MRP proteins. Secretion into the blood ultimately 
leads to excretion via renal clearance. [71] 
Chemotherapeutics are common drugs for the treatment of cancer. However, while 
some patients can be cured, others respond temporarily or incompletely. This 
phenomenon is called cancer drug resistance[55]. It can be due to impaired drug 
delivery or to genetic or epigenetic alterations of the tumor cells [55, 83]. Cellular drug 
resistance is often gained during treatment and shows cross-resistance to other 
therapeutics which is called multidrug resistance. The classical multidrug resistance is 
mediated by overexpression of ATP transporters such as MDR1 and MRP which 
reduces the drug concentration in the tumor cell drastically [55, 83, 84]. The same effect 
is achieved by down-regulating influx transporters and inducing detoxifying enzymes 
such CYPs. Additionally, the tumors cells become more resistant by increasing the 
DNA repair and evading apoptosis. [55] 
CYPs and transporters have great impact on the pharmacokinetic and the toxicity of a 
substance. At the same time, drugs can change the expression levels of CYPs and 
transporters as well as act as inhibitors. Thereby they also change their own 
bioavailability, metabolism and elimination as well as the pharmacokinetics of co-
administered drugs. Therefor they are examined thoroughly during drug 
development [85-87]. In the preclinical phase, in vitro as well as animal in vivo models 
are used to predict kinetics and toxicity in man [43, 85, 88]. However, even though 
CYPs and transporters are highly conserved, the exchange of one amino acid can alter 
the substrate specificity and the catalytic activity [43]. Therefore, it is important to 
choose the right animal model with respect to the drug metabolism as well as the study 
objective. Drug development involves studies in mouse, rat, rabbit, dog, pig, monkey 
and man [85]. In addition, humanized mouse models have become important in recent 
years [89]. 
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2  Objective 
The objective was to develop TXP assays for the quantification of CYPs and 
transporters. Based on previously developed assays for human CYPs [22], TXP assays 
for human, rat and mouse ABC and SLC transporters should be developed. 
Additionally, the approach was expanded to also address CYPs in rat and mouse. 
The TXP methodology is very suitable for the quantification of CYPs and transporters. 
Both protein classes consist of very homologous superfamilies. They can be addressed 
efficiently by TXP antibodies by choosing conserved epitopes. At the same time, the 
methodology is not limited by unspecific antibody binding because of the MS – based 
read – out. The immunoprecipitation with TXP antibodies is a sample preparation 
method which allows to address very low abundant analytes like transporters as well 
as highly inducible proteins like CYPs. Additionally, by addressing surrogate peptides 
instead of proteins, solubility issues of intact transmembrane proteins such as 
transporters are circumvented. Furthermore, conserved TXP epitopes cannot only be 
used to address several proteins in the same species with one antibody, but to analyze 
target proteins in several species using the same antibody.  
The project included the selection of suitable TXP epitopes, the development of 
multiplexed TXP assays as well as the analysis of several studies in man, rat and mouse 
(Figure 2). The developed assays were applied to compare the protein expression 
profiles of sample sets, e.g. normal versus tumor tissue, as well as to investigate the 
induction potential of fungicides in different in-vitro and in-vivo models. 
  
Figure 2: Workflow of the TXP assay development.
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3 Materials and Methods 
3.1 Materials 
3.1.1 Expendable items 
Table 3: Expendable items 
Item  Type denotation Manufacturer  
96 tip comb for PCR magnets KingFisher®™ 96 tip comb 
Thermo Fisher Scientific, 
Waltham, MA, USA 
analytical column 
Acclaim PepMap RSLC 75 µm x 15 
cm, nanoViper 
Thermo Fisher Scientific, 
Waltham, MA, USA 
autosampler glass bottle 
Vial short thread, 1.5 mL, amber 
glass + label 
VWR, Darmstadt, DE 
autosampler glass insert 
Micro-Insert, 0.1 mL, clear glass 
15mm, top 
VWR, Darmstadt, DE 
Disposable bag  Sarstedt. Nümbrecht, DE 
glass bottle 500 mL, 1000mL 
DURAN® Laboratory bottle with 
DIN thread, GL 45 
Duran Group GmbH, 
Wertheim/Main, DE 
Glass pasteur pipette  WU Mainz, Mainz, DE 
Heat Sealing Foil Sheets Peelable Heat Sealing Foil Sheets 
Thermo Fisher Scientific, 
Waltham, MA, USA 
hypodermic needles on Luer 
connectors 
Sterican® Gr. 1, G 20 x 1 1/2" / ø 0,90 
x 40 mm 
B. Braun Melsungen AG, 
Melsungen, DE 
Ligand-Coupled magnetic beads Dynabeads® Protein G 
Thermo Fisher Scientific, 
Waltham, MA, USA 
Microplate sealing tape  Axygen® AxySeal 
Corning Incorporated, 
Corning, NY, USA 
microtiter plate, 96 well, F bottom 
Microplate, 96 well, PS, F-Bottom, 
clear 
Greiner Bio-One, 
Frickenhausen, DE 
microtiter plate, 96 well, V 
bottom 
0.2 mL Skirted 96-well Robotic Plate 
Thermo Fisher Scientific, 
Waltham, MA, USA 
nano electrospray emitter Stainless Steel Nano-bore emitters 
Thermo Fisher Scientific, 
Waltham, MA, USA 
Needle collecting box Medibox  
B. Braun Melsungen AG,  
Melsungen, DE 
nitrile gloves 
Nitrile, unsterile, powder free, 
structured surface 
VWR, Darmstadt, DE 
pH indicator paper Universal indicator paper pH 1-14 Carl Roth, Karlsruhe, DE 
pipette tips 10 µL epT.I.P.S. Standard 0.1-10 µL Eppendorf, Hamburg, DE 
pipette tips 1000 µL  epT.I.P.S. Standard 50-1000 µL Eppendorf, Hamburg, DE 
pipette tips 1200 µL  
Tips, 1250 µL, QUICKRACK Tip 
Transfer System 
Biozym Scientific, Hessisch 
Oldendorf, DE 
pipette tips 200 µL epT.I.P.S. Standard 2-200 µL Eppendorf, Hamburg, DE 
pipette tips 250 µL LTS tips 250 µL 
Mettler-Toledo, Columbus, 
OH, USA 
pipette tips 300 µL LTS tips 300 µL 
Mettler-Toledo, Columbus, 
OH, USA 
pipette tips 5000 µL epT.I.P.S. Standard 100-5000 µL Eppendorf, Hamburg, DE 
Materials and Methods 
22 
Item  Type denotation Manufacturer  
pipette tips for positive 
displacement pipette 
25 µL Drummond Microdispenser 
Replacement tubes 
Drummond Scientific 
Company, Broomall, PA, 
USA 
plastic medical syringe, 2 mL Injekt®-F 
B. Braun Melsungen AG,  
Melsungen, DE 
Plastic bottles 
Wash Bottles Narrow-Neck, 
Technical Grade-PFA 
Brand GMBH + CO KG, 
Wertheim, DE 
Precolumn 
µ-Precolumn 300µm i.d. x 5 mm 
C18 PepMap 100, 5 µm, 100 Å 
Thermo Fisher Scientific, 
Waltham, MA, USA 
reaction tube 0.2 mL PCR Tube Strips 0.2 mL Eppendorf, Hamburg, DE 
reaction tube 0.65 mL Mµlti®-safety microcentrifuge tubes Carl Roth, Karlsruhe, DE 
reaction tube 1.5 mL Eppendorf Tubes® 3810X Eppendorf, Hamburg, DE 
reaction tube 15 mL 
Cellstar tubes, 15 mL, PP, 
graduated, conical bottom 
Greiner, Frickenhausen, 
DE 
reaction tube 50 mL 
Cellstar tubes, 50 mL, PP, 
graduated, conical bottom with 
support 
Greiner, Frickenhausen, 
DE 
screw cap for autosampler glass 
bottle 
PP screw cap 9 mm, tr. Natural 
Rubber red-orange/TEF, 1mm 
VWR, Darmstadt, DE 
screw cap for reaction tubes (1.5 
mL and 2 mL) 
screw cap neoLab, Heidelberg, DE 
screw cap glass bottle GL 45 Screw Caps 
Duran Group GmbH, 
Wertheim/Main, DE 
screw cap reaction tube 1.5 mL 
neoLab-Reaction vessels with screw 
thread, 1.5 ml, conical 
neoLab, Heidelberg, DE 
screw cap reaction tube 2 mL 
neoLab-Reaction vessels with screw 
thread, 2.0 ml, self-standing 
neoLab, Heidelberg, DE 
 
 
3.1.2 Chemicals and Biochemicals 
Table 4: Chemicals and Biochemicals 
Reagent Abbreviation Manufacturer 
2-Propanol, LC-MS Grade IPA BioSolve BV, Valkenswaard, NL 
3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate 
Chaps Carl Roth, Karlsruhe, DE 
Acetic Acid 100 %  Carl Roth, Karlsruhe, DE 
Acetonitrile, LC-MS Grade ACN LGC Promochem, Wesel, DE 
Albumin fraction V (protease-free) BSA Carl Roth, Karlsruhe, DE 
Ammonia solution 25 %, Rotipuran  Carl Roth, Karlsruhe, DE 
Ammonium bicarbonate ABC Sigma-Aldrich, St. Louis, MO, USA 
Benzonase Nuclease, >99 % purity  Merck, Darmstadt, DE 
Blocking Reagent for ELISA  Roche Diagnostics, Mannheim, DE 
Complete (protease inhibitor cocktail) tablets Complete Roche Diagnostics, Mannheim, DE 
Customized polyclonal antibody sera  
Pineda Antikörper Service, Berlin, 
DE 
Customized synthetic standard peptides  Intavis AG, Tübingen, DE 
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Reagent Abbreviation Manufacturer 
Deoxycholic Acid sodium salt DOC Carl Roth, Karlsruhe, DE 
Dimethyl sulfoxide DMSO Sigma-Aldrich, St. Louis, MO, USA 
Dionex™ Cytochrome C Digest  
Thermo Fisher Scientific, Waltham, 
MA, USA 
Di-sodium hydrogen phosphate 2-Hydrate  Carl Roth, Karlsruhe, DE 
Ethylenediamine tetraacetic acid EDTA Carl Roth, Karlsruhe, DE 
Formic Acid, 99 % FA 
Thermo Fisher Scientific, Waltham, 
MA, USA 
Hydrochloric acid fuming 37 % HCl Carl Roth, Karlsruhe, DE 
Iodoacetamide IAA Sigma-Aldrich, St. Louis, MO, USA 
LTQ Velos ESI Positive Calibration Solution  
Thermo Scientific, Waltham, MA, 
USA 
Magnesium chloride  Sigma-Aldrich, St. Louis, MO, USA 
Methanol, ROTISOLV  Carl Roth, Karlsruhe, DE 
n-octyl-β-glucopyranoside NOG AppliChem, Darmstadt, DE 
NP40 Surfact Amps Detergent Solution NP-40 
Thermo Scientific, Waltham, MA, 
USA 
phenylmethanesulfonyl fluoride PMSF Roche Diagnostics, Mannheim, DE 
Phosphate Buffered Saline, 10x PBS 
Thermo Fisher Scientific, Waltham, 
MA, USA 
Pierce Trypsin Protease, MS-Grade  
Thermo Fisher Scientific, Waltham, 
MA, USA 
Pierce™ BCA Protein Assay Kit  
Thermo Scientific, Waltham, MA, 
USA 
Sequencing Grade Modified Trypsin (with 
50 mM Acetic acid as resuspension buffer) 
 Promega Corporation, Fitchburg, WI, 
USA 
Sodium bicarbonate  Merck, Darmstadt, DE 
Sodium chloride NaCl Carl Roth, Karlsruhe, DE 
Sodium dihydrogen phosphate dihydrate  Carl Roth, Karlsruhe, DE 
Sodium dodecyl sulfate SDS Sigma-Aldrich, St. Louis, MO, USA 
Sodium hydroxide NaOH Carl Roth, Karlsruhe, DE 
Technical buffer solution pH 4.01  Mettler-Toledo, Columbus, OH, USA 
Technical buffer solution pH 7.00  Mettler-Toledo, Columbus, OH, USA 
Technical buffer solution pH 9.21  Mettler-Toledo, Columbus, OH, USA 
Triethanolamine TEA Carl Roth, Karlsruhe, DE 
Trifluoroacetic acid ULC/MS Optigrade TFA LGC Promochem, Wesel, DE 
Tris(2-carboxyethyl)phosphine TCEP Carl Roth, Karlsruhe, DE 
Triton X-100 Surfact Amps Detergent 
Solution 
 Thermo Scientific, Waltham, MA, 
USA 
Trypsin from bovine pancreas  Sigma-Aldrich, St. Louis, MO, USA 
Water (LC-MS grade)  Carl Roth, Karlsruhe, DE 
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3.1.3 Laboratory equipment 
Table 5: Laboratory equipment 
Apparatus Type denotation Manufacturer 
analytical balance explorer 
OHAUS Waagen, Bad Hersfeld, 
Deutschland 
analytical balance CPA225D-0CE 
Sartorius Stedim Biotech, Göttingen, 
DE 
Automated magnetic-particle 
processor 
KingFisher™ 96 
Thermo Scientific, Waltham, MA, 
USA 
Automated magnetic-particle 
processor 
KingFisher™ Flex 
Purification System 
Thermo Scientific, Waltham, MA, 
USA 
Ball mill Mikro-Disembrator U Sartorius, Göttingen, DE 
centrifuge for PCR plates Universal 30 F Hettich, Tuttlingen, DE 
centrifuge for PCR tubes MiniStar silverline VWR, Darmstadt, DE 
centrifuge for reaction tubes 
Rotilabo®-mini-
centrifuge "Uni-fuge" 
Carl Roth, Karlsruhe, DE 
centrifuge for reaction tubes 5415 D Eppendorf, Hamburg, DE 
centrifuge for reaction tubes and 
PCR plates, cooled 
5810R Eppendorf, Hamburg, DE 
centrifuge for reaction tubes, 
cooled 
5417 R Eppendorf, Hamburg, DE 
Electronic Pipette 5-200µL eppendorf research pro Eppendorf, Hamburg, DE 
Electronic Pipette 5-300µL E4 XLS Mettler-Toledo, Columbus, OH, USA 
Filter-based multi-mode 
microplate reader 
FLUOstar Optima 
Microplate Reader 
BMG Labtech, Ortenberg, DE 
Flake ice maker Scotman AF40 Frimont S.p.A., Pogliano Milanese, IT 
heat sealer 
Abgene Combi Thermo 
Plate Heat Sealer 
Thermo Scientific, Waltham, MA, 
USA 
magnet for microtiter plate Dynal -96 Side Skirted 
Thermo Scientific, Waltham, MA, 
USA 
Magnet for of Dynabeads in 
1.5mL reaction tubes 
DynaMag Spin 
Thermo Scientific, Waltham, MA, 
USA 
Magnetic comb for King Fisher 
system 
KingFisher®™ 96  PCR 
head 
Thermo Scientific, Waltham, MA, 
USA 
Magnetic stirrer RCT basic IKA®-Werke, Staufen, DE 
Mass Spectrometer 
Q Exactive™ - Orbitrap 
Mass Spectrometer 
Thermo Scientific, Waltham, MA, 
USA 
Mass Spectrometer 
Q Exactive Plus™ - 
Orbitrap Mass 
Spectrometer 
Thermo Scientific, Waltham, MA, 
USA 
micropipette  0.1 - 2.5 µL eppendorf research Eppendorf, Hamburg, DE 
micropipette  1 - 10 µL eppendorf research Eppendorf, Hamburg, DE 
micropipette  10 - 100 µL eppendorf research Eppendorf, Hamburg, DE 
micropipette  100 - 1000 µL eppendorf research Eppendorf, Hamburg, DE 
micropipette  2 - 20 µL eppendorf research Eppendorf, Hamburg, DE 
micropipette  20 - 200 µL eppendorf research Eppendorf, Hamburg, DE 
micropipette  50 - 5000 µL eppendorf research Eppendorf, Hamburg, DE 
Multichannel Electronic Pipette 
1-10µL 
eppendorf research pro Eppendorf, Hamburg, DE 
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Apparatus Type denotation Manufacturer 
Multichannel Electronic Pipette 
50-1200µL 
eppendorf research pro Eppendorf, Hamburg, DE 
Multichannel Electronic Pipette 
5-200µL 
eppendorf research pro Eppendorf, Hamburg, DE 
Multichannel Pipette 5-50µL Pipet-Lite XLS Mettler-Toledo, Columbus, OH, USA 
pH-meter pH-Meter 766 Knick, Berlin, DE 
porcelain mortar 
mortar with spout, 
glazed, Size 0 a 
Morgan Advanced Materials 
Haldenwanger GmbH, 
Waldkraiburg, DE 
porcelain pestles 
pestle, grinding surface 
unglazed, size 0 a 
Morgan Advanced Materials 
Haldenwanger GmbH, 
Waldkraiburg, DE 
positive displacement pipette 2-25 
µL 
Positive Displacement 
Digital Microdispensers 
Drummond Scientific Company, 
Broomall, PA, USA 
Rotating mixer RM5 Assistent, Sondheim, DE 
shaking incubator with 
temperature control 
Thermo Mixer Comfort Eppendorf, Hamburg, DE 
Sonication bath  Sonorex RK 31 Bandelin, Berlin, DE 
Sonication bath  Transsonic T780/H Elma, Singen, DE 
SWC Safety Weighing Cabinet 
SWC Safety Weighing 
Cabinet 
Sartorius Stedim Biotech, Göttingen, 
DE 
Ultra High Performance Liquid 
Chromatography System 
UltiMate 3000 RSLCnano 
System 
Thermo Scientific, Waltham, MA, 
USA 
vibrating and rotating sample 
mixer 
Hulamixer Sample mixer 
Life Technologies, Carlsbad, CA, 
USA 
vortex mixer Vortex-Genie 2 
Scientific Industries, Bohemia, NY, 
USA 
Water purification system Milli Q Plus Merck Millipore, Billerica, MA, USA 
Water purification system arium® 611VF 
Sartorius Stedim Biotech, Göttingen, 
DE 
 
 
3.1.4 Software 
Table 6: Software 
Software Distributor 
Adobe Illustrator CS5 Adobe, San Jose, CA, USA 
Adobe Photoshop CS5 Adobe, San Jose, CA, USA 
Chromeleon 6.8 Thermo Scientific, Waltham, MA, USA 
Chromeleon Client 6.8 Thermo Scientific, Waltham, MA, USA 
Endnote X7 Thomson, Philadelphia, PA, USA 
etiLABEL ETISOFT, Delmenhorst, DE 
MS Office 2010, 2013 and 2016 Microsoft, Redmond, WA, USA 
Origin 2015G OriginLab Corporation, Northampton, MA, USA 
Pinpoint 1.4 Thermo Scientific, Waltham, MA, USA 
Proteome Discoverer 1.3 Thermo Scientific, Waltham, MA, USA 
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Skyline 3.5.0.9319 
MacCoss Lab, Department of genome sciences, University of 
Washington, Seattle, WA, USA 
Tune 2.5 Thermo Scientific, Waltham, MA, USA 
TXP-Tools Internal script by Hannes Planatscher 
ultraVNC viewer 1.2.0.4 www.uvnc.com 
Windows XP, Windows 7 Microsoft, Redmond, WA, USA 
Xcalibur 3.0 Thermo Scientific, Waltham, MA, USA 
 
 
3.1.5 Databases 
Table 7: Databases 
Database Date Distributor 
Mascot Version 2.3.02 Matrix Science Ltd., London, GB 
PaxDb (Protein 
Abundance Database) 
Version 4 University of Zurich, Zurich, CH 
SEQUEST Version 28.0.0.0 University of Washington, Seattle, WA, USA 
unigene September 2015  
National Center for Biotechnology Information, 
U.S. National Library of Medicine, Bethesda, MD, 
USA  
UniProtKB (UniProt 
Knowledgebase) 
specified in the 
figure legends 
UniProt Consortium  
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3.1.6 Buffers and solutions 
3.1.6.1 Lysis 
Table 8: SDS stock solution 
reagent final concentration 
SDS  10 % (w/v) 
d. water  
 
 
 
Table 9: Lysis buffer 1 -/- 
reagent final concentration 
Triton (10 % (v/v)) 0.5 % (v/v) 
SDS (10 % (w/v)) 0.01 % (v/v) 
NaCl 0.15 M 
Sodium dihydrogen phosphate dihydrate 0.01 M 
EDTA 0.002 M 
d. water  
pH  7.2 
 
 
 
Table 10: Protease- Inhibitor stock solution 
reagent final concentration 
Complete 10 x 
Lysis buffer X -/-  
 
 
 
Table 11: Lysis buffer 1 +/- 
reagent final concentration 
Protease- Inhibitor stock solution 1 x 
Lysis buffer 1 -/-  
 
 
 
Table 12: Lysis buffer 1 +/+ 
reagent final concentration 
Benzonase 1 U 
Lysis buffer 1 +/-  
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Table 13: Lysis buffer 2 -/- 
reagent final concentration 
NP-40 (10 % (w/v)) 1 % (v/v) 
SDS (10 % (w/v)) 0.01 % (v/v) 
NaCl 0.15 M 
Sodium dihydrogen phosphate dihydrate 0.01 M 
EDTA 0.002 M 
d. water  
pH  7.2 
 
 
 
Table 14: Lysis buffer 2 +/- 
reagent final concentration 
Complete 1 x 
Lysis buffer 2 -/-  
 
 
 
Table 15: Lysis buffer 3 
reagent final concentration 
Deoxycholic acid sodium salt 1 % (w/v) 
SDS (10 % (w/v)) 0.01 % (v/v) 
NaCl 0.15 M 
Sodium dihydrogen phosphate dihydrate 0.01 M 
EDTA 0.002 M 
Complete 1 x 
d. water  
pH  7.2 
 
 
 
3.1.6.2 Enzymatic proteolysis 
Table 16: TEA buffer 
reagent final concentration 
TEA 200 mM 
d. water  
pH 8.5 
 
Adjust pH with 25 % ammonia solution. 
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Table 17: TCEP stock solution 
reagent final concentration 
TCEP 1 M 
d. Water  
 
Aliquots can be stored at -20°C. 
 
 
 
Table 18: NOG stock solution 
reagent final concentration 
NOG 10 % (w/v) 
d. water  
 
 
 
Table 19: IAA solution 
reagent final concentration 
IAA 0.5 M 
d. water  
 
Prepare IAA solution always right before use. 
 
 
 
Table 20: Trypsin solution 
reagent final concentration 
Trypsin 1 mg /mL 
Resuspension buffer  
 
Aliquots can be stored at -20°C. 
 
 
 
Table 21: PMSF stock solution 
reagent final concentration 
PMSF 200 mM 
Ethanol  
 
Aliquots can be stored at -20°C. 
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3.1.6.3 Immunoprecipitation 
Table 22: Blocking buffer 
reagent final concentration 
Blocking Reagent for ELISA 1 x 
d. water  
 
 
 
Table 23: CHAPS stock solution 
reagent final concentration 
CHAPS 10 % (w/v) 
d. water  
 
 
 
Table 24: ABC stock solution 
reagent final concentration 
ABC 100 mM 
d. water  
pH 7.4 
 
Adjust pH to 7.4 
 
 
 
Table 25: PBSC 
reagent final concentration 
PBS (10 x) 1 x 
CHAPS (10 %) 0.03 % (w/v) 
d. water  
 
 
 
Table 26: ABCC 
reagent final concentration 
ABC 50 mM 
CHAPS (10 %) 0.03 % (w/v) 
d. water  
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Table 27: Elution buffer 
reagent final concentration 
FA 1 % 
d. water  
 
 
 
3.1.6.4 LC-MS measurement 
Table 28: Loading buffer 
reagent final concentration 
ACN 2 % 
TFA 0.05 % 
water (LC-MS grade)  
 
 
 
Table 29: Mobile phase A 
reagent final concentration 
FA 0.1 % 
water (LC-MS grade)  
 
 
 
Table 30: Mobile phase B 
reagent final concentration 
ACN 80 % 
FA 0.1 % 
water (LC-MS grade)  
 
 
 
Table 31: Rear piston flush solution 
reagent final concentration 
IPA 10 % 
water (LC-MS grade)  
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3.1.7 Biological samples 
3.1.7.1 Cell pellets for human cell culture blend 
Frozen cell pellets of HepG2, HEK293 and HCT116 were kindly provided by 
Dr. Tränkle. 
 
3.1.7.2 Set of human liver tissue and preparations thereof 
Prof. Schwab and Prof. Zanger kindly provided a set of human liver tissue and 
preparations thereof, membrane enriched fractions, microsomes and cytosol. The set 
contained ten samples from five female and five male patients aged between 47 and 
75 years which were diagnosed with primary liver cancer or liver metastasis.  
 
3.1.7.3 Healthy human liver tissue 
Christine Wegler and Prof. Artursson kindly provided a set liver biopsies from twelve 
males and three females aged between 42 and 79 years. The diagnoses were, clear cell 
carcinoma, hepatocellular carcinoma, colorectal cancer or renal cell carcinoma. The 
biopsies do not contain tumor tissue, but healthy liver tissue. The medication is given 
in Table 32. Pooled lysates were used for development of human TXP assays (4.2.5, 
4.2.7, 4.2.8, 4.2.9). 
 
Table 32: Patient information 
Patient Medication 
1  
2 
metformin, gabapentin, atorvastatin, alfuzosin, paracetamol, warfarin, 
tiotropiumbromide, budesonide, formoterol 
3 candesartan, metoprolol, citalopram, acetyl salicylic acid, bicalutamide, insulin 
4 acetylsalicylic acid, atorvastatin, omeprazole, metoprolol, glyceryl trinitrate 
5  
6 omeprazole 
7 candesartan, felodipine, omeprazole 
8 metoprolol 
9  
10  
11 metformin 
12 omeprazole, propranolol 
13  
14 omeprazole, hydroxyzine, sumatriptan, zolpidem 
15 acetylsalicylic acid, metoprolol, amlodipine, ezetimibe 
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3.1.7.4 Paired human kidney samples 
This study contains healthy kidney tissue as well as kidney tumor samples from the 
same patients. Patients were aged between 51 and 82 years and diagnosed with clear 
cell renal cell carcinoma (ccRCC) or adrenocortical carcinoma. The relevant medication 
at the time of operation is given below. Samples were kindly provided by Prof. 
Stevanović.  
 
Table 33: Patient information 
patient gender age subtype medication 
1 male 61 
adrenocortical 
carcinoma 
 
2 male 61 ccRCC  
3 female 57 
eosinophile 
ccRCC 
 
4 female 82 
eosinophile 
ccRCC 
Acerbon 10; Cynt 0,2; Aquaphor 20; Norvasc 5; 
Cibacen 5; ASS 100 
5 male 61 ccRCC  
6 male 72 ccRCC Norvasc, Lasix 
7 female 59 ccRCC 
Eferox, Furosemide, Exjade, Citalopram, Simvastatin, 
BisoHexal, Neupro-patch, Lyrica, Folcur, Marcumar, 
Tramadol, Omeprazole, Amineurin, Xipamide, 
Allobeta 
8 male 58 ccRCC  
9 male 61 ccRCC 
Tarivid, Concor, Fortecortin, Saroten, Blopress, Omeg, 
vitamine B, Novalgin, Omnic, Durogesic 
10 female 51 ccRCC Amaryl, Ferrosanol 
11 male 80 ccRCC Beloc zok 
 
 
3.1.7.5 Liver tissue of phenobarbital-treated mice 
Dr. Singh and Prof. Schwarz kindly provided frozen liver tissue of phenobarbital-
treated mice for TXP method development (4.2.5, 4.2.7, 4.2.9). Male C3H/He mice were 
injected N-nitrosodiethylamine at the age of six weeks. After three treatment - free 
weeks, mice were fed with a diet containing 0.05 % phenobarbital for 27 weeks and 
sacrificed either 2 or 45 days thereafter. Animals were part of a study published 2013 
[90]. 
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3.1.7.6 Primary mouse hepatocytes 
Pericentral and perivenous primary hepatocytes were isolated from male C3H/HE 
mice via digitonin perfusion [69]. Cells were lysed and proteolyzed with trypsin. 
Proteolyzed samples were provided by Simon Kling. 
 
3.1.7.7 Fungicide-treated samples 
Dr. Braeuning and Dr. Marx-Stölting kindly provided a set of samples to study the 
effects of fungicides on protein expression in the liver. It contained rattine and murine 
liver tissue samples as well as lysates of cultivated HepaRG cells. 
The human HepaRG cells were differentiated and consequently treated with different 
fungicides and combinations thereof for 24 hours (Table 34). CITCO was used as 
positive control with either differentiation medium (DM) or work medium (WM). In 
the last case, cells were switched to work medium fifteen hours before the treatment. 
Harvested cell pellets were lysed with lysis buffer 2 -/-.  
 
Table 34: Conditions for HepaRG treatment. 
condition test substance concentration 
differentiation medium (DM)  9 % FCS + 1.8 % DMSO 
DM solvent control  9 % FCS + 1.9 % DMSO 
work medium (WM)  2 % FCS +0.5 % DMSO 
WM solvent control  2 % FCS + 0.6 % DMSO 
DM + CITCO  
1.9 % DMSO +  
0.6 µM, 2.5 µM, 10 µM CITCO 
WM + CITCO  
0.6 % DMSO +  
0.6 µM, 2.5 µM, 10 µM CITCO 
cyproconazole cyproconazole 0.6 µM, 2.5 µM, 10 µM, 40 µM  
epoxiconazole epoxiconazole 0.6 µM, 2.5 µM, 10 µM, 40 µM  
prochloraz prochloraz 0.6 µM, 2.5 µM, 10 µM, 40 µM 
mixture I cyproconazole + epoxiconazole 
0.3 µM, 1.25 µM, 5 µM,  
20 µM each 
mixture II 
cyproconazole + epoxiconazole 
+prochloraz 
0.2 µM, 0.83 µM, 3.33 µM,  
13.33 µM each 
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Male wistar rats were treated with different fungicides and combinations thereof for 
28 days and phenobarbital was used as positive control (Table 35). All substances were 
administered via the feed. At the beginning of the study, rats were nine weeks old. 
Animals were part of published studies [73, 91]. Liver tissue of phenobarbital-trea ted 
animals was also used for TXP method development (4.2.2, 4.2.4, 4.2.5, 4.2.7, 4.2.9). 
 
Table 35: Additives of rat diet. 
condition test substance concentration 
control   
phenobarbital phenobarbital 500 ppm 
cyproconazole cyproconazole 100 ppm, 1000 ppm 
epoxiconazole epoxiconazole 90 ppm, 900 ppm 
prochloraz prochloraz 100 ppm, 1000 ppm 
mixture I cyproconazole + epoxiconazole 100 ppm + 90 ppm, 1000 ppm + 900 ppm 
mixture II 
cyproconazole + epoxiconazole  
+ prochloraz 
100 ppm + 90 ppm + 100 ppm,  
1000 ppm + 900 ppm + 1000 ppm 
 
The murine set included samples from C57BL/6 mice as well as transgenic C57BL/6 
mice expressing only humanized forms of the receptors CAR and PXR (hCAR/hPXR). 
At the age of eight weeks, mice were treated with two fungicides and phenobarbital 
for 28 days. Fungicides were administered via the feed while phenobarbital was given 
via drinking water (Table 36).  
 
Table 36: Additives of mouse diet. 
condition test substance concentration 
control   
phenobarbital phenobarbital 0.05 % (w/v) 
cyproconazole cyproconazole 50 ppm, 500 ppm 
prochloraz prochloraz 50 ppm, 500 ppm 
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3.2 Methods 
3.2.1 Selection of suitable peptides and TXP-epitopes  
For the selection of suitable peptides, the amino acid sequences of all target proteins 
are fragmented in-silico based on tryptic cleavage. The resulting peptides are filtered 
to exclude all peptides with undesirable characteristics: All peptides which cannot be 
assigned uniquely to one protein are excluded, as well as all peptides either shorter 
than eight amino acids or longer than 25 amino acids. Peptides containing methionine 
will be excluded, if there is an alternative peptide which meets all criteria. Depending 
on the target protein, one to eleven peptides meet these criteria.  
This peptide screening is performed for each species separately. The subsequent 
selection of at least one peptide per target protein is done for all species together. The 
key aspect of the selection is to minimize the number of TXP antibodies needed to 
cover all target proteins. 
 
3.2.2 Sample preparation 
3.2.2.1 Preparation of peptide standards 
Between 0.5 and 1 mg lyophilized standard peptide is weighed with an analytical 
balance. A 5 mM solution is prepared by adding DMSO, mixing it vigorously and, if 
necessary, sonicating it. Subsequently it is diluted to 1 mM by adding LC-MS grade 
water. Peptide stock solutions are stored at -20°C. 
 
3.2.2.2 Tissue Lysis 
For tissue lysis, all equipment and samples have to be cooled with liquid nitrogen. 
Tissue samples are transferred into cooled cryovials and weighed. The sample should 
weigh between 8 and 80 mg. In case of larger tissue samples, they have to be 
fragmented in a mortar filled with liquid nitrogen. 
Samples are pulverized using a ball mill at 2000 rpm for 1.5 min. The pulverized tissue 
can either be stored at - 80°C or directly used for lysis. The samples are incubated with 
the 20 to 50-fold volume lysis buffer (20-50 µL buffer : mg sample) for one hour at 
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room temperature under constant rotation. The lysate is transferred into a new vial 
and centrifuged for 5 min at 16’000 g to sediment cell debris. The supernatant is stored 
at - 80°C until analysis. 
 
3.2.2.3 Cell lysis 
At the time of harvest, cells are washed twice with ice cold PBS, scraped of the cell 
culture dish and sedimented by centrifugation. The cell pellets can be stored at – 80°C. 
At the time of lysis, pellets are thawed on ice. Subsequently, they are re-suspended in 
double volume of lysis buffer and incubated for one hour at room temperature while 
mixing it vigorously every 15 min. 
 
3.2.2.4 Protein quantification  
The amount of extracted protein is determined in every lysate using the Pierce™ BCA 
Protein Assay Kit according to the manufacturer’s manual. 
 
3.2.2.5 Enzymatic proteolysis 
For enzymatic proteolysis 100 – 400 µg extracted protein is diluted with distilled water 
and TEA buffer. TCEP and NOG are added before the samples are heated for 5 min to 
95°C. Subsequently the samples are cooled to room temperature and IAA is added. 
After 30 min incubation in the dark while shaking continuously, trypsin is added in 
such a manner that it is the twentieth part of the used protein amount. Standard 
proteolysis takes place over night for 16 h while shaking the samples at 37°C. The 
enzymatic proteolysis is terminated by a 5 min heating step at 95°C and subsequent 
protease inhibitor addition (PMSF). The total volume of the proteolysis is 425 µL. If 
not stated otherwise, TPCK treated and methylated trypsin is used. 
Materials and Methods 
38 
Table 37: Reagents needed for enzymatic proteolysis 
reagent final concentration 
lysate 0.2 – 1 µg/µL 
d. water  
TEA buffer 44 mM 
0.1 M TCEP  5 mM 
NOG stock solution 0.4 % (w/v) 
IAA solution 10 mM 
Trypsin solution 1 : 20 (trypsin : protein) 
PMSF stock solution 1 mM 
 
 
3.2.2.6 Determination of assays accuracy and precision 
For recovery plots, all IS peptides of a multiplex are diluted with blocking buffer to the 
concentration which is used to spike samples for quantification. This solution is used 
to prepare a serial dilution of the respective endogenous peptides from 1000 fmol 
down to 0.05 fmol. After immunoprecipitation (3.2.3) and LC-MS-analysis (3.2.4), the 
results are used to evaluate precision and accuracy of the assays. Additionally, equal 
volumes of all IS and EN peptides are mixed and diluted to 5 fmol/µL with loading 
buffer. This input is used as positive control for LC-MS hardware performance as well 
as to determine the ratio between matching IS and EN peptide. The concentration of 
EN peptide stock solutions was adjusted by the input ratio. 
 
3.2.3 Immunoprecipitation 
The immunoprecipitation is performed semi-automated at room temperature using a 
magnetic particle processor. To do so, the proteolyzed samples are distributed into a 
96-well microtiter PCR plate (sample plate). Antibody stocks are diluted with PBSC 
and IS peptide stocks are diluted with blocking buffer. The corresponding TXP-
antibody and standard peptide dilutions are added and the volume is filled up to 
100 µL with PBSC. After 1 h incubation at room temperature with regular mixing 
intervals, magnetic beads are transferred into the sample plate. They are coated with 
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protein G to trap the TXP antibody – peptide complex. Therefor the beads are 
incubated for another hour while swirling them up every 10 min. Subsequently the 
beads are transferred into two washing plates containing PBSC and three containing 
ABCC. Finally, the protein G - TXP antibody – peptide complex is degraded in 20 µL 
elution buffer and the beads are removed from the elution plate. The eluate is 
transferred manually into a new microtiter plate to remove remnants of beads and heat 
sealed for LC-MS analysis. 
Table 38: Protocol for semi-automated immunoprecipitation using the KingFisher.
action plate content duration cycle speed 
number of 
cycles 
pick up comb sample plate     
mix sample sample plate 1 h 
mix 2 min 
pause 8 min 
middle 6 x 
collect beads beads + PBSC  
mix 10 s 
collect 3 x 
middle  
release beads sample plate  mix 10 s middle  
mix sample sample plate 1 h 
mix 2 min 
pause 8 min 
collect 3 x 
middle 
 
6 x 
 
wash 1 PBSC 4:30 min 
mix 1:50 min 
pause 25 s 
collect 3 x 
middle 
 
2 x 
 
wash 2 PBSC 4:30 min 
mix 1:50 min 
pause 25 s 
collect 3 x 
middle 
 
2 x 
 
wash 3 ABCC 4:30 min 
mix 1:50 min 
pause 25 s 
collect 3 x 
middle 
 
2 x 
 
wash 4 ABCC 4:30 min 
mix 1:50 min 
pause 25 s 
collect 3 x 
middle 
 
2 x 
 
wash 5 ABCC 4:30 min 
mix 1:50 min 
pause 25 s 
collect 3 x 
middle 
 
2 x 
 
elution elution buffer 4:30 min 
mix 1:50 min 
pause 25 s 
collect 3 x 
middle 
 
2 x 
 
release and 
leaf comb 
PBSC 5 s mix 5 s middle  
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3.2.4  LC-MS analysis 
3.2.4.1 LC 
After immunoprecipitation, the eluate is separated by high performance liquid 
chromatography. A precolumn is used to desalt the samples and to remove antibodies 
from the eluate. Therefor the eluate is mixed with loading buffer which is used to retain 
the peptides on the precolumn. Subsequently, the remaining peptides are transferred 
to and separated by an analytical C18 – column using a linear gradient of a changing 
mobile phase A and B ratio. This general LC method is adjusted to full MS and tSIM 
measurement requirements (Table 39): For full MS measurements, 10 µL eluate is 
injected and separated with a 20 min gradient. For the quantification of the target 
peptides by tSIM measurement, a 2.75 min gradient and 5 µL are sufficient. When 
multiplex assays are compiled, the tSIM gradient is optimized further to separate the 
increasing number of peptides efficiently. 
Table 39: Parameters of LC methods 
parameter full MS tSIM 
column oven temperature 40°C 55°C 
injected volume 10 µL 5 µL 
flow rate on precolumn 20 µL/min 20 - 120 µL/min 
flow rate on analytical 
column 
0.3 µL/min 1 µL/min 
method duration 45 min 10 min 
gradient duration 20 min 2.75 min 
gradient composition 4 – 55 % mobile phase B 4 – 45 % mobile phase B 
 
 
Figure 3: LC gradients for full MS and tSIM measurements 
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3.2.4.2 Full MS 
The full MS method is used for experiments in which the identification of peptides is 
the main focus. It is set to the positive mode with data dependent MS/MS of the top 
ten peaks with charge states two and three. The instrument settings are listed in Table 
40. 
 
Table 40: Properties of full MS / dd-MS/MS 
full MS 
Resolution  70 000  
AGC target  3e6  
Maximum IT  100 ms  
Scan range  300 to 2000 m/z  
 
dd-MS/MS / dd-SIM 
Resolution  17 500  
AGC target  5e5  
Maximum IT  60 ms  
Loop count  10  
TopN  10  
Isolation window  2.0 m/z  
Fixed first mass  ---  
NCE / stepped NCE  25  
  
dd settings 
Underfill ratio  0.0%  
Intensity threshold  0.0  
Apex trigger  ---  
Charge exclusion  unassigned, 1, 5-8, >8  
Peptide match  ---  
Exclude isotopes  on  
Dynamic exclusion  5.0 s  
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3.2.4.3 tSIM 
tSIM methods are employed to quantify a set of known target peptides. Coeluting IS 
and EN peptides confirm the peptide identity as well as the correct charge state and 
data dependent MS/MS which is triggered by signals higher than 20’000. Mass - to - 
charge – ratios and charge states of the target peptides are provided in the inclusion 
list. Method settings are listed in Table 41. 
 
Table 41: Properties of tSIM / dd-MS/MS 
SIM 
Resolution  35 000  
AGC target  5e6  
Maximum IT  60 ms  
Loop count  1 / 2  
MSX count  1 / 2  
Isolation window  3.0 m/z  
Scan range  300 to 1200 m/z  
 
dd-MS/MS 
Resolution  17 500  
AGC target  2e5  
Maximum IT  60 ms  
Loop count  1  
TopN  1  
Fixed first mass  ---  
NCE / stepped NCE  20  
  
  
dd settings 
Underfill ratio  0.6%  
Intensity threshold  2.0e4 
Apex trigger  ---  
Charge exclusion  --- 
Peptide match  ---  
Exclude isotopes   
Dynamic exclusion  2.0 s  
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3.2.4.4 Data analysis 
The Proteome Discoverer 1.3 is employed to analyze results of full MS measurements. 
Peptides are identified using Mascot and SEQUEST as reference data bases and 
medium peptide filter. The search parameters are specified in Table 42 and Table 43. 
Pinpoint, on the other hand, is used to analyze raw files of tSIM measurements. Import 
and analysis parameters are listed in Table 44. To ensure a robust analysis, peaks 
within 50 % intensity of base peak are used to calculate total peak areas and peptide 
amounts. The analysis is double-checked for random samples and low intensity 
signals by manually surveying the isotope pattern, charge state and peak form with 
Xcalibur. 
 
Table 42: Search settings for Mascot - Version 2.3.02 
parameter specification 
protein database  complete proteome Set (08/2013)  
enzyme name  Trypsin  
maximum missed cleavage sites  1  
instrument  ESI-TRAP  
taxonomy  all entries  
precursor mass tolerance  5 ppm  
fragment mass tolerance  0.05 Da  
use average precursor mass  false  
dynamic modifications  oxidation (M), oxidation (HW)  
static modifications  carbamidomethyl (C)  
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Table 43: Search settings for SEQUEST - Version 28.0.0.0 
parameter specification 
Protein Database  Complete Proteome Set (08/2013)  
Enzyme name  Trypsin  
Maximum Missed Cleavage Sites  1  
Precursor Mass Tolerance  5 ppm  
Fragment Mass Tolerance  0.05 Da  
Use Average Precursor Mass  false  
Use Average Fragment Masses  false  
Use Neutral Loss a Ions  True  
Use Neutral Loss b Ions  True  
Use Neutral Loss y Ions  True  
Weight of a Ions  0  
Weight of b Ions  1  
Weight of c Ions  0  
Weight of x Ions  0  
Weight of y Ions  1  
Weight of z Ions  0  
Dynamic Modifications  Oxidation / +15.995 Da (H, M, W)  
Static Modifications  Carbamidomethyl / + 57.021 Da (C)  
 
Table 44: Parameters of analysis with Pinpoint 1.3  
parameter setting 
MS1 accuracy  5 – 15 ppm 
Scan filter  SIM or Full (as available)  
MSMS accuracy 1000 ppm 
Isolation mode  MSMS isolation width 0.2 u 
Peak width 0.05 min 
minimum signal threshold 100 
possible alignment error 2 
What area option to use? Peaks within 50% intensity of base peak 
number of smoothing points 5 
 
3.2.5 Statistical analysis 
For analysis of possible effects ANOVA analyses with Fisher LSD or Bonferroni’s 
correction were performed using Origin 2015G. The cross-species study was analyzed 
with a Student’s-t-test (two tailed for heteroscedastic data) using Excel2016 to handle 
the size of the sample set. Bonferroni’s correction for multiple testing was applied. 
If results are evaluated as fold change, error propagation will be applied: 
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∆𝑓 = √(
𝜕𝑓
𝜕𝑥
∙ ∆𝑥)
2
+ (
𝜕𝑓
𝜕𝑦
∙ ∆𝑦)
2
+ ⋯  [92] 
The general formula was adopted as follows: 
∆𝑓 = √(
𝜎𝑥
?̅?𝑥
)
2
+ (
𝜎𝑐
?̅?𝑐
)
2
∙ (
?̅?𝑥
?̅?𝑐
) 
∆𝑓 = propagated error (PE) 
𝜎𝑥 = standard deviation of the treatment 
?̅?𝑥  = mean value of the treatment 
𝜎𝑐 = standard deviation of the control 
?̅?𝑐 = mean value of the control 
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4 Results 
4.1 Selection of epitopes and peptides 
For this project, 26 transporters in up to three different species (human, rat and mouse) 
and 45 CYPs for up to two different species (rat and mouse) were covered. In total this 
amounted to 109 different proteins (Table 56). To select suitable peptides and TXP 
epitopes, the sequences of all targets were fragmented in silico at tryptic cleavage sites. 
Resulting peptides were filtered to eliminate those with undesired characteristics, such 
as very long or methionine containing peptides (see 3.2.1 for specifications). This 
resulted in one to eleven peptide candidates per protein. Subsequently at least one 
peptide per protein was chosen in such a manner as to minimize the number of TXP 
antibodies needed to cover them all (Table 57). Therefor 72 different epitopes were 
necessary. Out of these, ten TXP epitopes covered more than four targets. The most 
versatile epitope could be used to analyze twelve different target proteins (FSGR). The 
majority of epitopes could be used to analyze two to four different targets of the set. 
Another 21 epitopes had to be selected to cover the remaining targets individually. 
The efficiency of the chosen TXP epitopes is visualized in Figure 4 and listed in Table 
58. As a side effect of this approach, some proteins are covered by up to four different 
TXP epitopes of the set. Each of these epitopes is required for at least one additional 
target protein of the set, which is addressed by only one epitope of the set. 
Results 
48 
 
Figure 4: Heat map displaying the efficiency of TXP epitopes. The number of target 
proteins covered by each TXP epitope is indicated in green. The color saturation 
corresponds to the number of species which are covered ( ab  one species, ab  two 
species,  and ab  three species).  
There are two aspects which have been discussed to be included in the selection 
process: The number of proteins per proteome which carry this epitope and whether 
high abundant proteins are targeted by the epitope [22]. Both features were not 
considered during the selection process but it was analyzed retrospectively whether 
they could be linked to successful assay development. The development is considered 
successful for epitopes which are part of the final TXP assay set. 
The number of proteins which can be addressed by a TXP epitope was determined 
using an in-house script called TXP tool. Only entries of the UniProtKB reference 
proteome were considered for this analysis. The percentage of proteins carrying the 
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AAYR X
ALEK 2 X
ALPR 3 X
ANFK 2 X
APAR 3 X
AVDR 3 X
AYDR 2 X
DAPK 2 X
DFFR X
DLFR 3 X 3 X 3 X
DLVR X 3 X
DPPR X
DTQR X
EATR 2 X
EAVK X X X X X
EEAK X
EELK 2 X
EGCK X
EIQK X
ELSK 2 X
ESIK 2 X
ESTR 2 X
ETFR 2 X
EVLR X
FAFK 3 X
FFFK 3 X
FSGR X X X X X X X X 2 X 2 X
FTNR X X X X X
FWLK 3 X
GDLK 3 X
GFCR X
GGEK X X 3 X
GQVR X X
GSLR 3 X 2 X
GTVR 3 X
GYYR 3 X
IFFK 2 X
KPHR X
LAER X
LDDK X 2 X
LDDR X
LEVR X
LGYR 2 X
LIDK X
LISK X X
LPNK X X X X X
LPSK X
LSGK 3 X
LTIR X
LTTR 3 X X 2 X X
NFSK X X X
NGER X X X X X
PFQR 3 X
PSGR 3 X
PSSK X
PWGK X
QDEK 2 X X
QDIR X X X
QLLK 3 X
QPPR X X X 2 X
QQER X
RPER X 2 X X X X
SAIR 3 X
SIGK 2 X X
SLNK 3 X
SLQR X
STGK X X X X X
TNPR X X X
TTDR 2 X
TVEK 3 X
VILR 3 X
YQVR 3 X
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TXP epitope with respect to the proteome was calculated with following formula for 
each species:  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛𝑠 (𝑇𝑋𝑃,𝑠𝑝𝑒𝑐𝑖𝑒𝑠)
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑎𝑙𝑙 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑝𝑟𝑜𝑡𝑒𝑜𝑚𝑒 𝑒𝑛𝑡𝑟𝑖𝑒𝑠 (𝑠𝑝𝑒𝑐𝑖𝑒𝑠)
∗ 100 = 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑟𝑎𝑡𝑖𝑜  
The chosen epitopes address between 0.03 and 20 % of the tested proteomes. 
Subsequently, the epitopes were grouped according to successful and non-successful 
assay development during this thesis. The outcome is presented in Figure 5: The 
groups of one species cannot be distinguished by the protein ratio.  
 
Figure 5: Comparison of TXP epitopes with respect to assay development. The percentage 
of proteins which contain a TXP epitope in relation to the size of the proteome 
was calculated. Then the epitopes were additionally classified according to 
whether a functional assay could be developed during this thesis or not. Each 
species was analyzed separately.  (UniPortKB reference proteome 20.12.2015)  
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Table 45: High abundant proteins and their coverage by TXP epitopes in all species. The 
fifteen most abundant proteins are indicated in gray according to the PaxDb 
entries for human liver (integrated), mouse liver (integrated) and rat whole 
organism. Only proteins with S wiss-Prot entries were included.  The canonical 
sequences as well as all isoforms were checked whether they include any of the 
chosen TXP epitopes.  
high abundant protein human rat mouse 
10 kDa heat shock protein, mitochondrial  LDDK  
3-ketoacyl-CoA thiolase, mitochondrial    
60S ribosomal protein L19    
60S ribosomal protein L21    
60S ribosomal protein L3    
60S ribosomal protein L39    
78 kDa glucose-regulated protein   DLFR 
Actin, cytoplasmic 1    
Alcohol dehydrogenase 1    
Alcohol dehydrogenase 1A    
Alcohol dehydrogenase 1B    
Alcohol dehydrogenase 4    
Argininosuccinate synthase    
ATP synthase subunit beta, mitochondrial    
Carbamoyl-phosphate synthase [ammonia], mitochondrial  EATR EATR 
Carbonic anhydrase 3    
Cytochrome b5  EIQK, EVLR  
Elongation factor 1-alpha 1    
Endoplasmin    
Fatty acid-binding protein, liver    
Ferritin light chain    
Fructose-bisphosphate aldolase B    
Glutathione S-transferase A1    
Glutathione S-transferase A3    
Heat shock cognate 71 kDa protein   DLFR 
Hemoglobin subunit alpha    
Hemoglobin subunit beta    
Hemoglobin subunit beta-1    
Hemoglobin subunit delta    
Myelin basic protein    
Peroxiredoxin-1    
Phosphatidylethanolamine-binding protein 1 LSGK   
Protein disulfide-isomerase   EAVK, NGER 
Serum albumin    
Superoxide dismutase [Cu-Zn]    
Thymosin beta-4  LPSK  
Ubiquitin-60S ribosomal protein L40    
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High abundant proteins are the second aspect which might be used to improve the 
epitope selection process. The hypothesis is that all peptides bind competitively to the 
binding sites of the antibodies. Peptides of high abundant proteins could block the 
antibodies and suppress the binding of low abundant peptides. To investigate this, the 
fifteen most abundant proteins in liver were chosen for each species according to 
PaxDb [93]. For rat, whole organism data was used, because organ specific data was 
not available. Nine TXP epitopes are present in at least one of the proteins (Table 45). 
It was analyzed whether the presence of TXP epitopes in these proteins correlates with 
the success rate of assay development (Table 46): Overall it was possible to develop at 
least one functional assay for 35 % of the epitopes. By excluding epitopes which 
address a high abundant protein, the ratio would have been decreased by 5 %. 13 % of 
the assays in the final assay set would be missing. 
 
Table 46: Ratio of TXP epitopes with which a successful assay was developed. The TXP  
epitopes were analyzed in total as well as only TXP epitopes which did or did not 
address a HAP. Following ratio is given:  
epitopes for which assay development was successful / all tested epitopes 
 human rat mouse 
all epitopes 10 / 43 20 / 55 14 / 48 
epitopes which address no HAP 10 / 42 16 / 50 12 / 44 
epitopes which address HAPs 0 / 1 4 / 5 2 / 4 
 
 
4.2 Assay development 
The development of new TXP assays was initially based on the PhD thesis of Frederik 
Weiss [22]. His approach was further optimized and additional experiments were 
included in the development. The critical components of a TXP assay are the peptides 
and antibodies. Both were produced customized by Intavis AG and Pineda Antikörper 
Service respectively. The antibodies were delivered as rabbit sera and purified in-
house. Each serum got an identifier which contains following information: clonality 
(monoclonal mAB / polyclonal pAB), antigen, host species and a consecutive number. 
During assay development, the purified antibodies were characterized and the 
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antibody amount used for immunoprecipitation was adjusted individually. On this 
basis multiplex assays were compiled of which the accuracy, precision and 
reproducibility was determined. Additionally, the sample preparation was optimized.  
Since polyclonal antibodies purified from serum were used, the assay development 
had to be performed for each serum individually. Therefore, characterization of the 
purified antibodies was the first step of the development. 
 
4.2.1 Antibody characterization and functionality in complex matrix 
The antibody was characterized in two aspects: What is the actual binding motif of the 
antibody? Is the antibody able to enrich the according standard peptide in complex 
matrix?  
Both questions have been addressed by using human cell line blend as an artificial 
matrix. Human cell line blend was generated from human cell lysates: HepG2, 
HEK293 and HCT116 were cultivated under standard conditions and harvested at 80-
100 % confluency. After lysis with lysis buffer 1 +/-, the protein concentration was 
determined and lysates were mixed in a 1 : 1 : 1 protein ratio. Enzymatic proteolysis 
and immunoprecipitation (20 µg protein and 5 µg AB / IP) were performed as needed. 
To examine the antibody epitopes, the immunoprecipitation was performed without 
standard peptides and the eluate was analyzed with the full MS method. A 
monoclonal antibody against Myc proto-oncogene protein (mAB_cMyc_ms1) was 
used as negative control, as well as matrix processed without Protein-G coupled beads 
and antibodies. Identified peptides were used to generate sequence logos to depict the 
C-termini which lead to retention during immunoprecipitation [22, 35]. Detailed 
information for all antibodies is given in Table 64. 
The sequence logos of all antibodies which are part of the final TXP-assay set (4.2.6) 
are presented in Figure 6. Additionally, the number of peptide sequences and tags the 
logos based on are listed. The tags are defined as the four C-terminal amino acids of a 
peptide. Furthermore, the ratio of enriched peptides is given. This ratio is obtained by 
referring the number of enriched peptides with the target TXP epitope to the number 
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of peptides theoretically present in the proteome sharing this epitope (UniProtKB 
reference proteome June 2014). 80 % of the generated antibodies significantly enriched 
peptides and a binding motif could be determined. Up to 38 % of the theoretically 
possible peptides containing the target TXP epitope were precipitated. The antibodies 
chosen for the final TXP assay set enriched up to 33 % of all peptides in the human 
proteome with the target TXP epitope. For two antibodies, pAB_TXP_LDDK_rbt1 and 
pAB_TXP_QPPR_rbt1, it was not possible to determine a binding motif. Nevertheless, 
it was possible to establish TXP – assays using these antibodies. The most diverse 
binding motif of a single antibody comprised up to 31 C-terminal amino acid sequence 
variations. The antibodies chosen for the final TXP assay set precipitated up to 22 
different tags. For 15 antibodies, the experiment was not performed, because a 
preliminary experiment showed, that they do not precipitate the desired peptides in 
buffer. Therefore, the functionality in complex matrix was not tested. This experiment 
was also not performed for the peptide specific antibodies.  
To ensure the transferability of the results between different species and tissues, 
sequence logos for three selected antibodies were also generated using mouse and rat 
liver tissue as well as rat heart and kidney tissue. The similarity of motifs obtained 
from different human cell line samples had already been shown [35]. The sequence 
logos of all sample types and species were similar (Figure 7). In general, the murine 
and rattine sequence logos were based on less peptide sequences and fewer C-terminal 
tags were included. In the case of pAB_TXP_GYYR_rbt2, the first and fourth position 
were preserved. In the second and third position, hydrophobic amino acids were 
preferred. Between 7 -14 % of the known GYYR peptides were enriched. In the binding 
motif of pAB_TXP_QDIR_rbt1, the second and fourth positions were preserved, while 
the first position tolerated seven different amino acids. On the third position the 
hydrophobic amino acids isoleucine, leucine and valine were preferred. 15 – 20 % of 
the known QDIR-peptides were enriched, with the exception of the heart sample. Here 
only 8 % of the known QDIR – peptides were precipitated. For pAB_TXP_SLNK_rbt4 
only the first position is variable and precipitated 5 -13 % of the possible peptides. 
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pAB_TXP_ALEK_rbt1 
# sequences 36 
# tags 4 
peptide ratio 
 
8.6 % 
 
 
pAB_TXP_DLFR_rbt3 
# sequences 90 
# tags 15 
peptide ratio 20.4 % 
 
 
pAB_TXP_EATR_rbt1 
# sequences 69 
# tags 11 
peptide ratio 11.8 % 
 
 
pAB_TXP_EIQK_rbt1 
# sequences 73 
# tags 4 
peptide ratio 20.2 % 
 
 
pAB_TXP_FSGR_rbt1 
# sequences 195 
# tags 21 
peptide ratio 21.2 % 
 
 
pAB_TXP_FTNR_rbt2 
# sequences 97 
# tags 14 
peptide ratio 
 
19.9 % 
 
 
pAB_TXP_GGEK_rbt1 
# sequences 61 
# tags 7 
peptide ratio 17.7 % 
 
 
pAB_TXP_GQVR_rbt1 
# sequences 29 
# tags 7 
peptide ratio 6.5 % 
 
 
pAB_TXP_GSLR_rbt1 
# sequences 14 
# tags 3 
peptide ratio 3.0 % 
 
 
pAB_TXP_GTVR_rbt1 
# sequences 149 
# tags 22 
peptide ratio 9.5 % 
 
 
pAB_TXP_LDDR_rbt1 
# sequences 126 
# tags 17 
peptide ratio 
 
33.3 % 
 
 
 
pAB_TXP_LISK_rbt2 
# sequences 90 
# tags 5 
peptide ratio 22.6 % 
 
pAB_TXP_LPNK_rbt2 
# sequences 21 
# tags 5 
peptide ratio 20 % 
 
 
pAB_TXP_LPSK_rbt2 
# sequences 110 
# tags 14 
peptide ratio 0 % 
 
 
pAB_TXP_LTTR_rbt2 
# sequences 122 
# tags 13 
peptide ratio 10.8 % 
 
 
pAB_TXP_NFSK_rbt1 
# sequences 167 
# tags 19 
peptide ratio 
 
31.3 % 
 
 
pAB_TXP_NGER_rbt1 
# sequences 49 
# tags 9 
peptide ratio 9.1 % 
 
 
pAB_TXP_PSSK_rbt2 
# sequences 136 
# tags 10 
peptide ratio 21.4 % 
 
 
pAB_TXP_QDEK_rbt2 
# sequences 44 
# tags 9 
peptide ratio 13.2 % 
 
 
pAB_TXP_QDIR_rbt1 
# sequences 97 
# tags 16 
peptide ratio 20.0 % 
 
 
pAB_TXP_TNPR_rbt2 
# sequences 124 
# tags 19 
peptide ratio 21.9 % 
 
 
pAB_TXP_TVEK_rbt1 
# sequences 56 
# tags 11 
peptide ratio 15.8 % 
 
 
pAB_TXP_YQVR_rbt1 
# sequences 71 
# tags 13 
peptide ratio 29.2 % 
  
 
  
 
Figure 6: Binding motifs characterizing the actual epitopes of TXP antibodies. The 
antibody ID specifies amongst others the target  epitope. The actual b inding motif 
is presented as sequence logo. The number of peptide sequences and C-terminal 
tags the logo is based on are listed. Additionally,  the ratio of enriched peptides 
with the expected TXP epitope is given in percent  (UniProtKB ref.  prot.  June2014). 
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human cell 
culture blend 
mouse liver rat liver rat heart rat kidney 
 
pAB_TXP_GYYR_rbt2 
# sequences 45 
# tags 10 
peptide ratio 
 
14.3 % 
 
 
pAB_TXP_GYYR_rbt2 
# sequences 9 
# tags 2 
peptide ratio 7.1 % 
 
 
pAB_TXP_GYYR_rbt2 
# sequences 8 
# tags 3 
peptide ratio 7.1 % 
 
 
pAB_TXP_GYYR_rbt2 
# sequences 10 
# tags 4 
peptide ratio 7.1 % 
 
 
pAB_TXP_GYYR_rbt2 
# sequences 19 
# tags 6 
peptide ratio 7.1 % 
 
     
 
pAB_TXP_QDIR_rbt1 
# sequences 97 
# tags 16 
peptide ratio 
 
20.0 % 
 
 
pAB_TXP_QDIR_rbt1 
# sequences 48 
# tags 10 
peptide ratio 19.0 % 
 
 
pAB_TXP_QDIR_rbt1 
# sequences 39 
# tags 10 
peptide ratio 17.8 % 
 
 
pAB_TXP_QDIR_rbt1 
# sequences 30 
# tags 9 
peptide ratio 8.9 % 
 
 
pAB_TXP_QDIR_rbt1 
# sequences 61 
# tags 14 
peptide ratio 15.5 % 
 
 
pAB_TXP_SLNK_rbt4 
# sequences 116 
# tags 13 
peptide ratio 
 
13.2 % 
 
 
pAB_TXP_SLNK_rbt4 
# sequences 44 
# tags 9 
peptide ratio 6.0 % 
 
 
pAB_TXP_SLNK_rbt4 
# sequences 43 
# tags 8 
peptide ratio 5.1 % 
 
 
pAB_TXP_SLNK_rbt4 
# sequences 31 
# tags 5 
peptide ratio 7.7 % 
 
 
pAB_TXP_SLNK_rbt4 
# sequences 57 
# tags 12 
peptide ratio 8.5 % 
 
     
Figure 7: Comparison of binding motifs resulting from different species and tissues. The 
sequence logos of three antibodies generated with human cell culture b lend are 
compared to sequence logos generated with mouse and rat tissue samples.  
Additionally, the number of peptide sequences and C-terminal tags logos are 
based on are listed as well as the ratio of enriched peptides with the expected TXP 
epitope (rat and mouse:  UniProtKB reference proteome December 2014). 
 
The sequence logos characterize the binding motif of the antibodies, but nevertheless 
it was observed, that some peptides with the targeted C-terminal epitope were not 
precipitated. Hence, the complex matrix human cell culture blend was spiked with 
1 pmol of each standard peptide, to test whether it is enriched during 
immunoprecipitation with 5 µg antibody. The eluate was analyzed with the tSIM 
method. If the total file area exceeded 104, the peptide was considered enriched.  
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Antibodies which enriched none of the spiked-in target peptides and peptides which 
were not enriched by any antibody were excluded from further assay development. 
85 % of the standard peptides passed the total file area threshold (Table 65) and 87 % 
of the TXP – epitopes are covered with at least one functional antibody (Table 64). Only 
a subset of the spiked-in standard peptides was enriched for the following six TXP 
epitopes: DLFR, EAVK, EELK, QLLK, STGK, and TFDR. All others either precipitated 
all offered peptides or none.  
 
 
4.2.2 Optimization of lysis conditions 
Lysis buffer 1 +/- had been established before [22] and was used for human cell culture 
blend production. It contained Triton as main detergent and a protease inhibitor 
cocktail to prevent protein degradation during lysis. It was tested whether the lysis 
process could be further optimized for transmembrane proteins by either additional 
sonication of the samples or use of additives and different detergents. Therefor a liver 
tissue sample of a phenobarbital treated rat was fragmented into pieces of about 10 mg. 
For each condition, three pieces were lysed with the 50-fold volume of lysis buffer. 
Subsequently the amount of extracted protein was determined by BCA assay and a 
subset of nine peptides was quantified by immunoprecipitation and tSIM 
measurement (Figure 8):  
Samples lysed with lysis buffer 1 +/- were additional sonicated for 1.5 min in a 
sonication bath. This did not influence the amount of quantified target proteins. 
Likewise, it was also not altered significantly by addition of Benzonase Nuclease (lysis 
buffer 1 +/+). The omission of the protease inhibitor cocktail (lysis buffer 1 -/-), on the 
other hand, increased the quantified amount of the majority of targets. Especially the 
detectable amount of Cyp2b1/2 and NTCP via the GDLK peptide were enhanced. The 
third tested aspect was the detergent: Beside Triton the detergents NP-40 (lysis 
buffer 2 +/-) and DOC (lysis buffer 3) were tested. NP-40 and DOC slightly improved 
the quantified amount of eight and seven target proteins respectively. In comparison 
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to DOC, the quantified amount was increased or equal with NP-40. The conclusion of 
the optimization was that further experiments were performed with NP-40 containing 
lysis buffer 2 -/- without additives and sonication. 
A 
 
B 
 
C 
 
 
Figure 8: Optimization of lysis buffer and 
conditions. Lysis conditions were 
optimized for membrane proteins and 
LC-MS  compatib ility. (A) Additional 
sonication of the samples does not 
improve lysis efficiency. (B) Addition 
of Benzonase Nuclease does not 
improve lysis significantly, but the 
omission of protease inhibitors 
improves consequent enzymatic 
proteolysis. (C) S ubstitution of Triton 
with NP –  40 advances lysis  
significantly in comparison to 
exchange with DOC. Fold change to 
standard condition and PE are shown, 
n=3. ANOVA Fisher LS D analysis was 
performed (p≤0.05). 
The optimized lysis buffer 2 -/- was used to investigate the impact of the lysis buffer 
volume and the temperature at which lysis was performed. Pulverized tissue samples 
were mixed with 10-, 50- or 100-fold volume lysis buffer (x µL lysis buffer : mg tissue). 
The amount of lysis buffer did not affect quantification of the target peptides 
significantly (Figure 9A). Last but not least, it was tested whether the quantified 
peptide amount will be altered if lysis is performed at room temperature or at 4°C. The 
temperature did not influence the quantification of the target peptides (Figure 9B). 
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For convenience, in all following experiments lysis was performed using 20- to 50-fold 
volume of lysis buffer and at room temperature. 
A 
 
B 
 
Figure 9: Optimization of lysis conditions. The effect of lysis in different volumes and 
at different temperatures was tested.  Neither the tested ratios of lysis buffer and 
tissue weight (A) nor the temperature at which lysis was performed (B) affected 
lysis efficiency. Fold change to standard condition  and PE are given. n=3,  ANOVA 
Fisher LS D analysis was performed (p≤0.05).  
 
4.2.3 Analysis of subcellular liver fractions 
Despite the optimized lysis conditions, some target proteins could not be detected 
even though they were expected to be expressed in the sample, e.g. overexpressing cell 
lines (data not shown). Since many other MS-based quantification methods for 
transporters and CYPs rely on enrichment of the analytes by subcellular fractionation 
[26, 94-99], it was tested whether subcellular fractionation improves the sensitivity of 
the TXP approach. Therefor a set of human liver tissue and preparations thereof, 
membrane enriched fractions, microsomes and cytosol, were examined. The tissue 
samples were processed according to the optimized lysis protocol. The preparations 
were incubated for one hour with the same volume of double concentrated lysis buffer 
2 -/- before determining the protein concentration and followed by the 
immunoprecipitation and the MS-analysis. Immunoprecipitation was performed with 
50 µg extracted protein. 
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A B 
  
C D 
  
Figure 10: Analysis of subcellular liver fractions. Human liver tissue and three 
preparations thereof, membrane enriched fraction, microsome and cytosol, were 
analyzed. The quantified amount was in the same range in the different sample 
types. Values below LLOQ were set to 0.5  LLOQ for further analysis.  Mean and 
S D are given (A). The analytes were enriched two to fivefold in the membrane 
enriched fraction and up to twofold in the microsomes (B). The quantified 
amounts from tissue and membrane enriched fr actions correlate well (Pearson  
R = 0.93) while the am ount from tissue and microsomes do correlate slightly 
(Pearson R = 0.74). Values below LLOQ were excluded from the correlation (C, D). 
n=8 
 
Eight out of ten targets could be quantified in all sample types (Figure 10A). For BSEP, 
some tissue samples revealed levels below the LLOQ (see 4.2.8), while all membrane 
enriched fractions could be quantified. Seven transporters were enriched two or 
fivefold in the membrane enriched fraction (Figure 10B). One was only slightly 
enriched. All targets were less enriched in the microsomal fraction. Four targets were 
not enriched in the microsomal preparation. In the cytosolic fraction, all target proteins 
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but SLCO1B1 were strongly depleted. SLCO1B1 was quantified in all sample types 
within in the same range.  
It was analyzed whether the analyte amounts quantified in the tissue correlate with 
the preparations thereof (Table 47). Since most of the transporters could not be 
quantified in the cytosol preparations, they did not correlate with the amounts 
quantified from tissue. The quantified amounts of five proteins correlated very well 
between tissue and the membrane enriched fraction (R > 0.9). Between tissue and the 
microsomes, six proteins correlated well (R > 0.8). The data points of all analytes are 
depicted as scatter plots (Figure 10, C-D). The quantified amounts from tissue and 
membrane enriched fractions correlated well (Pearson R = 0.93) while the amount from 
tissue and microsomes did correlate slightly (Pearson R = 0.74). 
 
Table 47: Correlation of analyte quantification in different sample preparations. The 
quantified amounts of nine analytes from t hree different sample preparations 
were compared to the amounts quantified from  tissue. Pearson R is given. n=8  
analyte membrane enriched fraction microsome cytosol 
BSEP (GGEK) -0.75 0.96  
MDR1 (LPNK) 0.93 0.98  
MRP1    
MRP2 (GSLR) 0.66 0.87  
MRP3 0.98 0.92  
NTCP 0.39 0.37 0.76 
OAT2 0.94 0.88  
OAT3 0.94 0.87  
OAT7 0.99 0.54 0.75 
SLCO1B1 0.75 0.77 0.52 
 
 
4.2.4 Analyte stability on protein and peptide level 
For a small sample set, it is possible to perform sample preparation without further 
storage. Sample lysis and BCA assay are executed on the first day. Enzymatic 
proteolysis is done overnight, followed by immunoprecipitation on the next morning. 
MS analysis can be started on the afternoon of the second day. But most of the times it 
is more convenient or even necessary to be able to pause the sample preparation and 
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store the samples. Therefore, analyte stability after several freeze-thaw cycles was 
tested on protein and peptide level. Liver tissue of a phenobarbital treated rat was 
lysed for this purpose and split into aliquots after determination of the protein content. 
To test the stability of the proteins, enzymatic proteolysis was started either directly 
or after up to three freeze-thaw cycles. The freezing periods lasted at least four hours 
at - 20°C, the thawing periods one hour at room temperature. Subsequently the 
proteolyzed samples were stored at - 20°C. Analyte stability was determined by 
quantifying ten transporter peptides after immunoprecipitation by tSIM 
measurement. To examine the peptide stability on the other hand, the proteolyzed 
sample was subjected to freeze-thaw cycles. Lysates were frozen once before 
enzymatic proteolysis was started. Immunoprecipitation was either performed 
directly or after one freeze-thaw cycle. The experiment was performed twice with three 
technical replicates each. 
A 
 
B 
 
 Figure 11: Analyte stability on protein and peptide level. The analyte stability on 
protein level was examined by subjecting rat liver lysate to up to three freeze-
thaw cycles (A). The stability on peptide level was det ermined by testing the 
proteolyzed sample (B). Fold change to 1  freeze-thaw cycle and PE are given (n=6). 
ANOVA Bonferroni analysis was performed (p≤0.05).   
The examined analytes were stable on protein level. The quantified amount of all 
analytes was slightly decreased after two freeze-thaw cycles but it did not meet the 
significance criteria (ANOVA Bonferroni (p≤0.05)). Furthermore, no decrease was 
detected after three freeze-thaw cycles ( Figure 11A). The stability of the examined 
analytes in the proteolyzed samples was decreased significantly after one freeze-thaw 
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cycle ( Figure 11B). The quantified amount of all tested peptides was slightly increased, 
after immediate immunoprecipitation. For BSEP, MRP2 and MRP3 this effect was 
more pronounced. 
 
4.2.5 Adjustment of antibody and sample amount 
This experiment served the purpose to determine the minimum amount of antibody 
and proteolyzed sample which was sufficient for stable quantification, as well as to 
choose the best antibody serum, if more than one was available and functional. Three 
different amounts of antibody (1, 2 and 5 µg) were tested as well as three amounts of 
digested sample (10, 20 and 40 µg). The optimal conditions may vary for the same 
antibody – peptide combination between the species. Therefore, all assays were tested 
with pooled human liver samples as well as liver tissue of phenobarbital-treated rats 
and mice.  
The protein amount of tissue lysates was determined before tryptic proteolysis. For 
each purified antibody, nine different immunoprecipitations were performed testing 
each antibody amount with every protein amount. 50 fmol of all respective IS peptides 
were spiked-in. In some cases, when earlier experiments indicated so, 100 fmol 
(LTIIPQDPILFSGSLR, ITIIPQDPVLFSGSLR) or 150 fmol (SPSFADLFR, 
VQQEIDEVIGQVR and VQQEIDAVIGQVR) were spiked in. Eluates were measured 
with tSIM method. 
The amount of quantified target protein per µg proteolyzed protein was determined. 
Data was further analyzed by calculating mean and relative standard deviation of all 
measurements with 1, 2 or 5 µg antibody as well as 10, 20 or 40 µg protein. For better 
discrimination, this was repeated with exclusion of measurements with 10 µg protein 
and 1 µg antibody respectively. A relative standard deviation below 20 % was set as 
criterion for reproducible quantification. All conditions which could not be quantified 
because of EN or IS peptide signal quality, were defined as 0 fmol / µg protein.  
The results for human assays are given below (Table 48), results for rat and mouse 
assays are given in the supplemental information (Table 66 and Table 67). Because 
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human sample material was very limited, antibody sera were excluded from this 
experiment in case of other experiments indicating so (data not shown). Thirteen 
purified antibodies were tested with human material. Six led to very reproducible 
results and can be used with 1 µg antibody and 10 µg extracted protein. Three assays 
can be run with 20 µg protein and either 2 or 5 µg antibody. Two assays required the 
maximal protein amount of 40 µg and at least 5 µg antibody. Only two target proteins 
could not be quantified with any of the tested conditions. 
Table 48: Adjustment of antibody and proteolyzed protein amount for human samples. 
Three different antibody and protein amounts were tested for reproducible 
analyte quantification. For each purified antibody 1, 2  and 5  µg were tested with 
10, 20, and 40 µg proteolyzed protein. Results are given as % RS D. If not stated 
otherwise, the conc lusion column gives the minimal amount of  antibody and 
protein necessary. Antibodies which did not enrich EN or IS  peptide suffi ciently 
for quantification were not used further (n.u.f.).  Antibodies which lead to suitable 
IS  signals and should be tested again when a sample containing this target is 
available are additionally indicated with (#).  
antibody peptide 
10-40 µg protein 20-40 µg protein 1-5 µg AB 2-5 µg AB conclusion 
AB: 
1 –      2 -    5µg 
AB: 
1 –      2 -    5µg 
protein: 
10 –   20 - 40µg 
protein: 
10 –   20 - 40µg 
protein / AB 
…DLFR_rbt3 
LSPSFADLFR 6.0 3.2 4.2 5.9 1.2 4.6 4.2 0.7 6.8 5.8 0.5 2.9 
20 µg / 2µg RPSYLDLFR 38 31 23 53 5.0 11 36 10 36 12 4.7 0.9 
YTASDLFR --- --- --- --- --- --- --- --- --- --- --- --- 
…FFFK_rbt2 FIGLQFFFK 20 51 28 0.9 19 24 36 33 16 14 17 12 40 µg / 6.5 µg 
…GDLK_rbt2 GIYDGDLK 1.6 9.8 2.8 1.8 1.5 3.1 11 6.0 2.5 16 2.1 0.5 10 µg / 1 µg 
…GSLR_rbt1 
LTIIPQDPILFSGSLR 24 28 14 27 0.7 9.2 38 20 25 6.1 27 17 
40 µg /5 µg 
ITIIPQDPVLFSGSLR --- --- --- --- --- --- --- --- --- --- --- --- 
…LEVR_rbt1 GGPEATLEVR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
…LIDK_rbt2 TLGGILAPIYFGALIDK --- 43 4.4 --- 1.4 2.4 106 87 87 58 0.2 4.0 20 µg / 2 µg 
…LTTR_rbt2 
NSPGALTTR 9.6 4.0 6.2 5.2 5.5 2.5 16 1.9 6.0 10 2.1 5.9 
10 µg / 1 µg 
NTTGALTTR 3.3 11 1.2 0.9 5.8 0.4 9.0 8.6 5.5 11 2.9 2.5 
…PSSK_rbt1 YVEQQYGQPSSK 21 6.6 3.3 28 2.2 2.9 13 17 5.9 9.8 1.6 3.5 use other AB 
…PSSK_rbt2 YVEQQYGQPSSK 11 4.5 6.5 9.9 4.3 7.5 12 3.6 2.0 7.0 0.4 2.8 10 µg / 1 µg 
…QDEK_rbt2 NKPLFDTIQDEK 6.0 3.5 4.7 3.8 4.2 4.4 6.4 1.8 4.8 6.4 0.1 0.2 10 µg / 1 µg 
…QDIR_rbt1 LYDPTEGMVSVDGQDIR 2.5 2.7 2.3 3.4 3.2 2.4 2.6 0.8 0.5 3.5 0.2 0.6 10 µg / 1 µg 
…TVEK_rbt1 SSISTVEK 42 17 1.4 26 19 1.8 53 38 17 4.4 30 9.1 20 µg / 5 µg 
…YQVR_rbt1 IQFNNYQVR 5.9 2.4 3.7 2.5 3.2 4.2 2.2 3.7 3.6 0.5 5.0 2.4 10 µg / 1 µg 
 
52 polyclonal antibodies were tested for rattine assays: 23 antibodies met the criteria 
for further method development. Thirteen purified antibody sera were excluded from 
further experiments because another antibody produced better results. For ten TXP -
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epitopes, none of the antibody sera met the criteria. The antibody 
pAB_TXP_LPSK_rbt2 was used further for the assay development, because spiked-in 
IS amount was too low for stable signals, but endogenous peptide could be detected 
in 40 µg proteolyzed protein with 5 µg antibody.  
For murine assay development, 66 purified antibody sera were tested: Nineteen 
antibodies met the criteria and were chosen for further assay development and 
fourteen antibodies were not used further, because another one produced better 
results. Sixteen TXP-epitopes could not be covered by any of the purified antibodies. 
 
4.2.6 Compilation of multiplex assays 
The results of the antibody and protein amount adjustment were used to compile 
multiplexed assays. Following criteria were applied to arrange the assays: 
1. The mass-to charge ratios of all peptides must differ by more than 1 due to data 
analysis requirements. 
2. The antibody amount must not exceed 7 µg. 
3. Each peptide is measured during a 0.6 min time frame. To generate enough data 
points per peak, less than five time frames should overlap at a time. 
4. Minimal sample amount needed for quantification should match. 
5. In case of more than one possible combination, the variant with the highest 
chromatographic resolution is chosen. 
There was an exception of criteria one, for peptides with the same TXP – epitope. In 
case they were separated well in the gradient, they could still be measured in the same 
multiplex. This was the case for the FTNR peptides. 
 
The slope of the LC step gradient was adjusted to improve peptide separation. The 
limiting factor however, was the amount of beads which can be transferred by the 
magnetic particle processor. This confines the total amount of antibody per assay to 
7 µg. During the following experiments, some of the assays were further improved by 
increasing the antibody amount or switching a pair of antibodies between multiplexed 
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assays. The amount of spiked-in IS peptide was also adapted to the expected level of 
endogenous peptide. Here the final assay sets are described. 
 
Figure 12: Adjusted LC gradients for multiplexed human assays. The LC gradients for 
tS IM measurements were flattened to ensure the separation of the increased 
number of peptides per assay. Peptide sequences indicate the retention times  
corrected for the dead time. 
For human samples, three multiplex and one singleplex assays were compiled. They 
allow quantification of eleven transporters, three of which can be analyzed with two 
independent assays. The improved LC step gradients are displayed in Figure 12. The 
percentage of mobile phase B at the time point of peptide elution was estimated by 
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means of the retention time and peptides are depicted at the respective time point. 
Further details are given in Table 49. 
Table 49: Multiplexed transporter assays for human samples. Three multiplex (MPh) and 
one singleplex (S Ph) assays were created. The percentage of mobile phase B at the 
time point of peptide elution was estimated by means of the retention time. The 
antibodies are sorted in alphabetical order, while the peptides are sorted by 
increasing retention time / eluent B percentage.  
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MPh1 10-25 
...DLFR_rbt3 2 µg GIYDGDLK NTCP 50 15 
...LPNK_rbt1 1 µg NKPLFDTIQDEK OAT7 30 16 
...QDEK_rbt2 1 µg YTASDLFR OAT3 100 20 
…GDLK_rbt2 1 µg EANIHAFIESLPNK MDR1 50 22 
  RPSYLDLFR OAT2 50 22 
MPh2 5-25 
...GSLR_rbt1 5 µg YVEQQYGQPSSK SLCO2B1 50 9 
...PSSK_rbt2 2 µg ITIIPQDPVLFSGSLR MRP1 50 25 
  LTIIPQDPILFSGSLR MRP2 50 25 
MPh3 5-25 
...LTTR_rbt2 1 µg NTTGALTTR MDR1 50 7 
...TVEK_rbt1 5 µg NSPGALTTR BSEP 100 7 
...YQVR_rbt1 1 µg SSISTVEK SLCO2B1 50 8 
  IQFNNYQVR MRP2 50 16 
SPh1 10-25 ...GGEK_rbt1 5 µg 
DLSLHVHGGEK MRP3 50 11 
TVAAFGGEK BSEP 50 12 
 
For the analysis of rat samples, 21 antibodies were arranged into seven multiplex and 
one singleplex assays (Table 50). The antibody pAB_TXP_QDIR_rbt1 was part of two 
multiplexed assays depending on the expected amount of endogenous peptide. By this 
means eleven transporters and seventeen CYPs could be quantified, three of which 
were covered by two independent assays.  
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Table 50: Multiplexed TXP assays for rattine samples. Seven multiplex (MPr) and one 
singleplex (SPr) assays were compiled. The percentage of mobile phase B at the time point of 
peptide elution was estimated by means of the retention time. The antibodies are sorted in 
alphabetical order, while the peptides are sorted by increasing retention time / eluent B 
percentage. 
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MPr1 10-25 
...GGEK_rbt1 2 µg NLTLHVQGGEK MRP3 50 12 
...NGER_rbt1 1 µg GIYDGDLK NTCP 50 14 
...QDIR_rbt1 2 µg EYGVIFANGER Cyp2B1/2 150 19 
…GDLK_rbt2 1 µg LYDPIEGEVSIDGQDIR MDR1a/b 100 24 
MPr2 5-25 
...GTVR_rbt1 5 µg NTTGSLTTR MDR1b 50 14 
...LTTR_rbt2 2 µg NTTGALTTR MDR1a 50 15 
  NNPGVLTTR BSEP 50 16 
  LTIIPQEPVLFSGTVR MRP5 100 23 
MPr3 5-25 
...ALEK_rbt1 2 µg AAATEDATPAALEK NTCP 150 11 
...DLFR_rbt3 5 µg ALQRPSYLDLFR OAT2 50 18 
  YGLSDLFR OAT3 30 19 
MPr4 5-30 
...LDDK_rbt1 1 µg EANHLISK Cyp1a2 50 6 
...LDDR_rbt1 1 µg EAEYLISK Cyp1a1 40 14 
...LISK_rbt2 2 µg EIDQVIGSHRPPSLDDR Cyp2b2 50 15 
...QDIR_rbt1 2 µg DFNPQHFLDDK Cyp2a2 50 22 
  LYDPIEGEVSIDGQDIR MDR1a/b 50 28 
  DFDPQNFLDDK Cyp2a1 50 29 
MPr5 5-30 
...EATR_rbt1 5 µg EALVDHGEEFSGR Cyp2c13 50 12 
...FSGR_rbt1 2 µg EALVDHAEAFSGR Cyp2b3 50 14 
  FINLVPSNLPHEATR Cyp2e1 50 18 
  EALDDLGEEFSGR Cyp2c55 50 24 
  EALIDYGEEFSGR Cyp2c12 50 24 
  EALVDLGEEFSGR Cyp2c11 100 27 
hMPr6 5-20 
...FTNR_rbt2 1 µg ECYSTFTNR Cyp3a9 50 11 
...LPNK_rbt2 1 µg TWDPDQPPR Cyp2d3 50 12 
...QPPR_rbt1 1 µg HGEIQFNNYQVR MRP2 50 14 
...YQVR_rbt1 1 µg ECYSVFTNR Cyp3a18 50 15 
  LQDEIDAALPNK Cyp3a9 50 18 
MPr7 10-40 
...EIQK_rbt1 1 µg LQEEIDGALPSK Cyp3a2 200 17 
...LPSK_rbt2 5 µg AMDSFPGPPTHWLFGHALEIQK Cyp4b1 50 28 
SPr1 5-25 ...GSLR_rbt1 5 µg 
ITIIPQDPVLFSGSLR MRP1 50 25 
LTIIPQDPILFSGSLR MRP2 50 25 
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Five multiplexed and two single assays were arranged, for murine samples. Thereby 
five transporters and sixteen CYPs could be quantified with fourteen antibodies. Three 
proteins could be analyzed with two independent assays. 
 
Table 51: Multiplexed TXP assays for murine samples. Five multiplex (MPm) and two 
singleplex (SPm) assays were created. The percentage of mobile phase B at the time point of 
peptide elution was estimated by means of the retention time. The antibodies are sorted in 
alphabetical order, while the peptides are sorted by increasing retention time / eluent B 
percentage. 
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MPm1 5-30 
...ALEK_rbt1 1 µg NVTVHVQGGEK MRP3 50 8 
...GGEK_rbt1 2 µg NTTGALTTR MDR1a 50 8 
...LTTR_rbt2 1 µg NNPGVLTTR BSEP 50 11 
  AAATEDATPAALEK NTCP 150 13 
MPm2 5-25 
...TVEK_rbt1 5 µg SSISTVEK SLCO2B1 50 8 
…GDLK_rbt2 1 µg GIYDGDLK NTCP 50 14 
MPm3 5-20 
...GQVR_rbt1 2 µg TWDPDQPPR Cyp2d40 100 13 
...QPPR_rbt1 5 µg NTWDPDQPPR Cyp2d10 50 13 
  TTWDPTQPPR Cyp2d22 100 15 
  VQQEIDEVIGQVR Cyp2d9 300 20 
  VQQEIDAVIGQVR Cyp2d10 300 20 
MPm4 10-40 
...EATR_rbt1 5 µg NVSQSLTNFSK Cyp2c39 50 16 
...NFSK_rbt1 2 µg NFNQSLTNFSK Cyp2c38 50 19 
  NISQSFTNFSK Cyp2c29 50 19 
  FINLVPSNLPHEATR Cyp2e1 100 23 
MPm5 5-25 
...FSGR_rbt1 2 µg ESLDVTNPR Cyp2c29 100 12 
...LDDK_rbt1 2 µg EALVDHAEAFSGR Cyp2b9 50 15 
...TNPR_rbt2 2 µg EALVGQAEAFSGR Cyp2b10 100 18 
  DFNPQHFLDDK Cyp2a12 50 23 
  EALDDLGEEFSGR Cyp2c55 50 24 
SPm1 5-45 ...NGER_rbt1 5 µg 
GYGVAFSNGER Cyp2a12 50 16 
GYGVTFSNGER Cyp2a22 50 16 
SPm2 5-45 ...FTNR_rbt2 5 µg 
ECYSVFTNR Cyp3a25 50 17 
DCLSVFTNR Cyp3a44 50 22 
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4.2.7 Kinetic of enzymatic proteolysis 
The TXP-method used here quantifies proteins on the basis of proteotypic surrogate 
peptides. Trypsin is highly effective, but the kinetic of proteolysis can vary strongly 
between proteins [100]. Therefore, it was essential to optimize the reaction time of the 
enzymatic proteolysis. 
The objective of this experiment was to determine the optimal duration, which allows 
to quantify all target proteins out of one sample preparation. In order to do so, 
enzymatic proteolysis of liver lysates was terminated at different time points after 2 to 
96 hours. Immunoprecipitation was performed with all antibodies chosen for further 
method development after the adjustment of antibody and lysate amount as well as 
all antibody sera which enriched a suitable amount IS peptide but no quantifiable 
amount endogenous peptide. In addition to the tryptic peptides chosen for 
quantification, the according peptides with one N-terminal tryptic missed cleavage 
site were monitored, but not quantified. The highest quantified amount of each 
peptide was set as one and all other results were given as ratios thereof. The majority 
of proteins, showed an increase up to six or sixteen hours, followed by a plateau or 
slow decrease.  
The digestion kinetics of the human proteins are given in Figure 13. Seventeen out of 
23 tested peptides could be quantified at least at one time point. BSEP was analyzed 
with two peptides, which both reach a plateau between 6 and 66 hours. MDR1 was 
determined via three different peptides. The LPNK and QDIR peptides peak after 6 
and 16 hours respectively followed by a rapid decrease of the quantified amount. The 
third peptide, on the other hand, fluctuates between 70 and 90 % of the maximum 
amount during the complete time course. Both peptides used for MRP2 quantification 
peak at six hours but the decrease is much stronger for the GSLR peptide. No missed 
cleavage peptides were detected at any time point (Table 68). To quantify all human 
targets out of one sample preparation, the best proteolysis duration is between 16 to 
18 hours.  
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Figure 13: Kinetics of tryptic proteolysis for human target proteins. Enzymatic 
proteolysis of a human liver lysate pool  was monitored during a 96 -hours’ time 
course. Results were normalized to the highest quantified amount. The first six 
measurements were performed in triplicates (2 -42h), all others as single  
measurements (66-96h) Means are given, if available. Proteins determined by 
more than one surrogate peptide, are specified by the TXP-epitope of the peptides. 
The best compromise is indicated as gray box.  
 
39 out of 58 tested peptides could be quantified in liver lysate of a PB-treated rat 
(Figure 14). The miscleaved variants of four peptides could be detected either at early 
time points or only in one replicate (Table 69). Another four were detected at all time 
points in at least two replicates. The last peptides were excluded from further method 
development. Three proteins were analyzed by two different peptides: Cyp3a9 was 
determined by means of a FTNR peptide which peaked at 6 hours followed by a strong 
decrease. The LPNK peptide on the other hand reached a plateau after 16 hours. The 
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EIQK peptide for Cyp4b1 quantification peaked already after 2 hours, while the ESTR 
peptide reached a plateau between 6 and 24 hours. At the same time signals for the 
endogenous ESTR peptide were often in the background and therefore not 
quantifiable, whereas the EIQK peptide was quantifiable in all replicates during the 
first 24 hours. The third protein analyzed by two different peptides was NTCP. Both 
peptides reached a plateau, but while the GDLK peptide amount increased for 
42 hours, the ALEK peptide was already at plateau level at the first measured time 
point. As for the human assays, the best compromise was between 16 and 18 hours to 
be able to quantify all targets with the same sample preparation. 
 
Figure 14 Kinetics of tryptic proteolysis for rattine target proteins. Enzymatic proteolysis 
of PB-treated rat liver lysate was monitored during a 96 -hours’ time course. 
Results were normalized to the highest quantified amount. The first six 
measurements were performed in triplicates (2 -42h), all others as single  
measurements (72 -96h) Means are given, if available.  Proteins determined by 
more than one surrogate peptide, are indicated by the TXP-epitope of the 
peptides.  The best compromise is indicated as gray box.  
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Figure 15 Kinetics of tryptic proteolysis for murine target proteins Enzymatic proteolysis 
of PB-treated mouse liver lysate was monitored during a 96 -hours’ time course. 
Results were normalized to the highest quantified amount. The first six 
measurements were performed in triplicates (2 -42h), all others as single  
measurements (72-96h) Means are given, if available. Proteins determined by 
more than one surrogate peptide, are indicated by the TXP-epitope of the 
peptides. The best compromise is indicated as gray box.  
 
In liver lysates of PB-treated mice, 36 out of 52 tested peptides could be quantified. 
Two according N-terminal missed cleavage peptides were detected at early time 
points or only in one replicate. In addition, further nine missed cleavage peptides were 
detected at all time points and in all replicates (Table 70). The latter were removed 
from further method development. Four proteins were determined by two 
independent peptides each. For Cyp2c29, the TNPR peptide reached a plateau after 
16 hours, the NFSK peptide on the other hand, reached a maximum between 6 and 
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16 hours. Both peptides which were used for Cyp2d10 analysis leveled out between 
16 and 42 hours. The peptides of SLCO2B1 also showed the same kinetic: they reached 
a plateau after 24 hours. The rattine and murine assays for NTCP used the same 
peptide and showed the same kinetics, too. As for the human and rattine assays, the 
best compromise of the proteolysis duration was between 16 and 18 hours for a 
standardized sample preparation which allows to quantify all target proteins. Further 
experiments were performed with all antibodies which were able to enrich their target 
peptides for quantification. 
 
4.2.8 Determination of the precise and accurate range of the assays 
In the previous chapters, it was shown, that the developed assays are sensitive and 
stable enough to quantify the target peptides in test samples. Since the expression level 
of the target proteins can vary strongly between sample types, treatments or species, 
it is important to know the range in which the assays are precise and accurate. Therefor 
three serial dilutions of all EN peptides of a multiplexed assay were prepared and 
quantified. The recovery of the EN peptides was determined in percent of the spiked-
in amount. An assay was considered precise and accurate enough, when the recovery 
rate was between 80 and 120 % and, at the same time, the standard deviation was 
below 20 %. This was defined as measuring range, and the limits as lower and upper 
limits of quantification (LLOQ and ULOQ). 
Recovery was determined for 58 peptides. For 54 of these, a measuring range between 
one and four orders of magnitude was observed. For four peptides, the assays were 
either not precise or not accurate enough. Two of the respective proteins could still be 
quantified with another peptide of the set. 
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Figure 16: Recovery plots of selected peptides. A serial dilution of EN peptides in 
b locking buffer and a constant amount of IS  peptides was prepared and 
quantified. Recovery of EN peptide as well as RS D were determined in percent. 
The range between 80  and 120 % is indicated by lines. The range in which peptides 
were quantified in rat samples (4.3.4) are indicated as gray boxes. (n=3) 
 
Representative recovery plots of four peptides are depicted in Figure 16. Most assays 
were precise and accurate for high amounts, but over- (A) or underestimated (B) small 
amounts of EN peptide as well as becoming less precise. The best assays were stable 
within four orders of magnitude (C). In some cases, the assays had also an upper limit 
becoming inaccurate and imprecise for high amounts of spiked-in EN peptide (D). 
Regardless of the characteristics, all assays were suitable for the intended samples: The 
amount quantified in liver tissue of azole treated rats was within the measuring range 
and is indicated in grey (4.3.4). 
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A   rattine assays B   murine assays 
  
C   human assays Figure 17: Measuring range of all assays. 
All EN peptides of a multiplex assay 
were diluted 1  :  3  in b locking buffer 
comprising constant amounts of the 
respective IS  peptides. The tested 
range is depicted in light gray. Each 
measuring point is indicated by a star. 
The measuring range is highlighted in 
dark gray. Here, recovery was between 
80 and 120  % and RS D less than 20  %. 
(n=3)  
 
The recovery plots of all peptides were summarized in Figure 17. Here, the range of 
the serial dilution is indicated in light gray, while the measuring range is highlighted 
in darker gray. In case a peptide was part of several multiplexed assays, a recovery 
plot was produced for each assay. Most of these peptides were in assays for different 
species but LYDPIEGEVSIDGQDIR, which was part of two rattine assays: The assay 
MPr3 was based on less spiked-in IS peptide, to lower the measuring range in 
comparison to MPr1. 
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4.2.9 Reproducibility of TXP-assays 
To investigate the reproducibility of the developed assays, the intraday and interday 
variation were determined. Due to sample availability, for each species a different 
starting point was chosen: For the rat assays, three pieces of liver from the same 
phenobarbital-treated animal were lysed and aliquots were processed individually 
with the TXP method for each intraday experiment. For the murine assays, nine pieces 
of liver from the same phenobarbital-treated animal were lysed and processed 
individually with the TXP method, three for each intraday experiment. Due to low 
sample quantity, an already existing liver lysate was processed thrice to test the human 
assays. Three intraday experiments were merged to obtain the interday variation. All 
data points below LLOQ were set to half LLOQ for following analysis and statistics.  
The LLOQs determined in 4.2.8 were not applicable for the human assays 
MDR1 (QDIR), NTCP and OAT7 because they were measured with preliminary 
multiplexed methods. Here, 1 % of the spiked-in IS peptide was set as lower limit. 
The results are depicted in Figure 18. Since the expression level of the target proteins 
varied between 0.02 and 75 fmol per µg extracted protein, standard deviation of intra - 
and interday variation is expressed in percent in the text for better comparability. 
Fourteen human peptides were tested, two of these were below LLOQ. Nine assays 
showed intraday variation of the quantified targets below 20 %. For two assays, 
MDR1 (QDIR) and SLCO1B1, one intraday experiment resulted in RSDs greater than 
20 %. MRP2 (GSLR) was the only assay which produced always RSDs greater than 
20 %. Eight assays also had an interday variation below 20 %.  
For the rattine assays, 26 out of 31 tested targets could be quantified. Sixteen of these 
assays resulted in an intraday variation of less than 15 % in all experiments, three 
additional ones in less than 20 %. The interday variations of nineteen were also below 
20 %. Only the OAT3 assay never revealed an RSD below 20 %, because one or more 
data points were always below LLOQ.  
Out of 24 murine assays, six quantified the target with intraday variations below 20 %. 
Another four assays, had always intraday variations greater than 20 % and five targets 
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were constantly below LLOQ. The remaining nine assays resulted in at least one 
replicate below 20 % RSD but also at least one with up to 35 % intraday variation. Ten 
of these showed interday variation below 30 %. 
A   rattine transporter assays B   rattine CYP assays 
  
C   murine transporter assays D    murine CYP assays 
  
E   human transporter assays  
 
Figure 18: Intra- and interday variation 
Liver tissue of phenobarbital-treated 
animals was used to determine 
intraday variation of rat and mouse 
TXP assays (A-D). Human assays were 
tested with one liver lysate (E) (n=3). 
All intraday experiments were merged 
to calculate interday variation (n=9). 
Data points below LLOQ were set to 
0.5  LLOQ. Mean and S D are given.  
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4.3 Application of the developed assays 
4.3.1 Study of transporter amount in healthy human liver tissue 
Transporter expression in healthy liver tissue which was removed in the course of 
carcinoma therapy was analyzed. Tissue was processed according to TXP method and 
immunoprecipitation was performed with 30 µg proteolyzed protein. Nine out of ten 
transporters could be quantified in the samples (Figure 19). The expression of the 
transporters was between 0.1 and 1.1 fmol per µg protein. MRP1 was below detection 
limit in all samples. Most transporters were expressed homogenously, but OAT2 and 
OAT7 showed a greater variety. The differences could not be linked to the medication 
of the patients. 
 
Figure 19: Transporter expression in healthy human liver tissue. Ten analytes were 
quantified in b iopsies of healthy liver tissue. Data po ints below LLOQ were set to 
0.5  LLOQ for further analysis and are indicated in red. MRP1 was below LLOQ in 
all samples and is not depicted.  n=15 
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4.3.2 Study of transporter amount in paired kidney samples 
Kidney biopsies from eleven patients were tested for differences of protein expression 
in normal tissue and tumor tissue. Protein expression profiles were compared to 
expressed sequence tag (EST) profiles of UniGene (Table 52). 
Two proteins, MDR1 and MRP1, could be quantified in both samples types. For MDR1, 
this was in accordance with the EST profiles, while MRP1 expression is not predicted 
for tumor tissue. OAT2 and OAT3 were detected only in normal tissue as predicted by 
the EST profiles. MRP2 showed a similar pattern, even though it should be expressed 
in both tissue types according to the EST profile. As predicted by the EST profiles, 
three proteins could not be detected in any sample: BSEP, OAT7 and SLCO1B1. 
Additionally, SLCO2B1, MRP3 and NTCP were also below LLOQ in most samples. 
 
 
Figure 20: Comparison of transporter expression in paired kidney samples. Expression in 
tumor and normal tissue samples of the same patient was quantified. Values 
below LLOQ were set to 0.5  LLOQ for further analysis. Results are expressed as 
logarithmized fold change. Positive values indicate upregulation  in the tumor 
tissue.  
 
The protein expression of four transporters was downregulated in the tumor, while 
two transporters were upregulated (Figure 20). The expression profile of patient 
eleven differed with respect to the downregulated transporters: MDR1, MRP2, OAT2 
and OAT3 were expressed less in normal tissue in comparison to the other patients. At 
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the same time, MDR1 and OAT2 were stronger expressed in the tumor tissue. This led 
to an upregulation of MDR1 and MRP2 and only a slight downregulation of OAT2 and 
OAT3 in the tumor tissue compared to the normal tissue sample. 
Table 52: Transporter quantification in malign and benign kidney tissue. The protein 
expression of eleven transporters was investigated  in normal (N) kidney tissue 
and tumor (T) tissue by TXP quantification . Immunoprecipitation was performed 
with 50  µg protein. Results are expressed as fmol per µg extracted protein. Gray 
fields indicate measurements below LLOQ. The last row indicates whether the 
ES T profile of UniGene predicts mRNA expression in healthy kidney (N) and 
kidney tumors (T).  
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N   1.21 0.04 0.20     0.35 1.95       
T   5.58 0.23                 
2 
N   1.36 0.07 0.30     0.29 2.16       
T   0.89 0.16   0.30             
3 
N   1.54 0.03 0.50     0.06 4.28       
T   0.09 0.70   0.82 0.05           
4 
N   1.07 0.09       0.47 1.88       
T   0.48 0.12                 
5 
N   1.77 0.03 0.46     0.42 4.54       
T   0.03                   
6 
N   1.58 0.03 0.35     0.53 3.22       
T   0.24 0.12 0.13               
7 
N   1.27   0.35     0.30 4.33       
T   0.07 0.05                 
8 
N   1.19   0.38     0.22 6.84       
T   0.34 0.22                 
9 
N   0.98 0.05 0.22     0.29 3.11       
T   0.07     0.47 0.01           
10 
N   3.54   1.11     0.70 6.36       
T   0.02                   
11 
N   0.31 0.08       0.12 0.04       
T   6.66 0.25 0.14 0.74   0.09         
kidney 
EST profile 
N   yes yes yes yes yes yes yes     yes 
T   yes   yes yes yes         yes 
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4.3.3 Protein expression in periportal and pericentral liver cells 
Periportal and pericentral liver cells were isolated selectively by digitonin/collagenase 
perfusion from murine liver. Immunoprecipitation of the processed samples was 
performed with 5 µg extracted protein because of the small sample amount. Four 
transporters and nine CYPs could be quantified. The transporters showed no different 
expression level, but three CYPs, Cyp2c29, Cyp2c55 and Cyp2e1, were expressed 
higher in pericentral cells.  
A B 
  
Figure 21: Protein expression in periportal and pericentral cells. Periportal (PP) and 
pericentral (PC) cells were isolated by perfusion from two mice each.  The amount 
is given for each mouse individually (A) as well as the logarithmized ratio of the 
means (B).  Results below LLOQ were set to 0.5  LLOQ for further analysis.  
 
4.3.4 Cross species study of fungicides affecting protein expression 
The effects of three azole fungicides, cyproconazole, epoxiconazole and prochloraz, as 
well as mixtures thereof were investigated in four different models: rats, mice, 
humanized mice and human cell culture. Frozen liver tissue and lysed cell pellets were 
processed according to the TXP – protocol.  
For the cell culture experiment, the human liver cell line HepaRG was used. Cells were 
treated for 24 h with the four concentrations of each substance and mixture except for 
the positive control Citco, which was applied in three doses and with two different 
media. The differentiation medium (DM) contained more DMSO and fetal calf serum 
than the work medium (WM). In general, the protein expression of the tested 
transporters did not change much as response to the different treatments (Figure 22). 
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MDR1 increased slightly with increasing concentration of mix II but not the single 
substances. Citco with differentiation medium, on the other hand, led to a slight 
decrease in comparison to the solvent control. MRP1 amounts increased with 
epoxiconazole concentration and less pronounced with increasing concentration of 
mix I. MRP2 was induced slightly with increasing epoxiconazole and mix II 
concentration but not by mix I. Transporter MRP3 expression was not affected by any 
treatment but by the change of media for the positive control. The reduction of DMSO 
and fetal calf serum resulted in higher MRP3 expression regardless of the addition of 
Citco. NTCP amounts decreased with increasing prochloraz concentration. In 
addition, treatment with mix I resulted in lower NTCP expression than treatment with 
the single substances and mix II. SLCO2B1 decreased strongly after treatment with 
40 µM prochloraz but was not affected by the other conditions. OAT2 and SLCO1B1 
amounts were close to and below the LLOQ of the respective TXP assay. This resulted 
in high SDs and it was not possible to draw a conclusion whether the expression was 
affected by the test substances. However, OAT2 did react to the different media used 
for the positive control. Reduction of DMSO and fetal calf serum led to increased OAT2 
amounts regardless of the addition of Citco. 
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B 
 
Figure 22: Protein expression of HepaRG cells treated with fungicides. HepaRG cells were 
treated for 24  h with cyproconazole (Cypro), epoxiconazole (Epoxi), prochloraz 
(Prz) or combinations thereof (mix  I: Cypro + Epoxi and mix II: Cypro +Epoxi+Prz) 
(A). Additionally,  Citco was used as control substance with two different media 
(DM and WM) (B). S olvent controls are indicated with S C . Values below LLOQ 
were set to 0.5  LLOQ for further analysis. Mean and S D are given. S ignificant 
differences to control (DM) are indicated ( Two sample t-test for unequal variances 
with Bonferroni correction). n=4, solvent control n=8  
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The rats were treated with the same substances as used in the cell culture experiment 
but only two concentrations were tested (Figure 23). Additionally, Citco was replaced 
by phenobarbital as positive control. Cyp1a1 and Cyp1a2 were induced significantly 
by the high doses of epoxiconazole and mix II. Cyp3a9, Cyp3a18, MRP2 and MRP3 
were induced by the high doses of cyproconazole, epoxiconazole and both mixes. The 
transporters were also induced by phenobarbital and were affected stronger by the 
mixes than by the single substances. All fungicides and mixes increased the amounts 
of Cyp2a2, Cyp2b1/2, Cyp2b2, Cyp2c13 and Cyp2c55 as well as the transporters BSEP, 
MDR1a and MDR1a/b. The induction of these proteins was mainly dose dependent 
and Cyp2b1/2, Cyp2b2, MDR1a and MDR1a/b were affected stronger by the mixes 
than by the single substances. Cyp2b1/2, Cyp2b2, MDR1a and MDR1a/b were also 
induced by phenobarbital. Cyp2b3 amounts were slightly increased after treatment 
with cyproconazole and mix II. Cyp2c12, Cyp2e1 and NTCP were not affected by the 
test substances. The amount of Cyp2d3 was decreased by treatment with high doses 
of cyproconazole and both mixes as well as phenobarbital. OAT2 amounts were 
reduced by phenobarbital, cyproconazole, epoxiconazole and both mixes. The 
expression of OAT3 was reduced by all substances in the high dose as well as both 
mixes in a dose dependent manner. Cyp2c11 amounts were reduced by treatment with 
the high doses of the mixes. All proteins were reduced stronger by the mixes than by 
the single substances. MDR1b, MRP1 and MRP5 were below LLOQ in all samples.  
Results 
85 
 
Figure 23: CYP and transporter protein expression in livers of fungicide treated rats. 
Animals were treated for 28 days with cyproconazole (Cypro), epoxiconazole 
(Epoxi), prochloraz (Prz) or combinations thereof (mix  I: Cypro + Epoxi and 
mix II: Cypro + Epoxi +  Prz) as well as PB as positive control. CYP and transporter 
expression in liver tissue was quantified. Values below LLOQ were set to 
0.5  LLOQ for further analysis. Mean and S D are given.  S ignificant differences to 
respective control are indicated (Two sample t-test for unequal variances with 
Bonferroni correction). Control groups did not differ significantly. 
n=5, mixes n=10 
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The mouse experiment was performed to compare how wildtype and humanized mice 
are affected by the fungicides. The humanized mice express only the human forms of 
the nuclear receptors CAR and PXR. Two concentrations of cyproconazole and 
prochloraz as well as phenobarbital as positive control were tested. In general, it could 
be observed, that the protein expression was induced by all test substances and that 
humanized animals were affected less strongly (Figure 24). Cyp2c38 was only induced 
by cyproconazole, while Cyp2b9 was induced by cyproconazole and phenobarbital 
but not by epoxiconazole. Cyp2e1 amounts were increased slightly by phenobarbital 
and epoxiconazole in wildtype mice. The high dose of cyproconazole, on the other 
hand, decreased the amount of Cyp2e1. In the humanized mice, Cyp2e1 was decreased 
slightly after cyproconazole and low epoxiconazole treatment. NTCP and SLCO2B1 
amounts were hardly affected by the treatments short of the high cyproconazole dose. 
It led to decreased expression of these transporters. BSEP and MDR1a were hardly 
affected and Cyp2a22, Cyp2d40 as well as Cyp3a44 were below LLOQ of the respective 
assay in all samples. 
Additionally, it was compared how the azole fungicides affected ortholog proteins in 
the different models. Cyproconazole and prochloraz were administered in all 
experimental set ups. For the comparison, only two concentrations of the cell culture 
experiment were considered. They correspond to the amounts quantified in rat liver 
tissue after cyproconazole and prochloraz treatment [91].  
 
Results 
87 
 
Figure 24: Protein expression in wildtype and humanized mice after fungicide treatment. 
Mice which express the human forms of the nuclear receptors CAR and PXR were 
compared to wildtype mice. Animals were treated for 28 days with cyproconazole 
(Cypro), prochloraz (Prz) or phenobarbital (PB). CYP and transporter expression 
in liver tissue was quantified.  Values below LLOQ were set to 0.5  LLOQ for 
further analysis.  Mean and S D are given.  S ignificant differences to respective 
control are indicated (* p<0.05 and # p<0.01) as well as differ ences to the wildtype  
group with same treatment (° p<0.05 and + p<0.01). (Two sample t-test for unequal 
variances with Bonferroni correction) n=5 
 
MDR1/a, MRP3 and NTCP were quantified with the same TXP assay in all models 
(Figure 25). MDR1a was induced by cyproconazole and to a lesser extent by 
epoxiconazole in the rodent models. In HepaRG cells, the transporter was not affected 
by the treatments. MRP3 amounts were increased by the fungicides in rats and 
wildtype mice. This effect was not observed in humanized mice and HepaRG. The 
expression of NTCP was only decreased by the high dose of cyproconazole in both 
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murine models. All other conditions did not affect its expression level. In general, 
MDR1 and MRP3 were expressed higher in HepaRG than in the rodent models. NTCP 
amounts, on the other hand, were much lower in the cell culture samples than in the 
rodent tissue samples. For the humanized mouse models, the expression levels were 
similar to the other rodent models, but the reaction to the treatment matched better 
with the HepaRG than the other rodent models did.  
 
Figure 25: Comparison of fungicide treatment in different experimental models. MDR1(a), 
MRP3 and NTCP were measured in all models with the same TXP assay while the 
CYPs were measured only in the rodent models with the same TXP assays. The 
HepaRG CYP data was kindly provided by Frederik  Weiß and thus analyzed with 
different TXP assays. Orthologous proteins are arranged in columns. The rodent 
Cyp2c55 is orthologous to the human Cyp2c8, Cyp2c9 and Cyp2c19 . Mean and SD 
are given. Rodent models n=5, HepaRG n=4.  
 
The rodent CYP data is complemented by data from HepaRG, which were kindly 
analyzed and provided by Frederik Weiß. Cyp2e1 was quantified with the same TXP 
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assay in rodents. For the human HepaRGs the peptide DEFSGR was used. The 
expression level of Cyp2e1 was higher in rodents than in HepaRG. Treatment with 
cyproconazole or prochloraz did not affect the expression in HepaRG and in rats. In 
the murine models cyproconazole reduced the Cyp2e1 expression. This was more 
pronounced in the wildtype mice. The human Cyp2b6 has several orthologs in 
rodents. Cyp2b9 in mice and Cyp2b3 in rats are two of them [47, 48]. In contrast to 
Cyp2b3 and Cyp2b9, Cyp2b6 was quantified using the peptide AEAFSGR. While the 
Cyp2b3 and Cyp2b6 were not affected by the treatment, the amount of murine Cyp2b9 
was increased by cyproconazole. Humanized mice were affected to a lesser extent than 
the wildtype animals. Furthermore, the basal expression level was highest in rats and 
lowest in the murine models. The rodent Cyp2c55 has several orthologs in humans: 
Cyp2c8 (EALIDNGEEFSGR), Cyp2c9 (GIFPLAER), Cyp2c18 (EALIDHGEEFSGR) and 
Cyp2c19 (GHFPLAER) [22, 47, 48]. Cyp2c55 was induced in rats and mice by all tested 
substances, but by far the most with the high dose of cyproconazole. At the same time, 
none of the human orthologous proteins was induced by the treatment. Cyp2c18 was 
below the LOQ of the respective TXP assay. 
Additionally, three analytes were quantified in two species: MRP2 was quantified in 
HepaRG and rat. In both models the expression was affected by epoxiconazole and the 
mixes. SLCO2B1 was not affected by the treatment in HepaRG and humanized mice, 
but was decreased by cyproconazole in wildtype mice. Cyp3a25 in mice and Cyp3a18 
in rats were analyzed with the same assay: Both analytes were induced by 
cyproconazole and epoxiconazole. Induction by the high cyproconazole dose had by 
far the greatest effect in all models.  
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5 Discussion 
5.1 Selection of TXP epitopes 
The TXP epitopes and proteotypic peptide standards for new TXP assays are chosen 
by bioinformatical means and peptides and epitopes with undesirable characteristics 
are excluded. Nonetheless, it is not possible to predict for which epitope a sensitive 
assay can be developed, because a multitude of factors influence the production of 
TXP antibodies. Retrospectively, two aspects which have been discussed to be 
included in the selection process have been analyzed: The number of proteins which 
are addressed by a TXP epitope and whether or not a high abundant protein is 
addressed [22].  
To investigate the effect of the number of proteins covered by a TXP epitope, the ratio 
of proteins covered and all UniProtKB reference proteome entries for this species were 
determined. The ratio was used to correct the bias of using a database which is still 
under progress. Subsequently, TXP epitopes were sorted into groups for successful 
and non-successful assay development for each species separately. These groups could 
not be discriminated by the protein ratios. 
To test the effect of high abundant proteins sharing the TXP epitope on the success rate 
of the assay development, fifteen high abundant liver proteins were chosen per species 
(Table 45). 13 % of the chosen TXP epitopes target one or more high abundant proteins. 
Excluding these epitopes from the assay development would not improve the success 
rate. In fact, 13 % of the assays in the final set use an antibody which addresses also a 
high abundant protein. The presence in high abundant proteins of representative 
epitopes was compared to the success of assay development in Table 53. The complete 
list is given in the supplemental information (Table 60). This selection of epitopes 
shows that the epitope presence in these high abundant proteins could not be linked 
to the success rate of assay development: The epitopes DLVR, LTTR, QDEK and YQVR 
did not address one of the high abundant proteins, but it was still not possible to 
establish a TXP assay for DLVR. On the other hand, it was possible to develop assays 
with the TXP epitope EATR even though it is present in a high abundant protein. This 
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becomes even more apparent, when the different species are taken into account. While 
LDDK and NGER addressed only high abundant proteins of one species, it was 
possible to establish a functional assay in all tested species. Vice versa, even though 
LSGK addressed only human phosphatidylethanolamine-binding protein 1, it was not 
possible to establish a functional assay in any of the tested species. 
 
Table 53: Comparison of epitope presence and successful assay development.  The 
presence of a TXP epitope in one or two of the high abundant proteins  (HAP) is 
indicated by light red (  1  ) or dark red ( 2  ) respectively. Green fields (ab) indicate 
successful assay development, gray fields ( ab) indicate either no presence in high 
abundant proteins or no successful method development and white fields ( ab) no 
measurement at all.  
epitope 
epitope present in HAP                        
human                 rat                  mouse 
successful assay development                   
human                  rat                mouse 
DLFR   2    
DLVR       
EATR  1 1    
EVLR  1     
LDDK  1     
LSGK 1      
LTTR       
NGER   1    
QDEK       
YQVR       
 
Therefore, the amount of addressed proteins and the epitope presence in high 
abundant proteins should not be considered in the selection process. It is likely that 
they influence the sensitivity of the TXP epitope but the effects are very small in 
comparison to other factors, for example the difference between the sera of two 
animals. Adding these criteria to the selection process would result in rejecting also 
epitopes which are suitable for TXP assays without improving the success rate of the 
assay development.  
 
5.2 TXP assay development 
The sequence logos were created with a standardized matrix produced from lysates of 
three different human cell lines. It has been shown that sequence logos generated for 
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different human cell lines vary only slightly [35]. To ensure that the sequence logos 
can also be applied for other species and tissues, three antibodies were analyzed with 
mouse and rat liver as well as rattine heart and kidney. All samples resulted in similar 
sequence logos. Restrictive positions of the epitope as well as preferences for certain 
amino acids were conserved in all sample types. This showed that the binding motif 
determined with the standardized matrix can be transferred between sample types, 
organs and species. The sequence logos served as quality control of the immunization 
process as well as reference for the selection process of new TXP assays. They could 
not be used as decision criterion whether to pursue assay development or not, because 
enrichment of the target peptide did not correlate well. Eight purified antibody sera 
enriched the spiked-in target peptide even though no statistically significant sequence 
logo could be determined. 
Several antibodies enriched spiked-in peptides well, but no endogen peptide could be 
detected in the samples used for the assay development. Two explanations could be 
that either the target proteins were not expressed in the sample or that the assays were 
not sensitive enough. To examine the latter, ten transporters were quantified in human 
liver tissue samples and preparations thereof: membrane enriched fractions, 
microsomes and cytosol as negative control. All analytes could be quantified either in 
all tissue samples and enriched sample preparations or none except for BSEP. It could 
be quantified in all membrane enriched fractions, but was below LLOQ for some tissue 
and microsomal samples. This was resolved by using a more sensitive assay (BSEP 
(LTTR)) which utilizes a different surrogate peptide. The analytes were enriched two- 
to fivefold in the membrane enriched fraction and up to twofold in the microsomal 
fractions. This can also be achieved by using more proteolyzed protein for the 
immunoprecipitation. Thus, there is no benefit in additional sample prefractionation 
like ultracentrifugation to enrich the target proteins. Furthermore, the quantified 
amounts correlated better between tissue and membrane enriched fractions which had 
been prepared by one additional step than between tissue and microsomal 
preparations. This is may be caused by sample loss during additional work steps of 
Discussion 
94 
the microsome preparation work flow. Additionally, fractionation of samples results 
in loss of the analytes, especially when an analyte is distributed over more than one 
fraction [101, 102]. Each step of the sample preparation is time consuming and an 
additional source of errors. Therefore, it was resigned from additional subcellular 
fractionation to enrich the analytes. 
Another important issue was after which steps of the preparation the analysis can be 
interrupted and the samples be stored. The stability experiments showed that the 
analytes were more stable at protein level than on the peptide level. Therefor it was 
preferred to store samples as lysates instead of proteolyzed solutions. Due to limited 
sample amounts and time, it was not possible to also test the stability of the frozen 
tissue samples. However, the sample set used to compare different forms of sample 
preparation was collected between December 1999 and August 2001. The samples used 
to study transporter expression in healthy human liver, on the other hand, were 
collected between August 2013 and March 2015. The samples had nothing in common 
but being human liver tissue samples. Nevertheless, the quantified amounts were in 
the same range for each target protein (Table 54 in the supplemental data). Therefor it 
can be assumed that storage of frozen tissue is not problematic for this assay. 
Following the functionality test of the antibodies, it was estimated how much antibody 
and proteolyzed protein was needed to ensure a stable quantification. This 
experiments was also used to choose the better antibody in case more than one passed 
the first threshold. The design of the experiment made it difficult to decide whether an 
assay could be set up only with 5 µg antibody and 40 µg proteolyzed protein because 
this decision had to be based on a single measurement. Hence RSD as criterion was 
not applicable. Therefore, MS signal quality was taken into account. In case the 
peptides were detectable under two other conditions but with high RSD, it was 
estimated as likely that the assay could be used with 5 µg antibody and 40 µg 
proteolyzed protein. Four antibodies were tested further with reservation: 
pAB_TXP_LPSK_rbt2 and pAB_TXP_GTVR_rbt1 as well as pAB_TXP_ESTR_rbt1 and 
pAB_TXP_KPHR_rbt1. The first two turned out to be suitable assays, while the 
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development for the latter two had to be terminated. Assays which reliably enriched 
the IS peptide but no endogenous peptide were excluded from further assay 
development unless the antibody was part of another assay which fulfilled the criteria. 
This was done in case they could be measured in other sample types. This was the case 
for MRP1 (GSLR) and ABCB1b (LLTR). While MRP1 could be quantified in human 
kidney and HepaRG, ABCB1b was below detection limit in all tested samples. Based 
on this experiment multiplexed assays were arranged to reduce the required sample 
amount and time. The limiting factor was the amount of bead solution, which could 
be transferred completely during the immunoprecipitation with the magnetic particle 
processor. Remnants in the eluate could clog the chromatography system and damage 
the columns. Four multiplexed assays for human samples, eight for rattine and seven 
for murine samples were established. 
The multiplexed assays were used to examine the kinetics of tryptic proteolysis which 
can vary strongly between different proteins [100] and even different cleavage points 
of the same protein. Three proteins with very differing kinetics are for example human 
MRP3, OAT3 and SLCO1B1. While the quantified amount of MRP3 decreased from 
the first measuring point after two hours, SLCO1B1 showed the other extreme: The 
quantified amount increased for 66 hours before it reached a plateau. OAT3, on the 
other hand, stayed on a plateau for 72 hours. The human transporter MDR1 was 
quantified by means of three peptides, while two peaked within 16 hours followed by 
a decrease, the third peptide stayed on a plateau for 96 hours. Therefore, it is very 
important to determine the proteolysis kinetics of every analyte. Overnight proteolysis 
was not optimal for several analytes, but it was the best compromise which allowed to 
quantify all analytes subsequently to the same sample preparation. This was observed 
for all three species independently.  
LLOQ and ULOQ of the assays were estimated by quantifying a dilution series of 
synthetic EN peptide in blocking buffer. It would have been more accurate to use 
forward and reverse curves as described for example by Razavi et al. [103] but this 
requires large amount of sample which is especially difficult for human tissue. 
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Therefore, the proteolyzed sample was imitated by digested fish gelatin. This had the 
additional advantage, that there were no endogenous levels of the analytes. The tested 
range was based on earlier experiments with one additional order of magnitude at the 
lower end [22]. The TXP assays covered a range of one to four orders of magnitude in 
which the recovery was precise and accurate. The characteristics of the recovery plots 
depend on the peptide as well as on the used purified antibody serum. Cyp2a1 and 
Cyp2a2 for example were both quantified by using the antibody 
pAB_TXP_LLDK_rbt1. Below the LLOQ Cyp2a1 amount was overestimated while 
Cyp2a2 was underestimated. Low analyte amounts resulted in imprecise and 
inaccurate measurements. For all assays the LLOQ lay within the tested range. It is 
very likely that the assays also become imprecise or inaccurate for very high amounts 
of EN peptide, but for most assays this was not the case within the tested range. The 
tested range was not extended, because it already spanned the range expected in the 
samples. 
Last but not least, the intra- and interday variation of the developed assays was 
determined. Due to sample availability, a different starting point was chosen for each 
species. For the human assay set, one lysate was processed nine times. For the rat assay 
set one tissue sample was split into three pieces and resulting lysates were processed 
for each intra assay experiment. For the murine assays, the tissue sample was split into 
nine pieces, three for each intraday experiment. This influenced also the RSDs of the 
intra- and interday experiments. While the vast majority of all intraday and interday 
variations were below 20 % in human and rattine samples, only four analytes of the 
murine sets achieved an interday variation below 20 %. This was especially apparent 
for NTCP which was quantified in every species with the GDLK peptide. While the 
RSD of all intraday and the interday variations were below 20 % in human and rat 
samples, they were between 26 and 57 % for the murine samples. This suggested, that 
the lysis of very small tissue pieces, which had been used for the murine experiment, 
was still the greatest source of imprecision. Therefore, the lysis of very small tissue 
Discussion 
97 
samples should be either further improved or it should be refrained from using tissue 
samples smaller than 15 mg. 
Measuring a target protein with more than one TXP assay is a good quality control. 
For the human MDR1, three TXP assays were tested: MDR1 (QDIR) and MDR1 (LTTR) 
as well as MDR1 (LPNK) which was developed by Frederik Weiss [22]. The set of 
healthy liver tissue samples (4.3.1) was analyzed with all MDR1 TXP assays (Figure 
26). While the results of the LPNK and the LTTR assay matched very well, the 
quantified amount of the QDIR assay differed tremendously. Since the QDIR antibody 
worked well with the rat peptide, this was probably due to the peptide of the human 
assay. According to UniProtKB, none of the peptides contains a known position for 
amino acid modification or natural sequence variants, which could explain the 
differences (Table 71). However, only the human QDIR peptide contained a 
methionine which is prone to oxidation. Therefore, the MDR1 (QDIR) assay was not 
used further. MDR1 (LTTR) was the assay of choice, because it had the lowest LLOQ 
and a lower intra- and interday variation. 
 
Figure 26: Comparison of three TXP assays for MDR1 quantification. The human liver  
b iopsies described in 4.3.1  were analyzed with three independent TXP assays for 
MDR1 quantification.  Fold change is given with respect to patient # 2 . 
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Figure 27: Comparison of two TXP assays for human BSEP quantification. The human 
liver b iopsies described in 4.3.1  were analyzed with two independent TXP assays 
for BS EP quantification. The samples of patients 7 -9, 11-13 and 15 were below the 
LLOQ of both assays. Fold change is given with respect to patient # 2 . 
Human BSEP could also be analyzed with two antibodies (Figure 27). The results were 
in line, but the LTTR assay had a lower LLOQ and the peptide a slightly better 
proteolysis kinetics. Since both antibodies were needed to cover other targets and 
natural sequence variants were reported for both peptides (Table 71), BSEP was 
quantified with the LTTR assay and the GGEK assay was used as quality control. The 
results gained with MRP2 (YQVR) and MRP2 (GSLR) were comparable (Figure 28) but 
the YQVR assay was favored because its peptide was more stable during proteolysis 
and the assay showed a lower LLOQ and inter- and intraday variation. Additionally, 
no modified amino acid or natural sequence variant was reported for the YQVR 
peptide while there were reported two for the GSLR peptide in patients with Dubin – 
Johnson – Syndrome (Table 71) [104]. 
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Figure 28: Comparison of two TXP assays for human MRP2 quantification.  MRP2 was 
quantified in HepaRG (4.3.4) with two independent TXP assays. Fold change to 
control is given. n=4  
 
While there was only one assay to quantify NTCP in human, an alternative assay was 
established for rodents. The assays demonstrated good comparability in the cross 
species approach even though only for the ALEK peptides a site of amino acid 
modification was reported (Table 71, Figure 29 and Figure 25). Both assays had similar 
measuring ranges and inter- and intraday variation. Since the ALEK peptide was 
released much faster during proteolysis than the GDLK peptide and was also stable, 
this assay was preferred for projects without human samples. 
 
 
Figure 29: Comparison of two TXP assays for rodent NTCP quantification.  NTCP was 
quantified in wild type mice and humanized mice ( 4.3.4) with two independent 
TXP assays. Fold change to wildtype control is given. n=5   
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Figure 30: CYP quantification by two independent TXP assays. Cyp2a12 (A), Cyp2c29 (B) 
and Cyp2d10 (C) were quantified in wild type mice and humanized mice (4.3.4) 
with two independent TXP assays each. Fold change to wildtype control is given. 
n=5 
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For murine Cyp2a12, Cyp2c29 and Cyp2d10, two independent TXP assays were 
developed, too. The CYP expression in the fungicide-treated mice was analyzed with 
two assays each (Figure 30). As for NTCP, the results matched very well. Cyp2c29 
(NFSK) and Cyp2d10 (QPPR) were the preferred assays, because they had lower intra - 
and interday variations as well as lower LLOQs. Additionally, the QPPR peptide was 
more stable during proteolysis. For Cyp2a12 the LDDK peptide was slightly more 
stable during proteolysis and had the lower LLOQ. However, the NGER assay was 
preferred, because it showed less intra- and interday variation and was sensitive 
enough for the expected expression levels in the samples. 
Four analytes were covered twice with the rattine TXP assay set. The quantified 
amounts of Cyp3a9 (FTNR) and Cyp3a9 (LPNK) did not agree as well as for the other 
assays (Figure 31, A). While the FTNR assays varied less in the intra- and interday 
experiment, the LPNK assay had a lower LLOQ and the peptide stayed on a plateau 
during proteolysis. Therefore, Cyp3a9 (LPNK) was chosen for the analysis of the 
fungicide treated rats. For Cyp4b1 quantification, two peptides were tested. The EIQK 
peptide peaked already after 2 hours proteolysis, while the ESTR peptide reached a 
plateau. At the same time, only the EIQK peptides was quantifiable in all replicates 
during the first 24 hours. The problematic reproducibility of the ESTR peptide was also 
reflected in the recovery plot. For this assay, no measuring range could be estimated 
because it was too imprecise. Therefore, only the Cyp4b1 (EIQK) assay was 
established. As for the human MRP2, the rattine MRP2 was best measured with the 
YQVR assay. The results matched very well (Figure 31), but inter- and intraday 
variation as well the LLOQ were lower. 
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Figure 31: Quantification of rat Cyp3a9 and MRP2 by two independent TXP assays each. 
Cyp3a9 (A) and MRP2 (B) were quantified in fungicide-treated rats (4.3.4) with 
two independent TXP assays each. Fold change to first control group is given. n=5, 
mixes: n=10  
 
5.3 Thresholds for effective assay development 
During this thesis, TXP assays for 71 proteins and three species should be developed. 
This included testing 151 purified antibodies and 144 peptides for their usability. The 
choice of thresholds was critical to reduce required sample amount, costs and time by 
sorting out unsuitable sera and peptides as early as possible. The first criterion was 
that each antibody had to enrich at least one spiked-in target peptide and each 
surrogate peptide had to be enriched by at least one antibody. The threshold was a 
total file area greater than 104 of the tSIM signal. This led to a reduction of the tested 
antibodies and peptides in the following experiments of 38 % and 29 % respectively. 
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By increasing the threshold to 105 the number of purified antibody sera could have 
been reduced by 53 %. Then again, four antibody sera and five peptides which are part 
of the final TXP assay set would have been sorted out by this threshold. This amounts 
to 10 % of the final assay set. The second experiment, which was used to select the 
most promising antibodies and peptides, was the adjustment of the required antibody 
and protein amount. With two experiments, the number of antibodies and peptides 
was reduced to 75 assays for which successful assay development was very likely. 23 
assays were quit even though they enriched spiked-in peptides well but no 
endogenous peptide could be detected. They can be continued with samples 
expressing the target proteins. The study of the enzymatic proteolysis was used to 
double-check the antibodies which were chosen with reservation during the 
adjustment or discarded because no endogenous peptide could be detected. None of 
the endogenous surrogate peptides of the discarded assays could be detected. Thereby 
the decision to quit these assays was confirmed. Additionally, surrogate peptides were 
sorted out for which missed cleavage peptide variants were detectable. Of the 
remaining 58 assays, only four had to be discarded because they did not meet the 
required precision and accuracy criteria. This shows that these three experiments and 
the respective thresholds were well suited to select the antibodies and peptides for 
which successful assay development was very likely.  
During this thesis, 54 single TXP assays which could be combined to 19 multiplexed 
assays have been developed. Even though the development already examined some 
aspects which are tested during assay validation, this has not been done as extensively 
as it is needed for a full validation. The accuracy of the quantification could be further 
improved by determining the amount of the peptide standards by means of amino 
acid analysis. This would also further improve the comparability of quantification 
with two independent TXP assays on the level of total amounts. Quantifying the 
standards by amino acid analysis was not necessary for the assay development, but 
will be done for the assay validation and future application of these assays. 
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5.4 Comparison to literature 
For most targets, it is difficult or impossible to find comparable references of the 
expressed amount in liver. Most publications used western blots, and 
immunohistochemistry on protein level or fold change of mRNA levels. If the protein 
amount was determined, it was not directly comparable because normally membrane 
enriched fractions were used for quantification. Nevertheless, the transporter amounts 
quantified in human liver (4.2.3 and 4.3.1) were compared to published values keeping 
the different sample preparations in mind (Table 54). Five transporters were quantified 
in membrane enriched fractions of human liver in the same range as published by 
others. Only SLCO1B1 was quantified less than published by Wang et al. [98]. This 
might be due to the different donors, small sample sets and intra-tumor heterogeneity. 
Another reason could be, that the protocol for membrane enrichment was not suitable 
for SLCO1B1 enrichment. Nevertheless, this comparison shows that protein 
quantification by means of the developed TXP assays is well in line with published 
data. This also suggests, that the other targets, which could not be compared to 
published data, were quantified in a reasonable range. 
 
Table 54: Protein amount in human liver determined by TXP compared to literature. Total 
transporter amounts quantified in human liver tissue ( 4.2.3  and 4.3.1) and 
membrane enriched fractions thereof ( 4.2.3) are listed together with values 
reported for membrane fractions. All values are expressed as fmol per  µg 
extracted protein.  
protein 
tissue 
(4.3.1) 
tissue 
(4.2.3) 
membrane enriched 
fraction (4.2.3) 
literature reference 
BSEP 0.2-0.6 0.4-0.6 1.2-2.5 3 [95] 
MDR1 0.1-0.3 0.1-0.4 0.2-1.3 0.5-0.7 [97, 99] 
MRP2 0.1-0.5 0.3-1 0.9-2.4 0.5-3 [94, 96, 99] 
MRP3 0.1-0.3 0.3-0.9 0.5-2 0.5 [98] 
NTCP 0.15-0.3 0.3-0.5 0.6-1.3 2 [98] 
SLCO1B1 0.06-0.1 0.2-0.4 0.2-0.5 2.5 [98] 
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Comparing the different quantification methods (Table 54), the main advantage of the 
TXP protocol was the speed. The immunoprecipitation in the TXP protocol allowed 
the LC-MS analysis with a 2.75 min gradient for peptide separation. The other 
protocols, on the other hand, relied on separation with 15 – 30 min gradients [94-98], 
resulting in 5 – to 10 -fold longer LC-MS occupancy. 
 
The results of the transporter expression in normal kidney tissue and kidney tumors, 
on the other hand, was compared to the according EST profiles. For six transporters, 
protein expression and EST profiles matched well. Four transporters were below 
LLOQ in some or even all samples even though the EST profile predicted expression. 
MRP1, on the other hand, was also detected in some tumor samples even though the 
EST profile predicted the expression only in normal tissue. Whether the transporters 
were upregulated or downregulated in the tumor tissue could neither be linked to the 
tumor type nor the medication. To do so, a greater sample set would have been 
necessary. Apart from basic research, the TXP approach could also be used to 
customize cancer treatment, by evaluating the transporter expression in the tumor. 
This knowledge of the transporter expression would allow a more specific selection of 
drugs. 
 
The differential expression of CYPs and transporters was examined in primary murine 
hepatocytes. Pericentral and periportal cells were isolated separately for analysis. This 
resulted in very low sample amount. Nevertheless, thirteen proteins of the murine set 
could be quantified from 5 µg extracted protein, which is between one fourth and one 
eighth of the normal amount. The results were in accordance with published PCR and 
immunohistochemistry data (Table 55). BSEP and NTCP were expressed equally in 
periportal and pericentral cells, while the three CYPs were predominately expressed 
in pericentral cells. 
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Table 55: Protein expression in periportal and pericentral hepatocytes   
protein localization literature method 
BSEP not zoned not zoned protein: immunofluorescence[105] 
NTCP not zoned not zoned protein: immunofluorescence[105] 
Cyp2c29 
mainly 
pericentral 
pericentral 
mRNA: microarray [106] 
protein immunohistochemistry [69] 
Cyp2c55 only pericentral pericentral 
mRNA: microarray [106] 
protein immunohistochemistry [69] 
Cyp2e1 
mainly 
pericentral 
pericentral 
mRNA: RT-PCR /microarray [68, 69, 106] 
protein: immunohistochemistry [69] 
 
The rattine sample set of the cross species study had been analyzed before. Heise et al. 
investigated the hepatotoxic effects of single fungicide administration. Liver weights 
and apoptosis rates were recorded as well as gene expression and activity of three CYP 
isoforms. The doses indicated as NOAEL and NOAELx10 correspond to 90 / 100 ppm 
and 900 / 1000 ppm fungicide respectively [73]. The protein amounts of Cyp1a2 and 
Cyp2b1/2 determined via the TXP assays were compared to the published mRNA 
induction (Figure 32). The TXP assay cannot discriminate between Cyp2b1 and 
Cyp2b2 but their regulation is closely related [107, 108]. Therefore, Cyp2b1 mRNA 
induction was compared to the combined induction of Cyp2b1 and Cyp2b2.  
Nevertheless, the data correlated well. For Cyp1a2 however, the fold change in the 
protein expression was much more pronounced than in the mRNA expression. 
Additionally, a correlation could only be observed because of the high inductive effect 
of 1000 ppm prochloraz. For Cyp1a1 it was possible to compare the TXP generated 
protein data to gene expression data as well enzyme activity. Cyp1a1 was induced 
massively by high dosed prochloraz on all levels. The strongest response could be 
observed on mRNA level, while the fold change of protein expression and activity was 
less pronounced. 
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Figure 32: TXP protein quantification compared to mRNA and activity data. The protein 
expression in liver tissue of rats treated with fungicides was compared  to mRNA 
expression determined by qPCR and CYP activity determined by EROD 
dealkylation published by Heise et al. [73]. Following treatment groups were 
used: control, PB, 1000  ppm cyproconazole, 900  ppm epoxiconazole and 1000  ppm 
prochloraz.  Protein induction of Cyp1a2 (A) and Cyp2b1 /2 (B) was correlated to 
mRNA expression. The data correlates well with Pearson R equaling 0.93 and 0.88 
respectively. The Cyp1a1 amount quantified by means of TXP is expressed as fold 
change to control to compare it to mRNA expression and enzyme activity (C). 
Cyp1a1 was mainly induced by prochloraz on all levels. The induction of mRNA 
was the strongest.  n=5 
 
Two analytes of murine sample set, MRP3 and Cyp2b10, were also compared to 
mRNA expression data [109]. Both methods showed that the MRP3 and Cyp2b10 were 
induced to a greater extent in the wildtype mice than in the humanized mice.  
However, while the mRNA was induced 20’00-fold in wildtype mice by the high 
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cyproconazole dose, the protein expression was induced 600-fold. MRP3, on the other 
hand, was induced 3-fold on the mRNA level and 5-fold on the protein level under the 
same conditions. [109] 
Overall, mRNA and protein expression both identified the inductive potential of the 
tested fungicides and qualitatively the results correlated well. However, the 
magnitude of the inductive effect differed strongly for some analytes. The results of 
Cyp1a1 suggest that the protein expression level may be a better surrogate for the 
protein activity than the mRNA expression level. 
 
5.5 Cross species analysis of the inductive potential of fungicides 
There are several in vitro and in vivo models which are used to predict toxicity and 
pharmacokinetics in man. Cell culture experiments are used to examine specific 
aspects, such as protein induction or substrate transport across membranes. For more 
complex questions, animal models are utilized, of which rat and mice are the most 
common [85]. Additionally, humanized animal models, in which one or more proteins 
were replaced by the human variants, gain importance [85, 89]. A great challenge of 
these studies is to compare the results of the different models and to draw the right 
conclusion for man [88]. Even though CYP enzymes are classified according to their 
homology, expression levels and isoforms can vary strongly between species. One 
amino acid exchange may alter the specificity of the enzyme [43]. In the cross species 
study, the human cell line HepaRG, rats and mice as well as humanized mice were 
treated with azole fungicides and combinations thereof. All three fungicides induced 
the expression of CAR and PXR targets, such as Cyp2b1, Cyp2b2 and MDR1 in rat and 
Cyp2b10 in mouse [43, 73]. Additionally, the high cyproconazole dose reduced NTCP 
expression in mice and OAT2 expression in rats, which is also typical for CAR and 
PXR activation [74]. Only prochloraz treatment led to a strong induction of Cyp1a1 
and Cyp1a2 which are targets of AhR. This is in accordance with cyproconazole and 
epoxiconazole being described as CAR/PXR agonists and prochloraz as agonist of all 
three nuclear receptors [73, 109].  
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The quantitative comparison of the inductive potential of substances can be made 
easier by TXP assays, which can be applied for several species. MDR1/a, MRP3 and 
NTCP were quantified with the same TXP assay in all models. The basal expression 
levels differed between the models. Qualitatively, the target proteins were affected 
similarly in all rodent models, e.g. induction of Cyp2c55 and MDR1a by 
cyproconazole, but the magnitude of the effects varied. In contrast to that, the target 
proteins were only slightly affected in HepaRG and significance criteria were not met. 
This might be either due to species differences or due to the fact, that cultured cells 
react differently than hepatocytes in a in vivo experiment. For the humanized mouse 
models, the basal expression levels were like the other rodent models, but the reaction 
to the treatment was less pronounced. Therefore, it matched better with the HepaRG 
than the other rodent models did even though the effects were more distinct in the 
humanized mouse model than in HepaRG. This might be due to the fact, that human 
receptors are addressed in the context of a murine liver. Species differences of the 
affinity and ligand specificity of CAR and PXR have been described for several 
substances [110]. Human PXR for examples leads to stronger induction of a reporter 
gene after Mevastatin treatment than murine PXR [110]. TCPOBOP and CITCO, on the 
other hand, selectively bind to murine CAR and human CAR, respectively [75]. 
 
5.6 Potential areas of application for TXP assays 
TXP assays are fast and sensitive MS-based immunoassays. They are well suitable for 
low sample amounts and low abundant proteins as well as highly inducible proteins 
because the accurate and precise measuring range covers up to four orders of 
magnitude. Furthermore, the workflow is also applicable for hydrophobic proteins, 
because the use of surrogate peptides avoids solubility issues.  
The assays could be used for the molecular characterization of samples for scientific or 
medical purposes. As an example, the assays could be used to guide therapeutic 
strategies based on the transporter expression profile of tumor tissue to avoid or evade 
multiple drug resistance. 
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Another area of application could be the characterization of the inductive potential of 
chemicals within the framework of adverse outcome pathways (AOP). They are 
conceptual constructs which describe a causal linkage between molecular initiating 
events, key events and a biologically relevant adverse outcome on the level of the 
organism [111]. The molecular initiating event is defined as a specialized key event 
during which a chemical directly interacts with a biomolecule thereby disturbing the 
cellular homeostasis. Key events are measurable biological changes which are crucial 
for the progression from the molecular initiating event to the adverse outcome. [111] 
AOPs are based on the assumption that any chemical which triggers the initiating 
event sufficiently severe, will lead to the adverse outcome. The goal is to predict the 
outcome for regulatory purposes by measuring key events such as protein 
dysregulation [111]. The initiating event of the AOP for cholestatic liver injury is the 
inhibition of BSEP [112]. Key events which could be used to predict the outcome are 
the downregulation of NTCP and SLCO1B1 as well as the upregulation of Cyp2b10, 
MRP2 and MRP3 [112]. The developed TXP assays could be a valuable tool to assess 
whether an uncharacterized chemical triggers this AOP by monitoring the expression 
level of these proteins. 
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6 Summary 
CYPs and transporters are important for the turnover of xenobiotic compounds. Their 
expression levels and activity influence bioavailability and convey drug-drug 
interactions. Moreover, transporters mediate barrier maintenance of several organs 
such as the blood – brain - barrier and the placenta-barrier. Overexpression of export 
transporters in tumors can lead to multiple drug resistance. Therefore, they are 
investigated thoroughly during drug development. However, it is still difficult to 
establish conventional assays such as sandwich immunoassays to quantify these 
proteins because CYP and transporter families are homologous and additionally 
transporters are very hydrophobic. 
The objective of this thesis was to develop MS – based immunoassays for ABC and 
SLC transporters as well as CYPs in up to three species which are relevant for research 
and drug development.  
During this thesis, nineteen TXP – multiplex assays were successfully developed 
which allow the quantification of up to 14 transporters in human, rat and mouse as 
well as up to 18 CYPs in rat and mouse. In total this corresponds to 61 different 
proteins. Additionally, it was shown that the TXP methodology is sensitive enough to 
quantify the low abundant target proteins from whole cell lysates without further 
enrichment such as membrane enrichment. The developed TXP -assays were used to 
analyze several independent studies: The amounts of transporters quantified in 
healthy human liver tissue was well line with published data. The protein expression 
profile of pericentral and periportal murine hepatocytes was analyzed and correlated 
with published immunohistochemistry as well as RNA expression data. Furthermore, 
a cross species study investigating the effects of azole fungicides in human cell culture, 
rat and wildtype as well as humanized mouse models was analyzed. It could be shown 
that high dosed fungicide treatment induced CAR, PXR and AhR target proteins as 
well as that the extent of the response differed between the models.  
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7 Zusammenfassung 
CYPs und Transporter sind wichtige Bestandteile des Fremdstoffmetabolismus, deren 
Expression und Aktivität durch Nahrungsbestandteile und Medikamente moduliert 
werden. Sie beeinflussen die Bioverfügbarkeit von Medikamenten und vermitteln 
Wechselwirkungen zwischen verschiedenen Medikamenten oder Nahrungs-
bestandteilen. Des Weiteren sind Transporter an der Aufrechterhaltung von 
Blutschranken verschiedener Organe beteiligt wie zum Beispiel der Blut – Hirn – 
Schranke. Das Phänomen der multiple drug resistance wird unter anderem durch die 
Überexpression von Exportpumpen vermittelt. Da CYPs und Transporter an so vielen 
Prozessen beteiligt sind, werden sie während der Medikamentenentwicklung 
ausführlich untersucht. Allerdings ist es immer noch schwierig sie mit 
konventionellen Methoden wie zum Beispiel Sandwich - Assays zu quantifizieren, 
weil sie zu sehr homologen Proteinfamilien gehören und Transporter des Weiteren 
auch noch sehr hydrophob sind.  
Aus diesem Grund, war das Ziel dieser Arbeit MS-basierte Immunoassays zu 
entwickeln um ABC und SLC Transporter sowie CYPs in bis zu drei für die Forschung 
und Medikamentenentwicklung wichtigen Spezies zu quantifizieren. 
Es wurden neunzehn TXP-Assays entwickelt mit denen bis zu 14 Transporter in 
Mensch, Ratte und Maus sowie bis zu 18 verschiedene CYPs in Ratte und Maus 
gemessen werden können. Das entspricht insgesamt 61 verschiedenen Proteinen. 
Zusätzlich konnte gezeigt werden, dass die TXP – Methode sensitiv genug ist, sodass 
auf zusätzlich Anreicherungsverfahren wie verzichtet werden kann. Die entwickelten 
TXP – Assays wurden verwendet um bei vier verschiedenen Studien CYPs und 
Transporter zu quantifizieren. Die in humanem Normalgewebe aus der Leber 
bestimmten Mengen sowie die Zonierung in Mausleber, stimmten gut mit den 
Literaturwerten überein. Des Weiteren wurde eine speziesübergreifende Studie zu 
den Effekten von Pyrrolfungiziden analysiert. Humane Zellkultur, Ratten und 
Wildtyp - sowie humanisierte Mäuse wurden als Modelle verwendet. Es konnte 
gezeigt werden, dass die Fungizide in hohen Dosen die Expression von CAR, PXR und 
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AhR Zielproteinen in den vier Modellen beeinflussen. Das Ausmaß der Antwort hängt 
jedoch von dem verwendeten Modell ab.  
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10 Supplemental Information 
Table 56: Proteins covered in this thesis. All proteins covered in this thesis are listed 
together with the used acronym.  The recommended name (UniProtKB), gene name 
and UniProt entry ID are given for clear identification, too.  
Protein name Acronym 
recommended name 
(UniProtKB) 
Gene 
name 
UniProt entry ID 
human              rat              mouse 
Neutral amino acid 
transporter B(0) 
ATB(0) 
Neutral amino acid 
transporter B(0) 
Slc1a5 Q15758   
Neutral amino acid 
transporter B(0) 
ATB(0) 
Neutral amino acid 
transporter ASCT2 
Slc1a5   Q9ESU7 
Breast cancer 
resistance protein 
BCRP 
ATP-binding cassette 
sub-family G member 2 
Abcg2 Q9UNQ0 Q80W57 Q7TMS5 
Bile salt export  pump BSEP Bile  salt export pump Abcb11 O95342 O70127 Q9QY30 
Cytochrome P450 
1A1 
Cyp1a1 Cytochrome P450 1A1 Cyp1a1  P00185 P00184 
Cytochrome P450 
1A2 
Cyp1a2 Cytochrome P450 1A2 Cyp1a2  P04799 P00186 
Cytochrome P450 
1B1 
Cyp1b1 Cytochrome P450 1B1 Cyp1b1  Q64678 Q64429 
Cytochrome P450 
2A1 
Cyp2a1 Cytochrome P450 2A1 Cyp2a1  P11711  
Cytochrome P450 
2A2 
Cyp2a2 Cytochrome P450 2A2 Cyp2a2  P15149  
Cytochrome P450 
2A4 
Cyp2a4 Cytochrome P450 2A4 Cyp2a4  P20812 P15392 
Cytochrome P450 
2A5 
Cyp2a5 Cytochrome P450 2A5 Cyp2a5   P20852 
Cytochrome P450 
2A12 
Cyp2a12 Cytochrome P450 2A12 Cyp2a12   P56593 
Cytochrome P450 
2A22 
Cyp2a22 Cyp2a22 protein Cyp2a22   B2RXZ2 
Cytochrome P450 
2B1 
Cyp2b1 Cytochrome P450 2B1 Cyp2b1  P00176  
Cytochrome P450 
2B2 
Cyp2b2 Cytochrome P450 2B2 Cyp2b2  P04167  
Cytochrome P450 
2B3 
Cyp2b3 Cytochrome P450 2B3 Cyp2b3  P13107  
Cytochrome P450 
2B9 
Cyp2b9 Cytochrome P450 2B9 Cyp2b9   P12790 
Cytochrome P450 
2B10 
Cyp2b10 Cytochrome P450 2B10 Cyp2b10   P12791 
Cytochrome P450 
2C6 
Cyp2c6 Cytochrome P450 2C6 Cyp2c6  P05178  
Cytochrome P450 
2C7 
Cyp2c7 Cytochrome P450 2C7 Cyp2c7  P05179  
Cytochrome P450 
2C11 
Cyp2c11 Cytochrome P450 2C11 Cyp2c11  P08683  
Cytochrome P450 
2C12 
Cyp2c12 Cytochrome P450 2C12 Cyp2c12  P11510  
Cytochrome P450 
2C13 
Cyp2c13 Cytochrome P450 2C13 Cyp2c13  P20814  
Cytochrome P450 
2C29 
Cyp2c29 Cytochrome P450 2C29 Cyp2c29   Q64458 
Cytochrome P450 
2C37 
Cyp2c37 Cytochrome P450 2C37 Cyp2c37   P56654 
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Protein name Acronym 
recommended name 
(UniProtKB) 
Gene 
name 
UniProt entry ID 
human              rat              mouse 
Cytochrome P450 
2C38 
Cyp2c38 Cytochrome P450 2C38 Cyp2c38   P56655 
Cytochrome P450 
2C39 
Cyp2c39 Cytochrome P450 2C39 Cyp2c39   P56656 
Cytochrome P450 
2C55 
Cyp2c55 Cytochrome P450 2C55 Cyp2c55  P33273 Q9D816 
Cytochrome P450 
2D1 
Cyp2d1 Cytochrome P450 2D1 Cyp2d1  P10633  
Cytochrome P450 
2D3 
Cyp2d3 Cytochrome P450 2D3 Cyp2d3  P12938  
Cytochrome P450 
2D9 
Cyp2d9 Cytochrome P450 2D9 Cyp2d9   P11714 
Cytochrome P450 
2D10 
Cyp2d10 Cytochrome P450 2D10 Cyp2d10   P24456 
Cytochrome P450 
2D11 
Cyp2d11 Cytochrome P450 2D11 Cyp2d11   P24457 
Cytochrome P450 
CYP2D22 
Cyp2d22 
Cytochrome P450 
CYP2D22 
Cyp2d22   Q9JKY7 
Cytochrome P450 
2D40 
Cyp2d40 
Cytochrome P450, 
family 2, subfamily d, 
polypeptide 40 
Cyp2d40   Q6P8N9 
Cytochrome P450 
2E1 
Cyp2e1 Cytochrome P450 2E1 Cyp2e1  P05182 Q05421 
Cytochrome P450 
3A1 
Cyp3a1 Cytochrome P450 3A1 Cyp3a1  P04800  
Cytochrome P450 
3A2 
Cyp3a2 Cytochrome P450 3A2 Cyp3a2  P05183  
Cytochrome P450 
3A9 
Cyp3a9 Cytochrome P450 3A9 Cyp3a9  P51538  
Cytochrome P450 
3A11 
Cyp3a11 Cytochrome P450 3A11 Cyp3a11   Q64459 
Cytochrome P450 
3A13 
Cyp3a13 Cytochrome P450 3A13 Cyp3a13   Q64464 
Cytochrome P450 
3A18 
Cyp3a18 Cytochrome P450 3A18 Cyp3a18  Q64581  
Cytochrome P450 
3A25 
Cyp3a25 Cytochrome P450 3A25 Cyp3a25   O09158 
Cytochrome P450 
3A41 
Cyp3a41 Cytochrome P450 3A41 Cyp3a41a   Q9JMA7 
Cytochrome P450 
3A44 
Cyp3a44 
Cytochrome P450, 
CYP3A 
Cyp3a44   Q9EQW4 
Cytochrome P450 
4B1 
Cyp4b1 Cytochrome P450 4B1 Cyp4b1  P15129 Q64462 
Cytochrome P450 
7B1 
Cyp7b1 
25-hydroxycholesterol 
7-alpha-hydroxylase 
Cyp7b1  Q63688  
Cytochrome P450 
19A1 
Cyp19a1 Aromatase Cyp19a1  P22443 P28649 
Multidrug and toxin 
extrusion protein 1 
MATE1 
Multidrug and toxin 
extrusion protein 1 
Slc47a1 Q96FL8  Q8K0H1 
Multidrug and toxin 
extrusion protein 2 
MATE2 
Multidrug and toxin 
extrusion protein 2 
Slc47a2 Q86VL8   
Multidrug resistance 
protein 1 
MDR1 
Multidrug resistance 
protein 1 
Abcb1 P08183 P43245  
Multidrug resistance 
protein 1A 
MDR1a 
Multidrug resistance 
protein 1A 
Abcb1a  Q9JK64 P21447 
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Protein name Acronym 
recommended name 
(UniProtKB) 
Gene 
name 
UniProt entry ID 
human              rat              mouse 
Multidrug resistance 
protein 1B 
MDR1b 
Multidrug resistance 
protein 1B 
Abcb1b   P06795 
Multidrug resistance-
associated protein 1 
MRP1 
Multidrug resistance-
associated protein 1 
Abcc1 P33527 Q8CG09 O35379 
Multidrug resistance-
associated protein 2 
MRP2 
Canalicular 
multispecific organic 
anion transporter 1 
Abcc2 Q92887 Q63120 Q8VI47 
Multidrug resistance-
associated protein 3 
MRP3 
Canalicular 
multispecific organic 
anion transporter 2 
Abcc3 O15438 O88563 B2RX12 
Multidrug resistance-
associated protein 5 
MRP5 
Multidrug resistance-
associated protein 5 
Abcc5 O15440 Q9QYM0 Q9R1X5 
Multidrug resistance-
associated protein 8 
MRP8 
ATP-binding cassette 
sub-family C member 
11 
Abcc11 Q96J66   
Sodium/bile acid 
cotransporter 
NTCP 
Sodium/bile  acid 
cotransporter 
Slc10a1 Q14973 O08705 P26435 
Organic anion 
transporter 2 
OAT2 
Solute carrier family 22 
member 7 
Slc22a7 Q9Y694 Q5RLM2 Q91WU2 
Organic anion 
transporter 3 
OAT3 
Solute carrier family 22 
member 8 
Slc22a8 Q8TCC7 Q9R1U7 O88909 
Organic anion 
transporter 7 
OAT7 
Solute carrier family 22 
member 9 
Slc22a9 Q8IVM8   
Solute carrier organic 
anion transporter 
family member 1B1 
SLCO1B1 
Solute carrier organic 
anion transporter 
family member 1B1 
Slco1b1 Q9Y6L6   
Solute carrier organic 
anion transporter 
family member 1B3 
SLCO1B3 
Solute carrier organic 
anion transporter 
family member 1B3 
Slco1b3 Q9NPD5   
Solute carrier organic 
anion transporter 
family member 2B1 
SLCO2B1 
Solute carrier organic 
anion transporter 
family member 2B1 
Slco2b1 O94956 Q9JHI3 Q8BXB6 
Organic cation 
transporter 1 
OCT1 
Solute carrier family 22 
member 1 
Slc22a1 O15245 Q63089 O08966 
Organic cation 
transporter 2 
OCT2 
Solute carrier family 22 
member 2 
Slc22a2 O15244 Q9R0W2 O70577 
Organic cation 
transporter 3 
OCT3 
Solute carrier family 22 
member 3 
Slc22a3 O75751   
Solute carrier family 
22 member 5 
SLC22A5 
Solute carrier family 22 
member 5 
Slc22a5 O76082 O70594 Q9Z0E8 
Solute carrier family 
28 member 3 
SLC28A3 
Solute carrier family 28 
member 3 
Slc28a3 Q9HAS3 Q8VIH3 Q9ERH8 
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Table 57: Peptide sequences and corresponding targets in three species. All peptide 
sequences which were chosen for method development, are listed below as well 
as corresponding proteins for each species.  
Peptide human rat mouse 
EVLDSFLDLVR    ATB(0) 
MVADPPR ATB(0)   
LFIHEYISGYYR BCRP BCRP BCRP 
GLSGDVLINGAPQPANFK  BCRP  
DPSGLSGDVLINGAPRPANFK BCRP   
AELHQLSGGEK BCRP   
NSPGALTTR BSEP   
NNPGVLTTR  BSEP BSEP 
TVAAFGGEK BSEP   
MSDSVILR BSEP BSEP BSEP 
ANIYGLCFAFSQGIAFLANSAAYR  BSEP  
LSDRPQLPYLEAFILETFR  Cyp1a1 Cyp1a1 
EAEYLISK  Cyp1a1  
ELWGDPNEFRPER   Cyp1a1 
EANHLISK  Cyp1a2  
DPFVFRPER  Cyp1a2 Cyp1a2 
CIGEELSK  Cyp1b1 Cyp1b1 
LQTEEGCK   Cyp1b1 
NAAFLPFSTGK  Cyp2a1  
DFDPQNFLDDK  Cyp2a1  
DFNPQHFLDDK  Cyp2a2 Cyp2a12 
SDAFVPFSIGK  Cyp2a4 Cyp2a4 
IVVLCGQEAVK   Cyp2a5 
NDAFVPFSIGK   Cyp2a5 
EALVDHAEEFSGR   Cyp2a12 
GYGVAFSNGER   Cyp2a12 
EALEDNAEEFSGR   Cyp2a22 
GYGVTFSNGER   Cyp2a22 
SEAFMPFSTGK  Cyp2b1 / Cyp2b2  
EYGVIFANGER  Cyp2b1 / Cyp2b2 Cyp2b10 
EALVGQAEAFSGR   Cyp2b10 
EIDQVIGSHRPPSLDDR  Cyp2b2  
EALVDHAEAFSGR  Cyp2b3 Cyp2b9 
CEAFLPFSTGK   Cyp2b9 
EHQESLDVTNPR  Cyp2c6  
IEEHQESLDVTNPR  Cyp2c7  
EALVDLGEEFSGR  Cyp2c11  
EALIDYGEEFSGR  Cyp2c12  
TYGPVFTLYFGSQPTVVLHGYEAVK  Cyp2c12  
EALVDHGEEFSGR  Cyp2c13  
AYGPVFTLYLGSKPTVILHGYEAVK   Cyp2c29 
NISQSFTNFSK   Cyp2c29 
ESLDVTNPR   Cyp2c29 
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Peptide human rat mouse 
SDYFIPFSTGK   Cyp2C37 
NFNQSLTNFSK   Cyp2c38 
AYGPVFTLYLGSRPTVVLHGYEAVK   Cyp2c39 
NVSQSLTNFSK   Cyp2c39 
EALDDLGEEFSGR  Cyp2c55 Cyp2c55 
VYGPVFTLYFGSKPTVVVHGYEAVK   Cyp2c55 
DETVWEKPHR  Cyp2d1  
VQQEIDEVIGQVR   Cyp2d9 
VQQEIDAVIGQVR   Cyp2d10 
NTWDPDQPPR   Cyp2d10 
TTWDPDQPPR   Cyp2d11 
TTWDPTQPPR   Cyp2d22 
TWDPDQPPR  Cyp2d3 Cyp2d40 
NEFSGR  Cyp2e1 Cyp2e1 
FINLVPSNLPHEATR  Cyp2e1 Cyp2e1 
DPQHWPEPEEFRPER  Cyp3a1  
LQEEIDGALPSK  Cyp3a2  
LQDEIDEALPNK   Cyp3a11 
YWPEPEEFRPER   Cyp3a13 
LQDEIDAALPNK   Cyp3a9 Cyp3a13 
ECYSTFTNR   Cyp3a9 Cyp3a13 
DPHYWPEPEEFRPER  Cyp3a9  
ECYSVFTNR  Cyp3a18 Cyp3a25 
LQEEIDETLPNK   Cyp3a41 
DCLSVFTNR   Cyp3a44 
LLTPGFHYDVLKPYVAIFAESTR  Cyp4b1 Cyp4b1 
AMDSFPGPPTHWLFGHALEIQK  Cyp4b1  
AALQDEK  Cyp4b1 Cyp4b1 
GDFVAVFPPMIHNDPEVFDAPK  Cyp7b1  
EQLDSLVCLESAILEVLR  Cyp7b1  
IQGYFNAWQALLIKPNIFFK  Cyp19a1 Cyp19a1 
MVEVCVESIK  Cyp19a1 Cyp19a1 
DLVGYIFTTDR   MATE1 
DHVGYIFTTDR MATE1   
GGPEATLEVR MATE1   
SECHVDFFR MATE2   
LAAEEAK  MATE2   
EANIHAFIESLPNK MDR1   
LYDPLEGVVSIDGQDIR   MDR1b 
LYDPTEGMVSVDGQDIR MDR1   
LYDPIEGEVSIDGQDIR  MDR1a/b  
NTTGALTTR MDR1 MDR1a MDR1a 
NTTGSLTTR  MDR1b  
QPLEGSDLWSLNK MRP1   
SSDLWSLNK  MRP1  
QPLESSDLWSLNK   MRP1 
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Peptide human rat mouse 
ITIIPQDPVLFSGSLR MRP1 MRP1 MRP1 
LTIIPQDPILFSGSLR MRP2 MRP2  
LAHDILLFLNPQLLK   MRP2 
LIHDLLVFLNPQLLK  MRP2  
LVNDIFTFVSPQLLK MRP2   
HGEIQFNNYQVR  MRP2  
IQFNNYQVR MRP2   
GEIQFNNYQVR   MRP2 
YLGGDDLDTSAIR MRP2 MRP2  
LEQYLGSDDLDLSAIR   MRP2 
LAILGYR  MRP3 MRP3 
SPQSFFDTTPSGR MRP3  MRP3 
APQSFFDTTPSGR  MRP3  
DLSLHVHGGEK MRP3   
NLTLHVQGGEK  MRP3  
NVTVHVQGGEK   MRP3 
LTIIPQEPVLFSGTVR  MRP5  
LAIIPQEPVLFSGTVR   MRP5 
LSIIPQEPVLFSGTVR MRP5   
SLSEASVAVDR MRP5 MRP5 MRP5 
TLSLEAPAR MRP5 MRP5 MRP5 
TYTLQDGPWSQQER MRP8   
DNTPTVLHGINLTIR MRP8   
AAVPPWGK MRP8   
AAATEDATPAALEK  NTCP NTCP 
GIYDGDLK NTCP NTCP NTCP 
RPSYLDLFR OAT2   
ALQRPSYLDLFR  OAT2  
VSQRPSYLDLFR   OAT2 
NLVLLALPR   OAT2 
NVALLALPR OAT2   
NLVLMALPR  OAT2  
WLVLSGK OAT3 OAT3 OAT3 
LSLEELK OAT3   
LTIEELK  OAT3  
YGLSDLFR  OAT3 OAT3 
YTASDLFR OAT3   
FVHPPNASLPNDTQR OAT3   
NKPLFDTIQDEK OAT7   
LSPSFADLFR OCT1   
SPSFADLFR  OCT1 OCT1 
LNPSFLDLVR OCT2 OCT2 OCT2 
SLPASLQR OCT2   
GPSAAALAER OCT3   
LGSILSPYFVYLGAYDR SLC22A5 SLC22A5  
DYDEVTAFLGEWGPFQR SLC22A5 SLC22A5 SLC22A5 
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Peptide human rat mouse 
YTDHFFAFK  SLC28A3 SLC28A3 
DHFFAFK SLC28A3   
HWFWLK  SLC28A3 SLC28A3 
LLNSHWFWLK SLC28A3   
YDTVCGFCR SLC28A3   
YVEQQYGQPSSK SLCO1B1   
TLGGILAPIYFGALIDK SLCO1B3   
FIGLQFFFK SLCO2B1 SLCO2B1 SLCO2B1 
SSISTVEK SLCO2B1 SLCO2B1 SLCO2B1 
 
 
Table 58: Number of proteins covered by TXP antibody epitope. Number of target 
proteins in human, rat and mouse covered by each TXP tag and the sum thereof.  
TXP tag human rat mouse sum 
AAYR  1  1 
ALEK  1 1 2 
ALPR 1 1 1 3 
ANFK 1 1  2 
APAR 1 1 1 3 
AVDR 1 1 1 3 
AYDR 1 1  2 
DAPK  1  1 
DFFR 1   1 
DLFR 2 3 3 8 
DLVR 1 1 2 4 
DPPR 1   1 
DTQR 1   1 
EATR  1 1 2 
EAVK  1 4 5 
EEAK 1   1 
EELK 1 1  2 
EGCK   1 1 
EIQK  1  1 
ELSK  1 1 2 
ESIK  1 1 2 
ESTR  1 1 2 
ETFR  1 1 2 
EVLR  1  1 
FAFK 1 1 1 3 
FFFK 1 1 1 3 
FSGR  6 6 12 
FTNR  2 3 5 
FWLK 1 1 1 3 
GDLK 1 1 1 3 
Supplemental Information 
132 
TXP tag human rat mouse sum 
GFCR 1   1 
GGEK 3 1 1 5 
GQVR   2 2 
GSLR 2 2 1 5 
GTVR 1 1 1 3 
GYYR 1 1 1 3 
IFFK  1 1 2 
KPHR  1  1 
LAER 1   1 
LDDK  2 1 3 
LDDR  1  1 
LEVR 1   1 
LGYR  1 1 2 
LIDK 1   1 
LISK  2  2 
LPNK 1 1 3 5 
LPSK  1  1 
LSGK 1 1 1 3 
LTIR 1   1 
LTTR 2 3 2 7 
NFSK   3 3 
NGER  2 2 4 
PFQR 1 1 1 3 
PSGR 1 1 1 3 
PSSK 1   1 
PWGK 1   1 
QDEK 1 1 1 3 
QDIR 1 1 1 3 
QLLK 1 1 1 3 
QPPR  1 4 5 
QQER 1   1 
RPER  3 3 6 
SAIR 1 1 1 3 
SIGK  1 2 3 
SLNK 1 1 1 3 
SLQR 1   1 
STGK  2 2 4 
TNPR  2 1 3 
TTDR 1  1 2 
TVEK 1 1 1 3 
VILR 1 1 1 3 
YQVR 1 1 1 3 
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Table 59: UniProt IDs of high abundant proteins in human, rat and mouse. The fifteen 
most abundant proteins for each species are listed according to the PaxDb entries 
for human liver (integrated), mouse liver (integrated) and rat whole organism. 
Only proteins with S wiss-Prot entries were included.  The canonical sequences as  
well as all isoforms were checked whether they include any of the chosen TXP  
epitopes.  
recommended name human rat mouse 
10 kDa heat shock protein, mitochondrial  P26772  
3-ketoacyl-CoA thiolase, mitochondrial P42765   
60S ribosomal protein L19   P84099 
60S ribosomal protein L21   Q9CQM8 
60S ribosomal protein L3   P27659 
60S ribosomal protein L39  P62893  
78 kDa glucose-regulated protein   P20029 
Actin, cytoplasmic 1  P60711  
Alcohol dehydrogenase 1   P00329 
Alcohol dehydrogenase 1A P07327   
Alcohol dehydrogenase 1B P00325   
Alcohol dehydrogenase 4 P08319   
Argininosuccinate synthase  P09034  
ATP synthase subunit beta, mitochondrial  P10719  
Carbamoyl-phosphate synthase [ammonia], mitochondrial P31327 P07756 Q8C196 
Carbonic anhydrase 3   P16015 
Cytochrome b5  P00173  
Elongation factor 1-alpha 1   P10126 
Endoplasmin   P08113 
Fatty acid-binding protein, liver P07148 P02692  
Ferritin light chain P02792   
Fructose-bisphosphate aldolase B P05062 P00884  
Glutathione S-transferase A1 P08263   
Glutathione S-transferase A3   P30115 
Heat shock cognate 71 kDa protein   P63017 
Hemoglobin subunit alpha P69905  P01942 
Hemoglobin subunit beta P68871   
Hemoglobin subunit beta-1  P02091  
Hemoglobin subunit delta P02042   
Myelin basic protein  P02688  
Peroxiredoxin-1  Q63716 P35700 
Phosphatidylethanolamine-binding protein 1 P30086   
Protein disulfide-isomerase   P09103 
Serum albumin P02768 P02770 P07724 
Superoxide dismutase [Cu-Zn] P00441 P07632  
Thymosin beta-4  P62329  
Ubiquitin-60S ribosomal protein L40  P62986  
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Table 60: Comparison of epitope presence and successful assay development (complete 
list). The presence of a TXP epitope in one or two of the high abundant proteins is  
indicated by light red (  1  ) or dark red ( 2  ) respectively. Green fields (ab) indicate 
successful assay development, gray fields ( ab) indicate either no presence in high 
abundant proteins or no successful method development and white fields ( ab) no 
measurement at all.  
epitope 
epitope present in protein               
human                 rat                  mouse 
Successful assay development                   
human                  rat                mouse 
AAYR       
ALEK       
ALPR       
ANFK       
APAR       
AVDR       
AYDR       
DAPK       
DFFR       
DLFR   2    
DLVR       
DPPR       
DTQR       
EATR  1 1    
EAVK   1    
EEAK        
EELK       
EGCK       
EIQK  1     
ELSK       
ESIK       
ESTR       
ETFR       
EVLR  1     
FAFK       
FFFK       
FSGR       
FTNR       
FWLK       
GFCR       
GGEK       
GQVR       
GSLR       
GTVR       
GYYR       
IFFK       
KPHR       
LAER       
LDDK  1     
LDDR       
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epitope 
epitope present in protein               
human                 rat                  mouse 
Successful assay development                   
human                  rat                mouse 
LEVR       
LGYR       
LIDK       
LISK       
LPNK       
LPSK  1     
LSGK 1      
LTIR       
LTTR       
NFSK       
NGER   1    
PFQR       
PSGR       
PSSK       
PWGK       
QDEK       
QDIR       
QLLK       
QPPR       
QQER       
RPER       
SAIR       
SIGK       
SLNK       
SLQR       
STGK       
TNPR       
TTDR       
TVEK       
VILR       
YQVR       
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Table 61: Overview of lysis buffers used for each experiment. Used buffers are indicated 
by x. In case samples of more than  one species were used in an experiment, the 
species are specified by single letters (human: h, rat: r,  mouse: m).  
experiment 
lysis 
buffer   
1 -/- 
lysis 
buffer 
1 +/- 
lysis 
buffer 
1 +/+ 
lysis 
buffer   
2 -/- 
lysis 
buffer 
2 +/- 
lysis 
buffer 3 
antibody functionality  x     
optimization of lysis 
conditions 
 x  x x x 
alternative sample 
preparations 
   x (h)   
stability on protein and 
peptide level 
   x   
antibody and lysate 
amount 
x (h)   x (r, m)   
kinetic of proteolysis x (h)   x (r)   
intra and interday 
variation 
x (h)   x (r, m)   
Human liver panel x (h)      
paired human kidney 
samples 
   x (h)   
cross species    x (h, r, m)   
 
 
Table 62: Overview of antibodies used in each experiment.  Used antibodies are 
indicated by x. In case samples of more than one species were used in an 
experiment, the species are specified by single letters (human: h, rat: r,  mouse: 
m). 
Antibody ID 
A
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mAB_cMyc_ms1 x            
pAB_GIYDGDLK_rbt1 x            
pAB_GIYDGDLK_rbt2 x x x x x (h, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x x  
x 
(h, r, m) 
pAB_TXP_AAYR_rbt1 x            
pAB_TXP_AAYR_rbt2 x    x (r) x (r)       
pAB_TXP_ALEK_rbt1 x x  x x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
pAB_TXP_ALEK_rbt2             
pAB_TXP_ALPR_rbt1 x            
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Antibody ID 
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pAB_TXP_ALPR_rbt2 x            
pAB_TXP_ANFK_rbt1             
pAB_TXP_ANFK_rbt2             
pAB_TXP_APAR_rbt1             
pAB_TXP_APAR_rbt2             
pAB_TXP_AVDR_rbt1     x (m)        
pAB_TXP_AVDR_rbt2 x    x (m) 
x 
(h, r, m) 
      
pAB_TXP_AYDR_rbt1 x     x (r)       
pAB_TXP_AYDR_rbt2 x     x (r)       
pAB_TXP_DAPK_rbt1 x     x (r)       
pAB_TXP_DAPK_rbt2 x            
pAB_TXP_DFFR_rbt1 x            
pAB_TXP_DLFR_rbt1 x            
pAB_TXP_DLFR_rbt2 x    x (m)        
pAB_TXP_DLFR_rbt3 x x x x x (h, r) 
x 
(h, r, m) 
x (h, r) x (h, r) x x  x (h, r) 
pAB_TXP_DLFR_rbt4 x            
pAB_TXP_DLVR_rbt1 x    x (m) 
x 
(h, r, m) 
      
pAB_TXP_DLVR_rbt2 x    x (m) x (r)       
pAB_TXP_DLVR_rbt3 x    x (m) x (r)       
pAB_TXP_DLVR_rbt4 x    x (m) x (r)       
pAB_TXP_DPPR_rbt1 x            
pAB_TXP_DPPR_rbt2 x            
pAB_TXP_DTQR_rbt1 x            
pAB_TXP_DTQR_rbt2 x            
pAB_TXP_EATR_rbt1 x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
pAB_TXP_EATR_rbt2 x    x (r, m)        
pAB_TXP_EAVK_rbt1 x    x (m)        
pAB_TXP_EAVK_rbt2 x    x (m)        
pAB_TXP_EEAK_rbt1 x            
pAB_TXP_EELK_rbt1 x            
pAB_TXP_EELK_rbt2 x            
pAB_TXP_EGCK_rbt1 x            
pAB_TXP_EGCK_rbt2 x            
pAB_TXP_EIQK_rbt1 x   x x (r) x (r) x (r) x (r)    x (r) 
pAB_TXP_ELSK_rbt1 x            
pAB_TXP_ESIK_rbt1 x    x (m) x (r, m)       
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Antibody ID 
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pAB_TXP_ESIK_rbt2 x   x x (r, m) x (r)       
pAB_TXP_ESTR_rbt1 x   x x (r) x (r) x (r)      
pAB_TXP_ETFR_rbt1 x     x (r)       
pAB_TXP_ETFR_rbt2 x     x (r)       
pAB_TXP_EVLR_rbt1 x     x (r)       
pAB_TXP_EVLR_rbt2 x     x (r)       
pAB_TXP_FAFK_rbt1 x     x (r)       
pAB_TXP_FAFK_rbt2 x     x (r)       
pAB_TXP_FFFK_rbt1 x            
pAB_TXP_FFFK_rbt2 x    x (h, m) 
x 
(h, r, m) 
x (m)      
pAB_TXP_FSGR_rbt1 x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
pAB_TXP_FSGR_rbt2 x    x (r, m)        
pAB_TXP_FTNR_rbt1 x    x (r, m)        
pAB_TXP_FTNR_rbt2 x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
pAB_TXP_FWLK_rbt1 x    x (r, m)        
pAB_TXP_FWLK_rbt2 x    x (r, m) x (r, m)       
pAB_TXP_GFCR_rbt1 x            
pAB_TXP_GFCR_rbt2 x            
pAB_TXP_GGEK_rbt1 x x x x x (r, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x x x 
x 
(h, r, m) 
pAB_TXP_GGEK_rbt2 x    x (m)        
pAB_TXP_GQVR_rbt1 x    x (m) x (m) x (m) x (m)   x x (m) 
pAB_TXP_GQVR_rbt2 x    x (m)        
pAB_TXP_GSLR_rbt1 x x x x 
x 
(h, r, m) 
x 
(h, r, m) 
x (h, r) x (h) x x  x (h, r) 
pAB_TXP_GSLR_rbt2 x            
pAB_TXP_GTVR_rbt1 x x  x x (r, m) 
x 
(h, r, m) 
x (r) x (r)    x (r) 
pAB_TXP_GTVR_rbt2 x    x (r, m)        
pAB_TXP_GYYR_rbt1 x    x (m) x (r)       
pAB_TXP_GYYR_rbt2 x    x (m) 
x 
(h, r, m) 
x (m)      
pAB_TXP_IFFK_rbt1 x    x (r, m) x (r, m)       
pAB_TXP_IFFK_rbt2 x    x (r, m)        
pAB_TXP_KPHR_rbt1 x    x (r) x (r)       
pAB_TXP_KPHR_rbt2 x    x (r)        
pAB_TXP_LAER_rbt1 x            
pAB_TXP_LAER_rbt2 x            
pAB_TXP_LAER_rbt3 x            
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Antibody ID 
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pAB_TXP_LDDK_rbt1 x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
pAB_TXP_LDDR_rbt1 x    x (r) x (r) x (r) x (r)    x (r) 
pAB_TXP_LDDR_rbt2 x    x (r)        
pAB_TXP_LEVR_rbt1 x    x (h) x (h)       
pAB_TXP_LFSK_rbt1 x            
pAB_TXP_LFSK_rbt2 x            
pAB_TXP_LGYR_rbt1 x            
pAB_TXP_LIDK_rbt1 x            
pAB_TXP_LIDK_rbt2 x    x (h) x (h)       
pAB_TXP_LISK_rbt1 x    x (r)        
pAB_TXP_LISK_rbt2 x    x (r) x (r) x (r) x (r)    x (r) 
pAB_TXP_LPNK_rbt1   x   x (h) x (h)  x   x (h) 
pAB_TXP_LPNK_rbt2 x    x (r, m) x (r, m) x (r) x (r)    x (r) 
pAB_TXP_LPNK_rbt3 x    x (r, m)        
pAB_TXP_LPSK_rbt1 x    x (r)        
pAB_TXP_LPSK_rbt2 x    x (r) x (r) x (r) x (r)    x (r) 
pAB_TXP_LSGK_rbt1 x    x (r, m) x (r, m)       
pAB_TXP_LSQR_rbt1 x            
pAB_TXP_LSQR_rbt2 x            
pAB_TXP_LTIR_rbt1             
pAB_TXP_LTIR_rbt2 x            
pAB_TXP_LTTR_rbt1 x            
pAB_TXP_LTTR_rbt2 x   x 
x 
(h, r, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x x x 
x 
(h, r, m) 
pAB_TXP_NFSK_rbt1 x    x (m) x (m) x (m) x (m)   x x (m) 
pAB_TXP_NFSK_rbt2 x    x (m)        
pAB_TXP_NGER_rbt1 x x  x x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
pAB_TXP_NGER_rbt2 x    x (r, m)        
pAB_TXP_PFQR_rbt1 x    x (r, m)        
pAB_TXP_PFQR_rbt2 x    x (r, m)        
pAB_TXP_PSGR_rbt1             
pAB_TXP_PSGR_rbt2             
pAB_TXP_PSSK_rbt1 x    x (h)        
pAB_TXP_PSSK_rbt2 x  x  x (h) x (h) x (h) x (h) x x  x (h) 
pAB_TXP_PTVK_rbt1 x            
pAB_TXP_PTVK_rbt2 x            
pAB_TXP_PWGK_rbt1 x            
pAB_TXP_PWGK_rbt2 x            
pAB_TXP_QDEK_rbt1 x            
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pAB_TXP_QDEK_rbt2 x  x  x (h) x (h, r) x (h) x (h) x x  x (h) 
pAB_TXP_QDIR_rbt1 x x  x 
x 
(h, r, m) 
x 
(h, r, m) 
x (r) x (h, r)    x (r) 
pAB_TXP_QDIR_rbt2     x (m)        
pAB_TXP_QLLK_rbt1 x    x (m)        
pAB_TXP_QLLK_rbt2 x    x (m) x (m)       
pAB_TXP_QLLK_rbt3             
pAB_TXP_QLLK_rbt4 x    x (m) x (r)       
pAB_TXP_QPPR_rbt1 x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
pAB_TXP_QPPR_rbt2 x    x (r, m)        
pAB_TXP_QQER_rbt1 x            
pAB_TXP_QQER_rbt2 x            
pAB_TXP_RPER_rbt1 x    x (r, m)        
pAB_TXP_RPER_rbt2 x    x (r, m) x (r)       
pAB_TXP_SAIR_rbt1             
pAB_TXP_SAIR_rbt2             
pAB_TXP_SIGK_rbt1 x    x (r, m)        
pAB_TXP_SIGK_rbt2 x    x (r, m) x (r, m)       
pAB_TXP_SLNK_rbt1             
pAB_TXP_SLNK_rbt2 x    x (m) x (r)       
pAB_TXP_SLNK_rbt3             
pAB_TXP_SLNK_rbt4 x    x (m) x (r, m)       
pAB_TXP_STGK_rbt1 x            
pAB_TXP_STGK_rbt2 x    x (r, m) x (m)       
pAB_TXP_TNPR_rbt1 x    x (r, m)        
pAB_TXP_TNPR_rbt2 x    x (r, m) x (r, m) x (m) x (m)    x (m) 
pAB_TXP_TTDR_rbt1 x            
pAB_TXP_TTDR_rbt2 x            
pAB_TXP_TVEK_rbt1 x    
x 
(h, r, m) 
x 
(h, r, m) 
x (h, m) x (h, m) x x x x (h, m) 
pAB_TXP_TVEK_rbt2 x    x (m)        
pAB_TXP_VILR_rbt1 x    x (r, m) x (r, m)       
pAB_TXP_VILR_rbt2 x    x (r, m)        
pAB_TXP_YQVR_rbt1 x    
x 
(h, r, m) 
x 
(h, r, m) 
x (h, r) x (h, r) x x  x (h, r) 
pAB_TXP_YQVR_rbt2 x    x (r, m)        
 
 
Supplemental Information 
141 
Table 63: Overview of peptide standards used in each experiment.  Used peptides are 
indicated by x. In case samples of more than  one species were used in an 
experiment, the species are specified by single letters (human: h, rat: r,  mouse: 
m). Peptides are sorted according to their TXP -tag. 
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ANIYGLCFAFSQGIAFL
ANS 
AAYR x    x (r) x (r)       
AAATEDATPA ALEK x x  x x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
NLVLL ALPR x            
NVALL ALPR x            
NLVLM ALPR x            
GLSGDVLINGAPQP ANFK             
DPSGLSGDVLINGAPR
P 
ANFK             
TLSLE APAR             
SLSEASV AVDR x    x (m) 
x 
(h, r, m) 
      
LGSILSPYFVYLG AYDR x     x (r)       
GDFVAVFPPMIHNDPE
VF 
DAPK x     x (r)       
SECHV DFFR x            
LSPSFA DLFR x    x (h) x (h)       
SPSFA DLFR x   x x (r) x (r) x (r)     x (r) 
RPSYL DLFR x  x  x (h) x (h) x (h) x (h) x x  x (h) 
ALQRPSYL DLFR x x  x x (r) x (r) x (r) x (r)    x (r) 
VSQRPSYL DLFR x            
YGLS DLFR x x  x x (r, m) x (r, m) x (r) x (r)    x (r) 
YTAS DLFR x  x  x (h) x (h) x (h) x (h) x x  x (h) 
EVLDSFL DLVR x    x (m) x (m)       
LNPSFL DLVR x     x (h, r)       
MVA DPPR x            
FVHPPNASLPN DTQR x            
FINLVPSNLPH EATR x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
IVVLCGQ EAVK x    x (m)        
TYGPVFTLYFGSQPTVV
LHGY 
EAVK x            
AYGPVFTLYLGSKPTVI
LHGY 
EAVK x    x (m)        
AYGPVFTLYLGSRPTVV
LHGY 
EAVK x    x (m)        
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VYGPVFTLYFGSKPTVV
VHGY 
EAVK x    x (m)        
LAA EEAK x            
LSL EELK x            
LTI EELK x            
LQTE EGCK x            
AMDSFPGPPTHWLFG
HAL 
EIQK x   x  x (r) x (r) x (r)    x (r) 
CIGE ELSK x            
MVEVCV ESIK x   x x (r, m) x (r, m)       
LLTPGFHYDVLKPYVAI
FA 
ESTR x   x x (r) x (r) x (r)      
LSDRPQLPYLEAFIL ETFR x     x (r)       
EQLDSLVCLESAIL EVLR      x (r)       
YTDHF FAFK x     x (r)       
DHF FAFK x            
FIGLQ FFFK x    x (h, m) 
x 
(h, r, m) 
x (m)      
EALVDHAEE FSGR x    x (m) x (m)       
EALEDNAEE FSGR x    x (m) x (m)       
EALVGQAEA FSGR x    x (m) x (m) x (m) x (m)   x x (m) 
EALVDHAEA FSGR x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
EALVDLGEE FSGR x    x (r) x (r) x (r) x (r)    x (r) 
EALIDYGEE FSGR x    x (r) x (r) x (r) x (r)    x (r) 
EALVDHGEE FSGR x    x (r) x (r) x (r) x (r)    x (r) 
EALDDLGEE FSGR x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
NE FSGR x    x (r, m) x (r, m)       
ECYST FTNR x    x (r, m) x (r, m) x (r) x (r)    x (r) 
ECYSV FTNR x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
DCLSV FTNR x    x (m) x (m) x (m) x (m)   x x (m) 
HW FWLK x    x (r, m) x (r, m)       
LLNSHW FWLK x            
GIYD GDLK x x x x x (h, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x x  
x 
(h, r, m) 
YDTVC GFCR x            
TVAAF GGEK x  x   x (h) x (h) x (h)    x (h) 
DLSLHVH GGEK x  x   x (h) x (h) x (h) x x  x (h) 
NLTLHVQ GGEK x x  x x (r) x (r) x (r) x (r)    x (r) 
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NVTVHVQ GGEK x    x (m) x (m) x (m) x (m)   x x (m) 
AELHQLS GGEK x            
VQQEIDAVI GQVR x    x (m) x (m) x (m) x (m)    x (m) 
VQQEIDEVI GQVR x    x (m) x (m) x (m) x (m)   x x (m) 
ITIIPQDPVLFS GSLR x x x x 
x 
(h, r, m) 
x 
(h, r, m) 
x (h, r) x (h, r) x x  x (h, r) 
LTIIPQDPILFS GSLR x x x x x (h, r) x (h, r) x (h, r) x (h, r)    x (h, r) 
LTIIPQEPVLFS GTVR x x  x x (r) x (r) x (r) x (r)    x (r) 
LAIIPQEPVLFS GTVR x    x (m) x (m)       
LSIIPQEPVLFS GTVR x     x (h)       
LFIHEYIS GYYR x    x (m) 
x 
(h, r, m) 
x (m)      
IQGYFNAWQALLIKPN IFFK x    x (r, m) x (r, m)       
DETVWE KPHR x    x (r) x (r)       
GPSAAA LAER x            
DFDPQNF LDDK x    x (r) x (r) x (r) x (r)    x (r) 
DFNPQHF LDDK x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
EIDQVIGSHRPPS LDDR x    x (r) x (r) x (r) x (r)    x (r) 
GGPEAT LEVR x    x (h) x (h)       
LAI LGYR x            
TLGGILAPIYFGA LIDK x    x (h) x (h)       
EAEY LISK x    x (r) x (r) x (r) x (r)    x (r) 
EANH LISK x    x (r) x (r) x (r) x (r)    x (r) 
EANIHAFIES LPNK   x   x (h) x (h)  x   x (h) 
LQDEIDEA LPNK x    x (m) x (m)       
LQDEIDAA LPNK x    x (r, m) x (r, m) x (r) x (r)    x (r) 
LQEEIDET LPNK x    x (m) x (m)       
LQEEIDGA LPSK x    x (r) x (r) x (r) x (r)    x (r) 
WLV LSGK x    x (r, m) x (r, m)       
DNTPTVLHGIN LTIR x            
NTTGA LTTR x   x 
x 
(h, r, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x 
(h, r, m) 
x x x 
x 
(h, r, m) 
NTTGS LTTR x   x x (r) x (r) x (r) x (r)    x (r) 
NSPGA LTTR x    x (h) x (h) x (h) x (h) x x  x (h) 
NNPGV LTTR x   x x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
NISQSFT NFSK x    x (m) x (m) x (m) x (m)   x x (m) 
NFNQSLT NFSK x    x (m) x (m) x (m) x (m)   x x (m) 
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NVSQSLT NFSK x    x (m) x (m) x (m) x (m)   x x (m) 
GYGVTFS NGER x    x (m) x (m) x (m) x (m)   x x (m) 
EYGVIFA NGER x x  x x (r, m) x (r, m) x (r) x (r)    x (r) 
GYGVAFS NGER x    x (m) x (m) x (m) x (m)   x x (m) 
DYDEVTAFLGEWG PFQR     x (r, m)        
SPQSFFDTT PSGR             
APQSFFDTT PSGR             
YVEQQYGQ PSSK x  x  x (h) x (h) x (h)   x  x (h) 
AAVP PWGK x            
AAL QDEK x     x (r)       
NKPLFDTI QDEK x  x  x (h) x (h) x (h) x (h) x x  x (h) 
LYDPLEGVVSIDG QDIR x    x (m) x (m)       
LYDPTEGMVSVDG QDIR x    x (h) x (h)  x (h)     
LYDPIEGEVSIDG QDIR x x  x x (r) x (r) x (r) x (r)    x (r) 
LAHDILLFLNP QLLK x    x (m) x (m)       
LIHDLLVFLNP QLLK x     x (r)       
LVNDIFTFVSP QLLK x            
NTWDPD QPPR x    x (m) x (m) x (m) x (m)   x x (m) 
TTWDPD QPPR x    x (m) x (m)       
TTWDPT QPPR x    x (m) x (m) x (m) x (m)   x x (m) 
TWDPD QPPR x    x (r, m) x (r, m) x (r, m) x (r, m)   x x (r, m) 
TYTLQDGPWS QQER x            
ELWGDPNEF RPER x    x (m)        
DPFVF RPER x    x (r, m) x (r)       
DPQHWPEPEEF RPER x    x (r)        
YWPEPEEF RPER x    x (m)        
DPHYWPEPEEF RPER x    x (r)        
YLGGDDLDT SAIR             
LEQYLGSDDLDL SAIR             
SDAFVPF SIGK x    x (r, m) x (r, m)       
NDAFVPF SIGK x    x (m) x (m)       
QPLEGSDLW SLNK x            
SSDLW SLNK x     x (r)       
QPLESSDLW SLNK x    x (m) x (m)       
SLPA SLQR             
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NAAFLPF STGK x    x (r)        
SEAFMPF STGK             
CEAFLPF STGK x            
SDYFIPF STGK x    x (m) x (m)       
ESLDV TNPR x    x (m) x (m) x (m) x (m)    x (m) 
EHQESLDV TNPR x    x (r) x (r)       
IEEHQESLDV TNPR x    x (r) x (r)       
DLVGYIF TTDR x            
DHVGYIF TTDR x            
SSIS TVEK x    
x 
(h, r, m) 
x 
(h, r, m) 
x (h, m) x (h, m) x x x x (h, m) 
MSDS VILR x    x (r, m) x (r, m)       
HGEIQFNN YQVR x    x (r) x (r) x (r) x (r)    x (r) 
IQFNN YQVR x    x (h) x (h) x (h) x (h) x x  x (h) 
GEIQFNN YQVR x    x (m) x (m)       
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Table 64: Detailed information of Sequence logos of all used antibodies. The antibody ID 
is unique for each serum and contains following information: clonality 
(monoclonal mAB / polyclonal pAB), antigen, host species and a consecutive 
number. The ratio of enriched peptides is obtained by referring the number of 
enriched peptides with the expected TXP epitope to the total number of peptides 
present in the proteome sharing this epitope ( UniProtKB reference proteome 
June2014). Additionally,  the sequence logo as well as the number of peptides and 
tags it is based on are listed. S ome antibodies were excluded from this experiment, 
because they either failed a preliminary test (*) or are peptide specific (**). A 
monoclonal anti-cMyc antibody was used as negative control (***).  
pAB_TXP_LPNK_rbt1 has already been characterized (+)  [22]. 
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mAB_cMyc_ms1 *** *** *** *** *** *** *** 
pAB_GIYDGDLK_rbt1 yes ** ** ** ** ** ** 
pAB_GIYDGDLK_rbt2 yes ** ** ** ** ** ** 
pAB_TXP_AAYR_rbt1 no 5 68 7.4 % 6 26 
 
pAB_TXP_AAYR_rbt2 yes 0 68 0.0 % 0 0  
pAB_TXP_ALEK_rbt1 yes 24 280 8.6 % 4 36 
 
pAB_TXP_ALEK_rbt2 * * * * * * * 
pAB_TXP_ALPR_rbt1 yes 0 165 0.0 % 0 0  
pAB_TXP_ALPR_rbt2 yes 0 165 0.0 % 2 4 
 
pAB_TXP_ANFK_rbt1 * * * * * * * 
pAB_TXP_ANFK_rbt2 * * * * * * * 
pAB_TXP_APAR_rbt1 * * * * * * * 
pAB_TXP_APAR_rbt2 * * * * * * * 
pAB_TXP_AVDR_rbt1 * * * * * * * 
pAB_TXP_AVDR_rbt2 yes 7 109 6.4 % 9 44 
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pAB_TXP_AYDR_rbt1 yes 10 221 4.5 % 2 13 
 
pAB_TXP_AYDR_rbt2 yes 11 221 5.0 % 15 66 
 
pAB_TXP_DAPK_rbt1 yes 7 43 16.3 % 10 62 
 
pAB_TXP_DAPK_rbt2 yes 12 43 27.9 % 10 64 
 
pAB_TXP_DFFR_rbt1 yes 11 42 26.2 % 13 69 
 
pAB_TXP_DLFR_rbt1 yes 21 98 21.4 % 5 39 
 
pAB_TXP_DLFR_rbt2 yes 16 98 16.3 % 9 46 
 
pAB_TXP_DLFR_rbt3 yes 20 98 20.4 % 15 90 
 
pAB_TXP_DLFR_rbt4 yes 15 98 15.3 % 5 32 
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pAB_TXP_DLVR_rbt1 yes 39 110 35.5 % 14 157 
 
pAB_TXP_DLVR_rbt2 yes 18 110 16.4 % 14 123 
 
pAB_TXP_DLVR_rbt3 yes 26 110 23.6 % 10 94 
 
pAB_TXP_DLVR_rbt4 yes 17 110 15.5 % 11 134 
 
pAB_TXP_DPPR_rbt1 yes 17 79 21.5 % 4 29 
 
pAB_TXP_DPPR_rbt2 yes 11 79 13.9 % 4 21 
 
pAB_TXP_DTQR_rbt1 yes 4 35 11.4 % 10 42 
 
pAB_TXP_DTQR_rbt2 yes 0 35 0.0 % 0 0  
pAB_TXP_EATR_rbt1 yes 12 102 11.8 % 11 69 
 
pAB_TXP_EATR_rbt2 yes 3 102 2.9 % 4 16 
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pAB_TXP_EAVK_rbt1 yes 0 167 0.0 % 20 28 
 
pAB_TXP_EAVK_rbt2 yes 21 167 12.6 % 8 66 
 
pAB_TXP_EEAK_rbt1 no 53 266 19.9 % 9 115 
 
pAB_TXP_EELK_rbt1 no 3 394 0.8 % 1 3 
 
pAB_TXP_EELK_rbt2 yes 6 394 1.5 % 4 19 
 
pAB_TXP_EGCK_rbt1 no 4 38 10.5 % 4 27 
 
pAB_TXP_EGCK_rbt2 no 0 38 0.0 % 7 55 
 
pAB_TXP_EIQK_rbt1 yes 23 114 20.2 % 4 73 
 
pAB_TXP_ELSK_rbt1 yes 33 206 16.0 % 11 129 
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pAB_TXP_ESIK_rbt1 yes 21 93 22.6 % 8 91 
 
pAB_TXP_ESIK_rbt2 yes 15 93 16.1 % 17 144 
 
pAB_TXP_ESTR_rbt1 yes 2 82 2.4 % 2 6 
 
pAB_TXP_ETFR_rbt1 yes 11 61 18.0 % 14 127 
 
pAB_TXP_ETFR_rbt2 yes 10 61 16.4 % 15 142 
 
pAB_TXP_EVLR_rbt1 yes 75 215 34.9 % 19 425 
 
pAB_TXP_EVLR_rbt2 yes 69 215 32.1 % 31 495 
 
pAB_TXP_FAFK_rbt1 yes 4 26 15.4 % 5 20 
 
pAB_TXP_FAFK_rbt2 yes 5 26 19.2 % 7 30 
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pAB_TXP_FFFK_rbt1 no 0 28 0.0 % 2 4 
 
pAB_TXP_FFFK_rbt2 yes 0 28 0.0 % 6 20 
 
pAB_TXP_FSGR_rbt1 yes 18 85 21.2 % 21 195 
 
pAB_TXP_FSGR_rbt2 yes 14 85 16.5 % 15 109 
 
pAB_TXP_FTNR_rbt1 yes 0 36 0.0 % 2 8 
 
pAB_TXP_FTNR_rbt2 yes 7 36 19.4 % 14 97 
 
pAB_TXP_FWLK_rbt1 yes 0 15 0.0 % 1 2 
 
pAB_TXP_FWLK_rbt2 yes 3 15 20.0 % 7 23 
 
pAB_TXP_GFCR_rbt1 yes 7 19 36.8 % 19 118 
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pAB_TXP_GFCR_rbt2 yes 5 19 26.3 % 5 24 
 
pAB_TXP_GGEK_rbt1 yes 17 99 17.2 % 7 61 
 
pAB_TXP_GGEK_rbt2 yes 14 99 14.1 % 3 21 
 
pAB_TXP_GQVR_rbt1 yes 3 46 6.5 % 7 29 
 
pAB_TXP_GQVR_rbt2 yes 0 46 0.0 % 2 4 
 
pAB_TXP_GSLR_rbt1 yes 7 233 3.0 % 3 14 
 
pAB_TXP_GSLR_rbt2 yes 3 233 1.3 % 1 3 
 
pAB_TXP_GTVR_rbt1 yes 9 95 9.5 % 22 149 
 
pAB_TXP_GTVR_rbt2 yes 10 95 10.5 % 9 51 
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pAB_TXP_GYYR_rbt1 yes 7 42 16.7 % 7 30 
 
pAB_TXP_GYYR_rbt2 yes 6 42 14.3 % 10 45 
 
pAB_TXP_IFFK_rbt1 yes 2 27 7.4 % 1 2 
 
pAB_TXP_IFFK_rbt2 yes 4 27 14.8 % 1 4 
 
pAB_TXP_KPHR_rbt1 yes 5 29 17.2 % 9 36 
 
pAB_TXP_KPHR_rbt2 yes 7 29 24.1 % 2 11 
 
pAB_TXP_LAER_rbt1 yes 51 201 25.4 % 18 233 
 
pAB_TXP_LAER_rbt2 yes 23 201 11.4 % 3 35 
 
pAB_TXP_LAER_rbt3 yes 17 201 8.5 % 6 45 
 
pAB_TXP_LDDK_rbt1 yes 0 69 0.0 % 0 0  
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pAB_TXP_LDDR_rbt1 yes 20 60 33.3 % 17 126 
 
pAB_TXP_LDDR_rbt2 yes 23 60 38.3 % 20 161 
 
pAB_TXP_LEVR_rbt1 yes 34 108 31.5 % 9 79 
 
pAB_TXP_LFSK_rbt1 no 28 124 22.6 % 6 62 
 
pAB_TXP_LFSK_rbt2 no 22 124 17.7 % 18 123 
 
pAB_TXP_LGYR_rbt1 no 0 70 0.0 % 10 73 
 
pAB_TXP_LIDK_rbt1 yes 14 71 19.7 % 13 102 
 
pAB_TXP_LIDK_rbt2 yes 16 71 22.5 % 5 153 
 
pAB_TXP_LISK_rbt1 yes 37 146 25.3 % 18 287 
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pAB_TXP_LISK_rbt2 yes 33 146 22.6 % 5 90 
 
pAB_TXP_LPNK_rbt1 + + + + + +  
pAB_TXP_LPNK_rbt2 yes 10 50 20.0 % 5 21 
 
pAB_TXP_LPNK_rbt3 yes 0 50 0.0 % 0 0  
pAB_TXP_LPSK_rbt1 yes 3 156 1.9 % 3 9 
 
pAB_TXP_LPSK_rbt2 yes 0 156 0.0 % 14 110 
 
pAB_TXP_LSGK_rbt1 yes 25 207 12.1 % 7 64 
 
pAB_TXP_LSQR_rbt1 yes 0 145 0.0 % 4 16 
 
pAB_TXP_LSQR_rbt2 yes 0 145 0.0 % 0 0  
pAB_TXP_LTIR_rbt1 * * * * * *  
pAB_TXP_LTIR_rbt2 yes 0 73 0.0 % 2 8 
 
pAB_TXP_LTTR_rbt1 no 0 65 0.0 % 0 0  
pAB_TXP_LTTR_rbt2 yes 7 65 10.8 % 13 122 
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pAB_TXP_NFSK_rbt1 yes 20 64 31.3 % 19 167 
 
pAB_TXP_NFSK_rbt2 yes 19 64 29.7 % 9 72 
 
pAB_TXP_NGER_rbt1 yes 5 55 9.1 % 9 49 
 
pAB_TXP_NGER_rbt2 yes 5 55 9.1 % 4 14 
 
pAB_TXP_PFQR_rbt1 yes 0 36 0.0 % 2 9 
 
pAB_TXP_PFQR_rbt2 yes 3 36 8.3 % 7 25 
 
pAB_TXP_PSGR_rbt1 * * * * * * * 
pAB_TXP_PSGR_rbt2 * * * * * * * 
pAB_TXP_PSSK_rbt1 yes 32 210 15.2 % 11 130 
 
pAB_TXP_PSSK_rbt2 yes 45 210 21.4 % 10 136 
 
pAB_TXP_PTVK_rbt1 no 0 73 0.0 % 1 2 
 
pAB_TXP_PTVK_rbt2 no 0 73 0.0 % 0 0  
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pAB_TXP_PWGK_rbt1 yes 5 15 33.3 % 16 91 
 
pAB_TXP_PWGK_rbt2 yes 4 15 26.7 % 14 84 
 
pAB_TXP_QDEK_rbt1 yes 6 53 11.3 % 12 65 
 
pAB_TXP_QDEK_rbt2 yes 7 53 13.2 % 9 44 
 
pAB_TXP_QDIR_rbt1 yes 9 45 20.0 % 16 97 
 
pAB_TXP_QDIR_rbt2 * * * * * * * 
pAB_TXP_QLLK_rbt1 yes 14 233 6.0 % 3 21 
 
pAB_TXP_QLLK_rbt2 yes 18 233 7.7 % 8 51 
 
pAB_TXP_QLLK_rbt3 * * * * * * * 
pAB_TXP_QLLK_rbt4 yes 48 233 20.6 % 18 173 
 
pAB_TXP_QPPR_rbt1 yes 0 130 0.0 % 0 0  
pAB_TXP_QPPR_rbt2 yes 0 130 0.0 % 0 0  
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pAB_TXP_QQER_rbt1 yes 15 69 21.7 % 12 99 
 
pAB_TXP_QQER_rbt2 yes 23 69 33.3 % 24 241 
 
pAB_TXP_RPER_rbt1 yes 0 70 0.0 % 1 2 
 
pAB_TXP_RPER_rbt2 yes 0 70 0.0 % 0 0  
pAB_TXP_SAIR_rbt1 * * * * * * * 
pAB_TXP_SAIR_rbt2 * * * * * * * 
pAB_TXP_SIGK_rbt1 yes 0 67 0.0 % 0 0  
pAB_TXP_SIGK_rbt2 yes 10 67 14.9 % 12 87 
 
pAB_TXP_SLNK_rbt1 * * * * * * * 
pAB_TXP_SLNK_rbt2 yes 18 114 15.8 % 14 95 
 
pAB_TXP_SLNK_rbt3 * * * * * * * 
pAB_TXP_SLNK_rbt4 yes 15 114 13.2 % 13 116 
 
pAB_TXP_STGK_rbt1 no 0 101 0.0 % 1 3 
 
pAB_TXP_STGK_rbt2 yes 0 101 0.0 % 0 0  
pAB_TXP_TNPR_rbt1 yes 6 32 18.8 % 17 143 
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pAB_TXP_TNPR_rbt2 yes 7 32 21.9 % 19 124 
 
pAB_TXP_TTDR_rbt1 yes 0 42 0.0 % 1 2 
 
pAB_TXP_TTDR_rbt2 yes 0 42 0.0 % 1 5 
 
pAB_TXP_TVEK_rbt1 yes 16 101 15.8 % 11 56 
 
pAB_TXP_TVEK_rbt2 yes 0 101 0.0 % 1 2 
 
pAB_TXP_VILR_rbt1 yes 3 95 3.2 % 2 6 
 
pAB_TXP_VILR_rbt2 yes 6 95 6.3 % 2 17 
 
pAB_TXP_YQVR_rbt1 yes 7 24 29.2 % 13 71 
 
pAB_TXP_YQVR_rbt2 yes 5 24 20.8 % 9 46 
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Table 65: AB functionality-results with respect to peptides. For further assay 
development, peptides had to be enriched by at least one purified antibody serum. 
The criterion for successful enrichment was a total file area greater than 10 4  after 
tS IM analysis. S ome peptides were excluded from this experiment, because they 
failed a preliminary test (*) or were already tested successfully (**).  
Peptide sequence enrichment 
ANIYGLCFAFSQGIAFLANS AAYR yes 
AAATEDATPA ALEK yes 
NLVLL ALPR no 
NVALL ALPR no 
NLVLM ALPR no 
GLSGDVLINGAPQP ANFK no* 
DPSGLSGDVLINGAPRP ANFK no* 
TLSLE APAR no* 
SLSEASV AVDR yes 
LGSILSPYFVYLG AYDR yes 
GDFVAVFPPMIHNDPEVF DAPK yes 
SECHV DFFR yes 
LSPSFA DLFR yes 
SPSFA DLFR yes 
RPSYL DLFR yes 
ALQRPSYL DLFR yes 
VSQRPSYL DLFR no 
YGLS DLFR yes 
YTAS DLFR yes 
EVLDSFL DLVR yes 
LNPSFL DLVR yes 
MVA DPPR yes 
FVHPPNASLPN DTQR yes 
FINLVPSNLPH EATR yes 
IVVLCGQ EAVK yes 
TYGPVFTLYFGSQPTVVLHGY EAVK no 
AYGPVFTLYLGSKPTVILHGY EAVK yes 
AYGPVFTLYLGSRPTVVLHGY EAVK yes 
VYGPVFTLYFGSKPTVVVHGY EAVK yes 
LAA EEAK no 
LSL EELK no 
LTI EELK yes 
LQTE EGCK no 
AMDSFPGPPTHWLFGHAL EIQK yes 
CIGE ELSK yes 
MVEVCV ESIK yes 
LLTPGFHYDVLKPYVAIFA ESTR yes 
LSDRPQLPYLEAFIL ETFR yes 
EQLDSLVCLESAIL EVLR no* 
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Peptide sequence enrichment 
YTDHF FAFK yes 
DHF FAFK yes 
FIGLQ FFFK yes 
EALVDHAEE FSGR yes 
EALEDNAEE FSGR yes 
EALVGQAEA FSGR yes 
EALVDHAEA FSGR yes 
EALVDLGEE FSGR yes 
EALIDYGEE FSGR yes 
EALVDHGEE FSGR yes 
EALDDLGEE FSGR yes 
NE FSGR yes 
ECYST FTNR yes 
ECYSV FTNR yes 
DCLSV FTNR yes 
HW FWLK yes 
LLNSHW FWLK yes 
GIYD GDLK yes 
YDTVC GFCR yes 
TVAAF GGEK yes 
DLSLHVH GGEK yes 
NLTLHVQ GGEK yes 
NVTVHVQ GGEK yes 
AELHQLS GGEK yes 
VQQEIDAVI GQVR yes 
VQQEIDEVI GQVR yes 
ITIIPQDPVLFS GSLR yes 
LTIIPQDPILFS GSLR yes 
LTIIPQEPVLFS GTVR yes 
LAIIPQEPVLFS GTVR yes 
LSIIPQEPVLFS GTVR yes 
LFIHEYIS GYYR yes 
IQGYFNAWQALLIKPN IFFK yes 
DETVWE KPHR yes 
GPSAAA LAER yes 
DFDPQNF LDDK yes 
DFNPQHF LDDK yes 
EIDQVIGSHRPPS LDDR yes 
GGPEAT LEVR yes 
LAI LGYR no 
TLGGILAPIYFGA LIDK yes 
EAEY LISK yes 
EANH LISK yes 
EANIHAFIES LPNK no** 
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LQDEIDEA LPNK yes 
LQDEIDAA LPNK yes 
LQEEIDET LPNK yes 
LQEEIDGA LPSK yes 
WLV LSGK yes 
DNTPTVLHGIN LTIR yes 
NTTGA LTTR yes 
NTTGS LTTR yes 
NSPGA LTTR yes 
NNPGV LTTR yes 
NISQSFT NFSK yes 
NFNQSLT NFSK yes 
NVSQSLT NFSK yes 
GYGVTFS NGER yes 
EYGVIFA NGER yes 
GYGVAFS NGER yes 
DYDEVTAFLGEWG PFQR no* 
SPQSFFDTT PSGR no* 
APQSFFDTT PSGR no* 
YVEQQYGQ PSSK yes 
AAVP PWGK yes 
AAL QDEK yes 
NKPLFDTI QDEK yes 
LYDPLEGVVSIDG QDIR yes 
LYDPTEGMVSVDG QDIR yes 
LYDPIEGEVSIDG QDIR yes 
LAHDILLFLNP QLLK yes 
LIHDLLVFLNP QLLK no 
LVNDIFTFVSP QLLK yes 
NTWDPD QPPR yes 
TTWDPD QPPR yes 
TTWDPT QPPR yes 
TWDPD QPPR yes 
TYTLQDGPWS QQER yes 
ELWGDPNEF RPER yes 
DPFVF RPER yes 
DPQHWPEPEEF RPER yes 
YWPEPEEF RPER yes 
DPHYWPEPEEF RPER yes 
YLGGDDLDT SAIR no* 
LEQYLGSDDLDL SAIR no* 
SDAFVPF SIGK yes 
NDAFVPF SIGK yes 
QPLEGSDLW SLNK yes 
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SSDLW SLNK yes 
QPLESSDLW SLNK yes 
SLPA SLQR no* 
NAAFLPF STGK yes 
SEAFMPF STGK no* 
CEAFLPF STGK yes 
SDYFIPF STGK yes 
ESLDV TNPR yes 
EHQESLDV TNPR yes 
IEEHQESLDV TNPR yes 
DLVGYIF TTDR no 
DHVGYIF TTDR yes 
SSIS TVEK yes 
MSDS VILR yes 
HGEIQFNN YQVR yes 
IQFNN YQVR yes 
GEIQFNN YQVR yes 
 
 
 
 
 
 
 
 
 
Table 66: Adjustment of antibody and proteolyzed protein amount for rat samples. Three 
different antibody and proteins amounts were tested whether they are sufficient for 
reproducible analyte quantification. For each antibody serum 1, 2 and 5 µg were tested with 
every protein amount. Results are given as % RSD. If not stated otherwise, the conclusion 
column gives the minimal amount of antibody and protein necessary, but more is also 
possible. Antibodies which did not enrich EN or IS peptide sufficiently for quantification were 
not used further (n.u.f.). Antibodies which lead to suitable IS signals and should be tested 
again when a sample containing this target is available are additionally indicated with (#). 
Decisions which were made with reservations are marked with *. 
antibody peptide 
10-40 µg protein 
AB: 
1 –      2 -     5µg 
20-40 µg protein 
AB: 
1 –      2 -     5µg 
1-5 µg AB 
protein: 
10 -   20 - 40 µg 
2-5 µg AB 
protein: 
10 -   20 - 40 µg 
conclusion 
protein / AB 
...AAYR_rbt2 ANIYGLCFAFSQGIAFLANSAAYR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...ALEK_rbt1 AAATEDATPAALEK 15 20 17 11 1.6 0.4 29 8.5 2.6 42 1.6 3.5 20 µg / 2µg 
...DLFR_rbt3 
ALQRPSYLDLFR 8.7 6.9 8.8 9.1 5.8 12 1.7 4.5 12 2.1 3.2 15 
40 µg / 5 µg SPSFADLFR --- --- --- --- --- --- --- --- --- --- --- --- 
YGLSDLFR --- --- --- --- --- --- --- --- --- --- --- --- 
...EATR_rbt1 FINLVPSNLPHEATR 16 36 3.6 0.4 23 5.1 25 31 33 12 17 35 10 µg / 5 µg 
...EATR_rbt2 FINLVPSNLPHEATR --- --- --- --- --- --- --- --- --- --- --- --- use other AB 
...EIQK_rbt1 
AMDSFPGP 
PTHWLFGHALEIQK 
12 7.2 12 9.5 9.5 3.7 9.5 11 6.7 3.7 9.5 3.7 20 µg / 1-2 µg 
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antibody peptide 
10-40 µg protein 
AB: 
1 –      2 -     5µg 
20-40 µg protein 
AB: 
1 –      2 -     5µg 
1-5 µg AB 
protein: 
10 -   20 - 40 µg 
2-5 µg AB 
protein: 
10 -   20 - 40 µg 
conclusion 
protein / AB 
...ESIK_rbt2 MVEVCVESIK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...ESTR_rbt1 LLTPGFHYDVLKPYVAIFAESTR 173 60 21 --- 22 16 99 88 101 88 12 49 40 µg / 5 µg * 
...FSGR_rbt1 
NEFSGR 28 9.4 7.8 8.7 11 9.1 17 2.0 15 0.5 2.8 1.2 
20 µg / 2µg 
EALVDHAEAFSGR 5.9 5.1 9.9 6.7 7.1 9.8 1.6 4.7 2.6 2.3 6.3 3.6 
EALVDLGEEFSGR 15 16 2.5 18 20 0.8 4.8 21 18 2.9 6.0 25 
EALIDYGEEFSGR 6.1 5.2 13 2.7 6.5 7.9 6.3 3.2 2.7 8.7 3.9 2.5 
EALDDLGEEFSGR 48 7.7 131 15 4.4 1.7 136 30 19 113 2.8 0.1 
EALVDHGEEFSGR 64 6.2 10 92 6.6 10.9 1.6 53 27 2.3 2.5 1.8 
...FSGR_rbt2 
NEFSGR --- 173 18 --- --- 2.6 98 173 173 43 141 141 
use other AB 
EALVDHAEAFSGR 15 8.7 5.8 16 4.5 0.1 2.8 3.7 12 1.9 3.1 1.3 
EALVDLGEEFSGR --- --- --- --- --- --- --- --- --- --- --- --- 
EALIDYGEEFSGR 119 103 49 77 141 5.8 87 23 107 0.6 24 141 
EALDDLGEEFSGR --- --- --- --- --- --- --- --- --- --- --- --- 
EALVDHGEEFSGR 101 22 129 141 25 3.8 139 11 87 119 13 8.3 
...FTNR_rbt1 
ECYSVFTNR 4.4 14 3.8 6.1 11 1.6 9.8 2.5 11 14 1.3 11 
use other AB 
ECYSTFTNR 1.5 7.5 5.2 0.8 3.2 4.9 8.9 4.0 2.3 12 0.9 2.6 
...FTNR_rbt2 
ECYSVFTNR 5.1 4.3 3.3 4.8 1.6 4.1 2.1 3.1 0.8 1.0 3.3 0.9 
10 µg / 1 µg 
ECYSTFTNR 5.3 5.6 1.9 7.3 6.9 1.1 3.6 2.3 2.8 4.9 2.2 3.6 
...FWLK_rbt1 HWFWLK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...FWLK_rbt2 HWFWLK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...GGEK_rbt1 NLTLHVQGGEK --- 31 45 --- 17 28 87 87 89 3.9 6.6 18 20 µg / 2 µg 
...GSLR_rbt1 
LTIIPQDPILFSGSLR --- 95 13 --- 36 3.8 173 87 93 141 0.2 32 
40 µg / 5 µg 
ITIIPQDPVLFSGSLR --- --- --- --- --- --- --- --- --- --- --- --- 
...GTVR_rbt1 LTIIPQEPVLFSGTVR --- 50 51 --- 33 26 90 88 90 21 17 23 40µg / 5 µg * 
...GTVR_rbt2 LTIIPQEPVLFSGTVR --- --- 58 --- --- 29 173 173 173 141 141 141 use other AB 
...IFFK_rbt1 IQGYFNAWQALLIKPNIFFK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...IFFK_rbt2 IQGYFNAWQALLIKPNIFFK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...KPHR_rbt1 DETVWEKPHR 87 173 51 141 --- 25 19 89 173 27 141 141 
10 µg / 1-2 µg 
10-40 µg / 5 
µg * 
...KPHR_rbt2 DETVWEKPHR 173 173 59 --- --- 65 17 173 173 23 141 141 use other AB 
...LDDK_rbt1 
DFNPQHFLDDK 3.8 5.5 3.1 3.6 7.5 2.5 5.1 5.6 5.9 3.4 0.2 5.2 
10 µg / 1 µg 
DFDPQNFLDDK 2.0 2.9 0.5 0.5 3.6 0.2 6.1 5.0 3.7 3.4 0.7 2.8 
...LDDR_rbt1 EIDQVIGSHRPPSLDDR 3.4 7.5 2.4 4.8 3.8 3.2 5.3 1.6 8.5 7.3 0.4 0.3 10 µg / 1 µg 
...LDDR_rbt2 EIDQVIGSHRPPSLDDR 2.5 3.1 16.6 3.5 3.9 18.4 2.2 0.9 17.9 3.0 1.2 21.0 use other AB 
...LISK_rbt1 
EAEYLISK --- --- --- --- --- --- --- --- --- --- --- --- 
use other AB 
EANHLISK 87 87 12 141 141 12 1.7 1.1 173 2.4 0.1 141 
...LISK_rbt2 
EAEYLISK --- --- --- --- --- --- --- --- --- --- --- --- 
20 µg / 2 µg 
EANHLISK 173 4.3 3.7 141 5.9 2.5 87 3.0 87 3.6 3.2 5.1 
...LPNK_rbt2 LQDEIDAALPNK 11 15 7.4 0.5 3.9 1.4 9.7 3.0 2.6 13 4.2 1.7 20 µg / 1 µg 
...LPNK_rbt3 LQDEIDAALPNK 32 99 56 12 75 71 22 38 122 29 56 130 use other AB 
...LPSK_rbt1 LQEEIDGALPSK --- --- --- --- --- --- --- --- --- --- --- --- use other AB 
...LPSK_rbt2 LQEEIDGALPSK --- --- --- --- --- --- --- --- --- --- --- --- 40 µg / 5 µg * 
...LSGK_rbt1 WLVLSGK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
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antibody peptide 
10-40 µg protein 
AB: 
1 –      2 -     5µg 
20-40 µg protein 
AB: 
1 –      2 -     5µg 
1-5 µg AB 
protein: 
10 -   20 - 40 µg 
2-5 µg AB 
protein: 
10 -   20 - 40 µg 
conclusion 
protein / AB 
...LTTR_rbt2 
NTTGSLTTR --- --- --- --- --- --- --- --- --- --- --- --- 
20 µg / 2 µg NNPGVLTTR 8.6 8.5 3.7 11 2.2 5.1 6.7 3.1 3.4 9.3 1.3 1.6 
NTTGALTTR 10 9.6 1.1 13 4.1 1.4 13 10 3.7 8.9 1.2 3.9 
...NGER_rbt1 EYGVIFANGER 2.4 3.6 1.4 3.2 0.1 1.5 4.9 5.6 2.3 3.6 2.7 1.1 10 µg / 1 µg 
...NGER_rbt2 EYGVIFANGER 11 5.9 1.9 15 8.4 2.4 5.0 2.9 7.5 0.9 4.2 1.8 use other AB 
...PFQR_rbt1 DYDEVTAFLGEWGPFQR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...PFQR_rbt2 DYDEVTAFLGEWGPFQR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...QDIR_rbt1 LYDPIEGEVSIDGQDIR 173 87 7.0 141 9.0 9.9 173 87 7.1 141 2.1 1.2 20 µg / 2 µg 
...QPPR_rbt1 TWDPDQPPR 3.3 34 87 3.2 46 1.6 87 3.1 35 141 3.1 47 10 µg / 1 µg 
...QPPR_rbt2 TWDPDQPPR 11 29 87 15 39 4.1 87 4.5 28 141 5.1 40 use other AB 
...RPER_rbt1 
DPFVFRPER --- --- --- --- --- --- --- --- --- --- --- --- 
n.u.f. DPQHWPEPEEFRPER --- --- --- --- --- --- --- --- --- --- --- --- 
DPHYWPEPEEFRPER --- --- --- --- --- --- --- --- --- --- --- --- 
...RPER_rbt2 
DPFVFRPER --- --- --- --- --- --- --- --- --- --- --- --- 
n.u.f. (#) DPQHWPEPEEFRPER --- --- --- --- --- --- --- --- --- --- --- --- 
DPHYWPEPEEFRPER --- --- --- --- --- --- --- --- --- --- --- --- 
...S IGK_rbt1 SDAFVPFSIGK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...S IGK_rbt2 SDAFVPFSIGK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...STGK_rbt2 NAAFLPFSTGK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...TNPR_rbt1 
EHQESLDVTNPR 4.4 3.7 3.5 3.0 4.6 1.3 1.4 1.7 1.4 1.9 2.1 1.3 
use other AB 
IEEHQESLDVTNPR 88 15 4.7 116 18 2.7 32 74 22 2.1 11 26 
...TNPR_rbt2 
EHQESLDVTNPR 4.4 0.6 0.9 2.1 0.0 0.9 4.0 3.3 4.6 4.5 4.0 4.9 40 µg / 2 µg 
10-40 µg / 5 
µg IEEHQESLDVTNPR 28 7.2 0.7 32 5.6 0.5 12 13 12 9.3 4.4 1.7 
...TVEK_rbt1 SSISTVEK 20 6.3 4.7 28 0.6 5.3 19 9.0 31 13 5.4 11 20 µg / 2 µg 
...VILR_rbt1 MSDSVILR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...VILR_rbt2 MSDSVILR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...YQVR_rbt1 HGEIQFNNYQVR 48 50 36 30 32 26 5.6 14 18 0.3 13 19 10 µg / 1 µg 
...YQVR_rbt2 HGEIQFNNYQVR 49 51 44 42 40 37 3.3 6.6 10 1.7 8.4 12 use other AB 
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Table 67: Adjustment of antibody and proteolyzed protein amount for mouse samples. 
Three different antibody and proteins amounts were tested whether they are sufficient for 
reproducible analyte quantification. For each antibody serum 1, 2 and 5 µg were tested with 
every protein amount. Results are given as % RSD. If not stated otherwise, the conclusion 
column gives the minimal amount of antibody and protein necessary, but more is also 
possible. Antibodies which did not enrich EN or IS peptide sufficiently for quantification were 
not used further (n.u.f.). Antibodies which lead to suitable IS signals and should be tested 
again when a sample containing this target is available are additionally indicated with (#). 
Decisions which were made with reservations are marked with *. 
antibody peptide 
10-40 µg protein 
AB: 
1 –      2 -     5µg 
20-40 µg protein 
AB: 
1 –      2 -     5µg 
1-5 µg AB 
protein: 
10 -   20 - 40 µg 
2-5 µg AB 
protein: 
10 -   20 - 40 µg 
conclusion 
protein / AB 
...ALEK_rbt1 AAATEDATPAALEK 15 4.9 3.2 7.7 4.6 1.6 18 7.9 5.6 17 11 7.7 20 µg / 2 µg 
...AVDR_rbt1 SLSEASVAVDR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...AVDR_rbt2 SLSEASVAVDR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...DLFR_rbt3 YGLSDLFR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...DLVR_rbt1 EVLDSFLDLVR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...DLVR_rbt2 EVLDSFLDLVR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...DLVR_rbt3 EVLDSFLDLVR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...DLVR_rbt4 EVLDSFLDLVR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...EATR_rbt1 FINLVPSNLPHEATR 159 30 3.9 141 37 4.4 83 100 39 5.3 47 15 10 µg / 5 µg 
...EATR_rbt2 FINLVPSNLPHEATR --- --- --- --- --- --- --- --- --- --- --- --- use other AB 
...EAVK_rbt1 
AYGPVFTLYLGSRPTVVLHGYEAVK --- --- --- --- --- --- --- --- --- --- --- --- 
n.u.f. 
AYGPVFTLYLGSKPTVILHGYEAVK --- --- --- --- --- --- --- --- --- --- --- --- 
VYGPVFTLYFGSKPTVVVHGYEAVK --- --- --- --- --- --- --- --- --- --- --- --- 
IVVLCGQEAVK --- --- --- --- --- --- --- --- --- --- --- --- 
...EAVK_rbt2 
AYGPVFTLYLGSRPTVVLHGYEAVK --- --- --- --- --- --- --- --- --- --- --- --- 
n.u.f. 
AYGPVFTLYLGSKPTVILHGYEAVK --- --- --- --- --- --- --- --- --- --- --- --- 
VYGPVFTLYFGSKPTVVVHGYEAVK --- --- --- --- --- --- --- --- --- --- --- --- 
IVVLCGQEAVK --- --- --- --- --- --- --- --- --- --- --- --- 
...ESIK_rbt1 MVEVCVESIK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...ESIK_rbt2 MVEVCVESIK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...FFFK_rbt2 FIGLQFFFK --- 173 6.8 --- 141 7.1 173 173 104 141 141 54 20 µg / 2 µg 
...FSGR_rbt1 
NEFSGR 7.2 173 8.8 1.3 --- 8.2 6.2 87 87 3.5 141 141 
20 µg / 2 µg 
EALVDHAEAFSGR 5.6 2.7 1.9 5.4 1.7 2.6 6.7 5.0 4.5 8.7 6.8 6.0 
EALVGQAEAFSGR 4.9 1.3 2.4 6.4 1.6 3.4 1.6 3.2 5.0 2.0 1.7 3.6 
EALVDHAEEFSGR 11 3.8 2.1 15 4.0 0.3 3.9 0.8 11 2.0 0.8 4.5 
EALDDLGEEFSGR 1.2 2.0 4.3 1.7 2.8 5.5 1.9 3.1 2.1 2.7 1.2 1.4 
EALEDNAEEFSGR --- --- 173 --- --- 141 --- --- 173 --- --- 141 
...FSGR_rbt2 
NEFSGR --- 117 39 --- 141 34 92 173 120 28 141 78 
use other AB 
EALVDHAEAFSGR 173 11 1.7 141 15 2.3 87 38 87 1.7 8.5 8.8 
EALVGQAEAFSGR 3.3 2.5 8.5 4.7 2.4 12 3.1 6.9 6.1 1.7 6.6 7.6 
EALVDHAEEFSGR --- 20 5.2 --- 24 7.0 87 87 90 1.2 5.8 23 
EALDDLGEEFSGR --- --- 15 --- --- 20 173 173 173 141 141 141 
EALEDNAEEFSGR --- --- --- --- --- --- --- --- --- --- --- --- 
...FTNR_rbt1 
ECYSVFTNR 91 18 3.7 141 25 3.3 9.6 17 89 6.5 9.7 19 
use other AB ECYSTFTNR 27 7.5 11 39 9.5 12 8.9 6.0 28 7.7 6.1 15 
DCLSVFTNR --- --- --- --- --- --- --- --- --- --- --- --- 
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antibody peptide 
10-40 µg protein 
AB: 
1 –      2 -     5µg 
20-40 µg protein 
AB: 
1 –      2 -     5µg 
1-5 µg AB 
protein: 
10 -   20 - 40 µg 
2-5 µg AB 
protein: 
10 -   20 - 40 µg 
conclusion 
protein / AB 
...FTNR_rbt2 
ECYSVFTNR 48 16 6.3 62 20 8.9 22 39 17 3.2 5.5 24 
10 µg / 5 µg ECYSTFTNR 14 5.7 6.3 17 7.3 8.1 13 12 24 1.3 6.1 9.3 
DCLSVFTNR --- --- --- --- --- --- --- --- --- --- --- --- 
...FWLK_rbt1 HWFWLK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...FWLK_rbt2 HWFWLK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...GDLK_rbt2 GIYDGDLK 2.8 3.4 15 1.2 2.2 10 7.8 2.5 6.2 9.3 1.3 6.8 10 µg / 1 µg 
...GGEK_rbt1 NVTVHVQGGEK 20 25 6.4 7.4 1.3 8.1 42 0.8 7.9 35 0.5 9.9 20 µg / 2 µg 
...GGEK_rbt2 NVTVHVQGGEK 32 11 6.1 3.0 14 8.2 38 16 4.1 1.9 6.7 0.5 use other AB 
...GQVR_rbt1 
VQQEIDEVIGQVR 18 16 3.9 21 9.8 3.3 2.3 15 14 2.4 14 8.0 
10-20 µg / 2 µg 
VQQEIDAVIGQVR 173 17 4.4 --- 24 5.9 7.1 87 90 10 3.7 22 
...GQVR_rbt2 
VQQEIDEVIGQVR --- --- --- --- --- --- --- --- --- --- --- --- 
use other AB 
VQQEIDAVIGQVR --- --- --- --- --- --- --- --- --- --- --- --- 
...GSLR_rbt1 ITIIPQDPVLFSGSLR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...GTVR_rbt1 LAIIPQEPVLFSGTVR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...GTVR_rbt2 LAIIPQEPVLFSGTVR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...GYYR_rbt1 LFIHEYISGYYR 89 87 8.2 20 11 10 173 22 28 141 0.5 0.3 use other AB 
...GYYR_rbt2 LFIHEYISGYYR 15 5.0 6.1 --- 4.9 6.3 7.8 4.6 0.0 8.8 1.4 0.0 10 µg / 1 µg 
...IFFK_rbt1 IQGYFNAWQALLIKPNIFFK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...IFFK_rbt2 IQGYFNAWQALLIKPNIFFK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...LDDK_rbt1 DFNPQHFLDDK 89 4.9 3.3 141 3.6 4.6 12 87 1.2 3.2 1.6 0.7 10 µg / 2 µg 
...LPNK_rbt2 
LQDEIDEALPNK 6.2 8.9 18 0.1 13 19 4.7 5.0 19 4.6 6.6 25 
10 µg / 1 µg LQDEIDAALPNK 6.0 9.2 5.7 0.9 13 0.1 5.2 4.9 6.1 7.2 6.9 6.1 
LQEEIDETLPNK 173 173 173 141 141 141 --- --- 11 --- --- 8.7 
...LPNK_rbt3 
LQDEIDEALPNK --- 25 14 --- 4.6 19 91 89 87 27 19 4.4 
use other AB LQDEIDAALPNK --- 146 87 --- 122 141 91 160 173 25 127 141 
LQEEIDETLPNK --- 173 130 --- --- 100 156 173 173 122 141 141 
...LSGK_rbt1 WLVLSGK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...LTTR_rbt2 
NTTGALTTR 87 4.3 87 2.9 2.6 7.0 173 6.2 7.4 141 3.9 5.7 
10 µg / 1 µg 
NNPGVLTTR 3.2 2.9 3.3 4.5 3.5 1.2 1.2 4.8 2.6 0.3 3.0 0.7 
...NFSK_rbt1 
NFNQSLTNFSK 105 91 88 55 27 16 --- 10 62 --- 7.0 49 
40 µg / 2 µg NVSQSLTNFSK --- --- --- --- --- --- --- --- --- --- --- --- 
NISQSFTNFSK 11 1.9 2.1 15 0.8 1.9 4.8 1.1 9.8 0.7 1.0 0.1 
...NFSK_rbt2 
NFNQSLTNFSK 91 39 92 141 51 141 22 173 41 29 141 49 
use other AB NVSQSLTNFSK --- --- --- --- --- --- --- --- --- --- --- --- 
NISQSFTNFSK 7.5 2.6 5.8 4.9 3.6 8.1 2.0 5.9 8.6 1.8 7.5 4.3 
...NGER_rbt1 
EYGVIFANGER 9.6 7.1 7.5 14 4.8 10 8.1 3.6 6.7 2.5 4.4 1.0 
40 µg / 5 µg GYGVAFSNGER 98 43 2.5 57 50 0.9 8.8 138 124 5.6 52 1.9 
GYGVTFSNGER --- --- --- --- --- --- --- --- --- --- --- --- 
...NGER_rbt2 
EYGVIFANGER --- 107 70 --- 59 90 173 120 98 141 78 43 
use other AB GYGVAFSNGER --- --- --- --- --- --- --- --- --- --- --- --- 
GYGVTFSNGER --- --- --- --- --- --- --- --- --- --- --- --- 
...PFQR_rbt1 DYDEVTAFLGEWGPFQR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...PFQR_rbt2 DYDEVTAFLGEWGPFQR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...QDIR_rbt1 LYDPLEGVVSIDGQDIR --- --- 173 --- --- 141 --- --- 173 --- --- 141 n.u.f. (#) 
...QDIR_rbt2 LYDPLEGVVSIDGQDIR --- --- 173 --- --- 141 --- --- 173 --- --- 141 n.u.f. 
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antibody peptide 
10-40 µg protein 
AB: 
1 –      2 -     5µg 
20-40 µg protein 
AB: 
1 –      2 -     5µg 
1-5 µg AB 
protein: 
10 -   20 - 40 µg 
2-5 µg AB 
protein: 
10 -   20 - 40 µg 
conclusion 
protein / AB 
...QLLK_rbt1 LAHDILLFLNPQLLK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...QLLK_rbt2 LAHDILLFLNPQLLK 73 173 173 95 141 141 173 107 105 --- 141 141 n.u.f. (#) 
...QLLK_rbt4 LAHDILLFLNPQLLK --- 173 --- --- 141 --- --- 173 --- --- 141 --- n.u.f. 
...QPPR_rbt1 
NTWDPDQPPR 4.8 9.7 7.8 1.4 5.1 9.8 4.7 3.7 4.2 6.2 2.4 2.4 
10-20 µg / 5 µg 
TTWDPDQPPR --- --- --- --- --- --- --- --- --- --- --- --- 
TWDPDQPPR 56 23 23 65 5.0 32 10 7.3 62 14 8.0 30 
TTWDPTQPPR --- 173 119 --- --- 141 111 --- 173 66 --- 141 
...QPPR_rbt2 
NTWDPDQPPR --- --- 30 --- --- 20 173 173 173 141 141 141 
use other AB 
TTWDPDQPPR --- --- --- --- --- --- --- --- --- --- --- --- 
TWDPDQPPR --- --- --- --- --- --- --- --- --- --- --- --- 
TTWDPTQPPR 121 87 4.2 107 141 4.6 25 11 136 10 1.2 141 
...RPER_rbt1 
ELWGDPNEFRPER --- --- --- --- --- --- --- --- --- --- --- --- 
n.u.f. DPFVFRPER 98 93 62 44 31 79 173 64 40 141 53 1.7 
YWPEPEEFRPER --- 173 57 --- 141 59 173 87 173 141 4.1 141 
...RPER_rbt2 
ELWGDPNEFRPER --- --- --- --- --- --- --- --- --- --- --- --- 
n.u.f. (#) DPFVFRPER --- 145 121 --- 109 62 173 87 109 141 12 62 
YWPEPEEFRPER --- 173 87 --- 141 141 173 92 --- 141 30 --- 
...S IGK_rbt1 
SDAFVPFSIGK --- --- --- --- --- --- --- --- --- --- --- --- 
use other AB 
NDAFVPFSIGK --- --- --- --- --- --- --- --- --- --- --- --- 
...S IGK_rbt2 
SDAFVPFSIGK 173 57 87 141 27 6.9 173 108 107 141 84 59 
40 µg / 5 µg 
NDAFVPFSIGK --- 8.7 16.8 --- 5.8 12 87 87 87 10 5.1 1.3 
...SLNK_rbt2 QPLESSDLWSLNK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...SLNK_rbt4 QPLESSDLWSLNK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...STGK_rbt2 SDYFIPFSTGK --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. 
...TNPR_rbt1 ESLDVTNPR 1.5 9.0 2.3 0.0 11 3.0 6.4 6.7 11 2.1 0.8 14 use other AB 
...TNPR_rbt2 ESLDVTNPR 6.7 1.6 2.4 2.0 0.2 1.9 4.7 1.5 0.4 0.5 2.0 0.1 10 µg / 2 µg 
...TVEK_rbt1 SSISTVEK 28 9.1 6.2 10 11 8.1 7.7 25 26 11 0.9 3.7 20 µg / 5 µg 
...TVEK_rbt2 SSISTVEK --- --- --- --- --- --- --- --- --- --- --- --- use other AB 
...VILR_rbt1 MSDSVILR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...VILR_rbt2 MSDSVILR --- --- --- --- --- --- --- --- --- --- --- --- n.u.f. (#) 
...YQVR_rbt1 GEIQFNNYQVR 1.2 2.8 5.4 1.7 3.4 0.7 5.2 2.6 3.0 7.3 0.2 2.6 10 µg / 1 µg 
...YQVR_rbt2 GEIQFNNYQVR 3.1 3.9 11 2.7 0.5 6.2 4.1 1.9 7.8 5.7 0.2 5.5 use other AB 
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Table 68: Results of peptides with N-terminal missed cleavage in human. During the 
proteolysis k inetics, proteotypic peptides were quantified at each time point. At 
the same time, the according peptides with one N-terminal missed cleavage site 
were monitored. S equences of the missed cleavage variants and the results of 
monitoring them are given.  
proteotypic peptide peptide with one N-terminal missed cleavage site 
peptide 
detected 
SLSEASV AVDR VTPFSVKSLSEASVAVDR no 
RPSYL DLFR VVRRPSYLDLFR no 
YTAS DLFR AKYTASDLFR no 
LSPSFA DLFR MLSLEEDVTEKLSPSFADLFR no 
LNPSFL DLVR KLNPSFLDLVR no 
FIGLQ FFFK NRFIGLQFFFK no 
GIYD GDLK 
GDMNLSIVMTTCSTFCALGMMPLLLYIYSRGIYDGD
LK 
too long 
DLSLHVH GGEK NYSVRYRPGLDLVLRDLSLHVHGGEK no 
TVAAF GGEK AGVVADEVISSMRTVAAFGGEK no 
LTIIPQDPILFS GSLR EKLTIIPQDPILFSGSLR no 
ITIIPQDPVLFS GSLR FKITIIPQDPVLFSGSLR no 
LSIIPQEPVLFS GTVR SKLSIIPQEPVLFSGTVR no 
LFIHEYIS GYYR KLFIHEYISGYYR no 
GGPEAT LEVR EAPEEPAPVRGGPEATLEVR no 
TLGGILAPIYFGA LIDK ALAMGFQSMVIRTLGGILAPIYFGALIDK too long 
EANIHAFIES LPNK AAKEANIHAFIESLPNK no 
NSPGA LTTR AMLGQDIAWFDDLRNSPGALTTR no 
NTTGA LTTR QDVSWFDDPKNTTGALTTR no 
YVEQQYGQ PSSK 
SILTNPLYVMFVLLTLLQVSSYIGAFTYVFKYVEQQY
GQPSSK 
too long 
NKPLFDTI QDEK 
AMGINATFANIAGALAPLMMILSVYSPPLPWIIYGV
FPFISGFAFLLLPETRNKPLFDTIQDEK 
too long 
LYDPTEGMVSVDG QDIR STTVQLMQRLYDPTEGMVSVDGQDIR no 
SSIS TVEK LFVLCHSLLQLAQLMISGYLKSSISTVEK too long 
IQFNN YQVR GKIQFNNYQVR no 
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Table 69: Results of peptides with N-terminal missed cleavage in rat. During the 
proteolysis k inetics, proteotypic peptides were quantified at each time point. At 
the same time, the according peptides with one N-terminal missed cleavage site 
were monitored. S equences of the missed cleavage variants and the results of 
monitoring them are given.  
peptide 
peptide with N-terminal missed 
cleavage 
peptide 
detected 
ANIYGLCFAFSQGIAFLANS AAYR KANIYGLCFAFSQGIAFLANSAAYR no 
AAATEDATPA ALEK ITYKAAATEDATPAALEK no 
SLSEASV AVDR VTPFSVKSLSEASVAVDR no 
LGSILSPYFVYLG AYDR 
NMGVGVSSTASRLGSILSPYFVYLGA
YDR 
no 
GDFVAVFPPMIHNDPEVF DAPK KGDFVAVFPPMIHNDPEVFDAPK no 
ALQRPSYL DLFR 
PVGEGSLSQEALNNVVTMERALQRP
SYLDLFR 
too long 
SPSFA DLFR RSPSFADLFR after 2h and 6h 
YGLS DLFR VKYGLSDLFR no 
LNPSFL DLVR KLNPSFLDLVR no 
FINLVPSNLPH EATR 
LDMPYMDAVVHEIQRFINLVPSNLP
HEATR 
too long 
AMDSFPGPPTHWLFGHAL EIQK LARAMDSFPGPPTHWLFGHALEIQK no 
MVEVCV ESIK ALTGPGLIRMVEVCVESIK no 
LLTPGFHYDVLKPYVAIFA ESTR KLLTPGFHYDVLKPYVAIFAESTR no 
LSDRPQLPYLEAFIL ETFR QPRLSDRPQLPYLEAFILETFR not determined 
EQLDSLVCLESAIL EVLR 
GPGISVHFTREQLDSLVCLESAILEVL
R 
no 
YTDHF FAFK 
QVQTFLGYTDAGAQFVFGEKYTDH
FFAFK 
too long 
FIGLQ FFFK NRFIGLQFFFK no 
NE FSGR EVLLNHKNEFSGR yes 
EALVDHAEA FSGR 
HGDVFTVYFGPRPVVMLCGTQTIRE
ALVDHAEAFSGR 
too long 
EALDDLGEE FSGR 
IYGPVFTLYFGPKPTVVVHGYEAVKE
ALDDLGEEFSGR 
too long 
EALVDLGEE FSGR 
VYGPIFTLYLGMKPFVVLHGYEAVK
EALVDLGEEFSG 
too long 
EALIDYGEE FSGR 
TYGPVFTLYFGSQPTVVLHGYEAVK
EALIDYGEEFSGR 
too long 
EALVDHGEE FSGR 
TYGPVYTLYVGSQPTVVLHGYEALK
EALVDHGEEFSGR 
too long 
ECYSV FTNR MVLVKECYSVFTNR no 
ECYST FTNR TVLVKECYSTFTNR no 
HW FWLK LLERHWFWLK no 
GIYD GDLK 
GDMNLSIVMTTCSSFSALGMMPLLL
YVYSKGIYDGDLK 
too long 
NLTLHVQ GGEK PGLELVLKNLTLHVQGGEK no 
LTIIPQDPILFS GSLR ERLTIIPQDPILFSGSLR no 
ITIIPQDPVLFS GSLR FKITIIPQDPVLFSGSLR no 
LTIIPQEPVLFS GTVR SKLTIIPQEPVLFSGTVR no 
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peptide 
peptide with N-terminal missed 
cleavage 
peptide 
detected 
LFIHEYIS GYYR KLFIHEYISGYYR no 
IQGYFNAWQALLIKPN IFFK KIQGYFNAWQALLIKPNIFFK no 
DETVWE KPHR GTTLIINLSSVLKDETVWEKPHR in 2 replicates 
DFDPQNF LDDK FFPSPKDFDPQNFLDDK no 
DFNPQHF LDDK FFPNHKDFNPQHFLDDK no 
EIDQVIGSHRPPS LDDR VQKEIDQVIGSHRPPSLDDR no 
EAEY LISK 
SFSIASDPTLASSCYLEEHVSKEAEYLI
SK 
too long 
EANH LISK 
SFSIASDPTSVSSCYLEEHVSKEANHL
ISK 
too long 
LQDEIDAA LPNK KLQDEIDAALPNK in 1 replicate 
LQEEIDGA LPSK KLQEEIDGALPSK no 
WLV LSGK 
WLQLTSSAPFFIFSLLSWWVPESIRW
LVLSGK 
too long 
DETVWE KPHR GTTLIINLSSVLKDETVWEKPHR in 2 replicates 
NTTGS LTTR QDISWFDDHKNTTGSLTTR no 
NNPGV LTTR AMLGQDIGWFDDLRNNPGVLTTR no 
NTTGA LTTR QDISWFDDPKNTTGALTTR no 
EYGVIFA NGER GTIAVIEPIFKEYGVIFANGER no 
AAL QDEK KAALQDEK between 2 – 16h 
LYDPIEGEVSIDG QDIR STTVQLLQRLYDPIEGEVSIDGQDIR too long 
LIHDLLVFLNP QLLK SFILKLIHDLLVFLNPQLLK no 
TWDPD QPPR KTWDPDQPPR in 1 replicate 
DPFVF RPER QWKDPFVFRPER no 
SDAFVPF SIGK KSDAFVPFSIGK no 
SSDLW SLNK QPLKSSDLWSLNK no 
EHQESLDV TNPR IKEHQESLDVTNPR yes 
IEEHQESLDV TNPR KIEEHQESLDVTNPR yes 
SSIS TVEK 
FFVLCHSILQLAQLMISGYLKSSISTV
EK 
too long 
MSDS VILR N-terminus N-terminus 
HGEIQFNN YQVR RPPADWPRHGEIQFNNYQVR no 
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Table 70: Results of peptides with N-terminal missed cleavage in mouse.  During the 
proteolysis k inetics, proteotypic peptides were quantified at each time point. At 
the same time, the according peptides with one N-terminal missed cleavage site 
were monitored. S equences of the missed cleavage variants and the results of 
monitoring them are given.  
peptide peptide with N-terminal missed cleavage 
peptide 
detected 
AAATEDATPA ALEK ITYKAAATEDATPAALEK 1 replicate 
SLSEASV AVDR VTPFSVKSLSEASVAVDR no 
YGLS DLFR VKYGLSDLFR no 
FINLVPSNLPH EATR 
MNMPYMDAVVHEIQRFINLVPSNLPHEA
TR 
too long 
MVEVCV ESIK ALTGPGLVRMVEVCVESIK no 
FIGLQ FFFK NRFIGLQFFFK no 
NE FSGR EVLLNHKNEFSGR in 2 replicates 
EALVDHAEA FSGR 
HGDVFTVHLGPRPVVVLCGTQTIREALVD
HAEAFSGR 
too long 
EALVGQAEA FSGR 
YGDVFTVHLGPRPVVMLCGTDTIREALVG
QAEAFSGR 
too long 
EALVDHAEE FSGR VVVLYGYDAVKEALVDHAEEFSGR yes 
EALDDLGEE FSGR 
VYGPVFTLYFGSKPTVVVHGYEAVKEALD
DLGEEFSGR 
too long 
EALEDNAEE FSGR VVVLYGYDAVKEALEDNAEEFSGR no 
ECYSV FTNR IVLVKECYSVFTNR no 
ECYST FTNR TVLVKECYSTFTNR yes 
DCLSV FTNR NVLVKDCLSVFTNR no 
HW FWLK LLDRHWFWLK no 
GIYD GDLK 
GDMNLSIVMTTCSSFTALGMMPLLLYIYSK
GIYDGDLK 
too long 
NVTVHVQ GGEK YRPGLELVLKNVTVHVQGGEK no 
VQQEIDEVI GQVR RVQQEIDEVIGQVR no 
VQQEIDAVI GQVR RVQQEIDAVIGQVR no 
ITIIPQDPVLFS GSLR FKITIIPQDPVLFSGSLR no 
LAIIPQEPVLFS GTVR SKLAIIPQEPVLFSGTVR no 
LFIHEYIS GYYR KLFIHEYISGYYR no 
IQGYFNAWQALLIKPN IFFK KIQGYFNAWQALLIKPNIFFK no 
DFNPQHF LDDK FFSSPKDFNPQHFLDDK no 
LQDEIDEA LPNK KLQDEIDEALPNK yes 
LQDEIDAA LPNK KLQDEIDAALPNK yes 
LQEEIDET LPNK KLQEEIDETLPNK no 
WLV LSGK 
WLQLSVSAAFFIFSLLSWWVPESIRWLVLS
GK 
no 
NNPGV LTTR QDIGWFDDLKNNPGVLTTR after 2 and 6h 
NTTGA LTTR QDVSWFDDPKNTTGALTTR no 
EVLDSFLD LVR  SAPTKEVLDSFLDLVR no 
NFNQSLT NFSK LPPGPTPFPIIGNFLQIDVKNFNQSLTNFSK too long 
NVSQSLT NFSK 
GSLPPGPTPFPIIGNFLQIDIKNVSQSLTNFS
K 
too long 
NISQSFT NFSK LPPGPTPLPIIGNFLQIDVKNISQSFTNFSK too long 
Supplemental Information 
173 
peptide peptide with N-terminal missed cleavage 
peptide 
detected 
EYGVIFA NGER GTVAVVEPTFKEYGVIFANGER yes 
GYGVAFS NGER GEQATFNTLFKGYGVAFSNGER no 
GYGVTFS NGER GEQATFNTLFKGYGVTFSNGER no 
LYDPLEGVVSIDG QDIR STTVQLMQRLYDPLEGVVSIDGQDIR no 
LAHDILLFLNP QLLK SFILKLAHDILLFLNPQLLK no 
NTWDPD QPPR SLLAIVENLLTENRNTWDPDQPPR no 
TTWDPD QPPR SFMAILDNLLTENRTTW DPDQPPR no 
TWDPD QPPR RTWDPDQPPR no 
TTWDPT QPPR AFVTMLDELLAEHKTTWDPTQPPR no 
SDAFVPF SIGK KSDAFVPFSIGK no 
NDAFVPF SIGK KNDAFVPFSIGK yes 
QPLESSDLW SLNK ITFWWITGMMVHGYRQPLESSDLWSLNK no 
SDYFIPF STGK KSDYFIPFSTGK no 
ESLDV TNPR EHKESLDVTNPR no 
SSIS TVEK FFVLCHSLLQLTQLMISGYLKSSISTVEK too long 
MSDS VILR SDSVILR yes 
GEIQFNN YQVR KGEIQFNNYQVR yes 
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Table 71: Sites of natural sequence variants and posttranslational modification.  The 
peptides are listed in the order of the multiplexes. S ites of natural sequence 
variants and posttranslational modification listed by UniProtKB (December 2016) 
are given.  
 peptide species 
natural sequence 
variants 
sites of 
posttranslational 
modification 
MPh1 
GIYDGDLK human no no 
NKPLFDTIQDEK human N --> K in  cancer no 
YTASDLFR human no no 
EANIHAFIESLPNK human no no 
RPSYLDLFR human no no 
MPh2 
YVEQQYGQPSSK human no no 
ITIIPQDPVLFSGSLR human no no 
LTIIPQDPILFSGSLR human 
Q --> R and R missing 
in DJS 
no 
MPh3 
SSISTVEK human 
E --> K in breast cancer 
samples 
no 
NTTGALTTR human no no 
NSPGALTTR human R --> Q in cholestasis no 
IQFNNYQVR human no no 
SPh1 
DLSLHVHGGEK human no no 
TVAAFGGEK human E--> G no 
MPr1 
NLTLHVQGGEK rat no no 
GIYDGDLK rat no no 
EYGVIFANGER rat no no 
LYDPIEGEVSIDGQDIR rat no no 
MPr2 
NTTGSLTTR rat no no 
NTTGALTTR rat no no 
NNPGVLTTR rat no no 
LTIIPQEPVLFSGTVR rat no no 
MPr3 
AAATEDATPAALEK rat no T phosphorylation 
ALQRPSYLDLFR rat no no 
YGLSDLFR rat no no 
MPr4 
EANHLISK rat no no 
EAEYLISK rat no no 
EIDQVIGSHRPPSLDDR rat no no 
DFNPQHFLDDK rat no no 
LYDPIEGEVSIDGQDIR rat no no 
DFDPQNFLDDK rat no no 
MPr5 
EALVDHGEEFSGR rat no no 
EALVDHAEAFSGR rat no no 
FINLVPSNLPHEATR rat no no 
EALDDLGEEFSGR rat no no 
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 peptide species 
natural sequence 
variants 
sites of 
posttranslational 
modification 
EALIDYGEEFSGR rat no no 
EALVDLGEEFSGR rat no no 
MPr6 
ECYSTFTNR rat no no 
TWDPDQPPR rat no no 
HGEIQFNNYQVR rat no no 
ECYSVFTNR rat no no 
LQDEIDAALPNK rat no no 
MPr7 
LQEEIDGALPSK rat no no 
AMDSFPGPPTHWLFGHALEIQK rat no no 
SPr1 
ITIIPQDPVLFSGSLR rat no no 
LTIIPQDPILFSGSLR rat no no 
MPm1 
NVTVHVQGGEK mouse no no 
NTTGALTTR mouse no no 
NNPGVLTTR mouse no no 
AAATEDATPAALEK mouse no T phosphorylation 
MPm2 
SSISTVEK mouse no no 
GIYDGDLK mouse no no 
MPm3 
TWDPDQPPR mouse no no 
NTWDPDQPPR mouse no no 
TTWDPTQPPR mouse no no 
VQQEIDEVIGQVR mouse no no 
VQQEIDAVIGQVR mouse no no 
MPm4 
NVSQSLTNFSK mouse no no 
NFNQSLTNFSK mouse no no 
NISQSFTNFSK mouse no no 
FINLVPSNLPHEATR mouse no no 
MPm5 
ESLDVTNPR mouse no no 
EALVDHAEAFSGR mouse no no 
EALVGQAEAFSGR mouse no no 
DFNPQHFLDDK mouse no no 
EALDDLGEEFSGR mouse no no 
SPm1 
GYGVAFSNGER mouse no no 
GYGVTFSNGER mouse no no 
SPm2 
ECYSVFTNR mouse no no 
DCLSVFTNR mouse no no 
 
 
